

Prospective purchasers of derivatives and structured products should ensure that they understand the nature of the relevant Products (as defined below) and the extent of their exposure to risks, including the risk of loss of their original investment, and that they consider the suitability and appropriateness of the relevant Products as an investment in the light of their own circumstances and financial condition. Products involve a high degree of risk, including in certain cases the risk of total loss of the purchase price. Potential investors are in particular asked to review the Section "Risk Factors" starting on page 8. The contents of this Base Prospectus (as defined below) are not to be construed as legal, business or tax advice. Each prospective investor should consult his or her attorney or business and tax adviser as to legal, business and tax advice.

## DERIVATIVE AND STRUCTURED PRODUCT PROGRAMME

### Base Prospectus

dated August 3, 2020

*Any Products issued on or after the date of this base prospectus (the "Base Prospectus") are issued subject to the provisions described herein.*

Under the terms of their derivative and structured product programme (the "Programme"), Helvetische Bank AG, acting through its office in Zurich ("HB" or the "Issuer") may from time to time issue Products, such term to include warrants ("Warrants"), certificates ("Certificates") and structured notes ("Notes") of any kind, including, but not limited to, all products contained in the Swiss Derivative Map<sup>®</sup>, as amended from time to time by the Swiss Structured Products Association (together the "Products"). Such Products will be linked e.g. to a specified index or a basket of indices, a specified share or a basket of shares, a specified debt instrument or a basket of debt instruments, a specified currency or a basket of currencies, a specified commodity or a basket of commodities, a specified strategy or a basket of strategies, or to any further Underlyings meant to serve as Underlying (each an "Underlying" or the "Underlying(s)").

Products issued under this Programme may be listed on the SIX Swiss Exchange AG, Switzerland ("SIX Swiss Exchange"), respectively, admitted to trading on SIX Structured Products Exchange, the trading platform of SIX Structured Products Exchange AG or any successor thereof ("SIX Structured Products Exchange"), if the terms of the applicable Final Terms provide for such a listing. This Programme is a prospectus in accordance with Art. 35 para. 1 FinSA and has been evaluated and approved pursuant to Art. 51 et seq. of the Financial Services Act ("FinSA") and Art. 59 et seq. of the Financial Services Ordinance ("FinSO") by the reviewing body SIX Exchange Regulation AG ("Reviewing Body") on August 3, 2020. According to Art. 55 FinSA, prospectuses shall be valid for public offers or admission to trading on a trading venue of the Products for 12 months after approval. After this period, the Programme will either be registered again with a prospectus reviewing body or it may be used exclusively for exempt offers pursuant to Art. 36 para. 1 FinSA. Together, this Programme (as amended or supplemented) and the applicable Final Terms (as amended or supplemented) represent the Prospectus (the "Prospectus") for Products both listed or not listed on SIX Swiss Exchange. Furthermore, the Issuer reserves the right to set forth all information which may be required in case of an offer to private clients in a key information document (*Basisinformationsblatt*) ("Key Information Document" or "KID") pursuant to Art. 58 FinSA. During the transitory period pursuant to Art. 111 FinSO the Issuer may publish a simplified prospectus alternatively to a KID.

Each issue of Products will be issued on the general terms and conditions of the Products set out herein which are applicable to such Products (the "Terms and Conditions"; each a "Condition") and on such additional terms as will be set out in additional Final Terms (the "Final Terms") relating thereto. If multiple Products with a similar structure and standard terms are issued (the terms "similar structure" and "standard terms" as interpreted by a reasonable discretion of the Issuer), the Issuer is at liberty to prepare single Final Terms covering all these Products if – and only if – such single Final Terms are permissible under the applicable laws and regulations. A description of the Final Terms is set out herein on page 55 and will specify with respect to the issue of the Products to which it relates, *inter alia* and where applicable, the specific designation of the Products, the aggregate number and type of the Products, the date of issue of the Products, the issue price, the exercise price, the Underlying, index or other item(s) to which the Products relate, the exercise period or date, the applicable interest terms and certain other terms relating to the offering and sale of the Products. The Final Terms supplement the Terms and Conditions and may specify other terms and conditions which shall, to the extent so specified or to the extent inconsistent with the Terms and Conditions, supplement, replace or modify the Terms and Conditions. The Final Terms shall be provided at least in a version with indicative information at the time of the (public) offer. At the end of the subscription period, they shall be published in a definitive version and, in case of a public offer or admission to trading on a trading venue (under the applicable Final Terms), filed with the Reviewing Body. An approval of the Final Terms by the Reviewing Body is not necessary. Each issue of Products will entitle the Holder thereof (the "Holder of the Products") (upon exercise or redemption and subject to certification as to non-U.S. beneficial ownership) either to receive a cash amount or the Underlying or coupons if and as specified in the Terms and Conditions and the applicable Final Terms (each a "Coupon" and collectively the "Coupons").

If not otherwise specified in the applicable Final Terms, each issue of Products and Coupons (if any) will be represented by a permanent global certificate according to Art. 973b of the Swiss Code of Obligations ("CO") (each a "Permanent Global Certificate") which will be issued and, as the case may be, deposited at a global depository, such as SIX SIS AG, Olten ("SIS"), Banque Internationale à Luxembourg, acting as global depository for Euroclear (as defined below) or Clearstream Luxembourg (as defined below), or any other suitable global depository selected by the Issuer. Definitive Products and Coupons, if any, shall only be issued by the Issuer in the event of the Issuer's default or if SIS goes out of business without a successor. If issued, definitive Products and Coupons, if any, shall exclusively be issued in registered form. The Issuer shall arrange for the printing of the definitive Products and Coupons, if any, in registered form at their own cost and arrange for delivery of the definitive Products and Coupons, if any, to SIS, Euroclear Bank S.A. / N.V., as operator of the Euroclear system ("Euroclear") or Clearstream Banking, société anonyme ("Clearstream Luxembourg"), as the case may be, for distribution (free of charge) to the Holders of the Products and Coupons.

If specified in the applicable Final Terms, Products will be booked into the SIS system as uncertificated securities (*unverurkundete Wertrechte*) according to Art. 973c CO and Art. 3 of the Swiss Federal Intermediated Securities Act ("FISA") and thereby become Intermediated Securities (*Bucheffekten*) (the "Intermediated Securities"). The integration of Intermediated Securities into the SIS-giro-system is based on an agreement concluded between SIS and the Issuer. The creation of a supply of Intermediated Securities is constitutive and replaces the issuance of individual security deeds or a global security deed. SIS may effect changes to the supply of Intermediated Securities (increase/decrease) in accordance with instructions given by the Issuer. After the creation of the Intermediated Securities supply, transactions in Intermediated Securities will be effected through securities accounts in accordance with the general terms and conditions of SIS and the further body of rules and regulations pursuant to Art. 10 of the general terms and conditions of SIS. The rights arising from the terms of the Products exist vis-à-vis the relevant Issuer and may be asserted against such Issuer with the respective supply disclosure statement issued by SIS. No legal claims with respect to Intermediated Securities, irrespective of their booking, may be asserted against SIS. The Products, or interests therein, may only be offered or distributed, directly or indirectly, in compliance with the selling restrictions of this Base Prospectus (see "Subscription and Sale") as well as the Final Terms.

**The Products do not constitute a collective investment scheme as defined in the Federal Collective Investment Schemes Act ("CISA") and are not subject to authorisation by the Swiss Financial Markets Supervisory Authority ("FINMA"). Accordingly, Holders of the Product do not have the benefit of the specific investor protection provided under the CISA. Holders of the Product bear the issuer risk.**

**HELVETISCHE BANK AG**

(incorporated with limited liability in Switzerland)



**The Issuer accepts responsibility for the information contained in this document. The Issuer has (to the best of its knowledge and belief) taken all reasonable care to ensure that the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information. The applicable Final Terms will specify the nature of the responsibility taken by the Issuer for the information relating to the Underlying(s) to which the Products described in the Final Terms relate. However, unless otherwise expressly stated in the applicable Final Terms, any information contained therein relating to the Underlying(s) to which the Products relate will only represent an extract from, or a summary of, the financial information or other information released publicly by the issuer, owner or sponsor, as the case may be, of such Underlying(s) to which the relevant Products relate. Unless otherwise expressly stated in the applicable Final Terms, the Issuer accepts responsibility for accurately reproducing such extracts or summaries (insofar as it is applicable) but does not accept any further or other responsibility in respect of such information.**

**No person is authorised to give any information or to make any representation not contained in or not consistent with this document or any other information supplied in connection with the Programme and, if given or made, such information or representation must not be relied upon as having been authorised by the Issuer or any manager of an issue of Products as applicable to such issue of Products (the "Managers" and each a "Manager"). If any Managers are appointed they shall be specified in the Final Terms. This document does not constitute, and may not be used for the purposes of, an offer or solicitation by anyone in any jurisdiction in which such offer or solicitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation and no action is being taken to permit an offering of the Products or the distribution of this document in any jurisdiction where any such action is required.**

**This Base Prospectus is to be read and construed in conjunction with any amendment or supplement hereto, with any applicable Final Terms hereto, and with any Key Information Document (where applicable). This Base Prospectus, together with the Issuer's last two annual reports, provides information with regard to the Issuer and the Products' issued under the Programme. The Final Terms prepared in connection with any issue of Products and any other supplements to this Base Prospectus will form an integral part hereof. The Issuer has undertaken to make available at his office in Zurich, free of charge for Holders of Products the latest annual reports of the issuer of the respective Underlying to which Products relate.**

**The Products will be exercisable or redeemed in the manner set forth herein and in the applicable Final Terms. Upon exercise or redemption, the Holder of a Product will be required to certify (in accordance with the provisions outlined in "Subscription and Sale" below) that (a) it is a Permitted Transferee, (b) it has not purchased such Products for resale to, or for the account or benefit of, persons other than Permitted Transferees, and (c) it is not exercising such Product on behalf, or for the account or benefit, of a person other than a Permitted Transferee.**

**The Products of each issue may be sold by the Issuer and/or any Manager at such time and at such prices as the Issuer and/or the Manager(s) may select. There is no obligation upon the Issuer or any Manager to sell all of the Products of any issue. The Products of any issue may be offered or sold from time to time in one or more transactions in the over-the-counter market or otherwise at prevailing market prices or in negotiated transactions, at the discretion of the Issuer. No Manager has separately verified the information contained herein. Accordingly, no representation, warranty or undertaking, expressly or implied, is made and no responsibility is accepted by any Manager as to the accuracy or completeness of the information contained in this Base Prospectus or any other information provided by the Issuer. No Manager accepts any liability in relation to the information contained in this Base Prospectus or any other information provided by the Issuer in connection with the Programme.**

**Neither this Base Prospectus nor any other information supplied in connection with the Programme (i) is intended to provide the basis of any credit or other evaluation or (ii) should be considered as a recommendation by the Issuer or any Manager that any recipient of this Base Prospectus or any other information supplied in connection with the Programme should purchase any Products. Each investor contemplating purchasing Products under this Programme should make its own independent investigation of the financial condition and**

affairs, and its own appraisal of the creditworthiness, of the Issuer. No representation is made to any offeree or purchaser of the Products regarding the legality of an investment therein by such offeree or purchaser under any applicable legal investment or similar laws or regulations. The contents of this Base Prospectus are not to be construed as legal, business or tax advice. Each prospective investor should consult his or her attorney or business and tax adviser as to legal, business and tax advice. Neither this Base Prospectus nor any other information supplied in connection with the Programme constitutes an offer or an invitation by or on behalf of the Issuer or any Manager or any person to subscribe for or to purchase any Products.

The delivery of this Base Prospectus does not at any time imply that the information contained herein concerning the Issuer is correct at any time subsequent to the date hereof or that any other information supplied in connection with the Programme is correct as of any time subsequent to the date indicated in the document containing the same. No Manager undertakes to review the financial condition or affairs of the Issuer during the life of the Programme. Investors should review, *inter alia*, the most recently published annual and semi-annual financial statements, if any, of the Issuer when deciding whether or not to purchase any Products.

The distribution of this Base Prospectus and the offering of Products in certain jurisdictions may be restricted by law. Persons into whose possession this Base Prospectus comes are required by the Issuer and each Manager to inform themselves about and to observe any such restrictions. In particular, the Products have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities law of any state or political sub-division of the United States. The Products are being offered and sold in reliance on an exemption from the registration requirements of the Securities Act pursuant to Regulation S thereunder ("Regulation S"). The Products, or interests therein, may not at any time be offered, sold, resold or delivered, directly or indirectly, except in an "offshore transaction" (as such term is defined in Regulation S) to or for the account or benefit of a Permitted Transferee (as defined herein). Any offer, sale, resale, trade or delivery made, directly or indirectly, within the United States or to, or for the account or benefit of, a person other than a Permitted Transferee will not be recognised. Furthermore, trading in the Products has not been approved by the United States Commodity Futures Trading Commission ("CFTC") and no person other than a Permitted Transferee may at any time trade or maintain a position in the Products. For a description of certain further restrictions on offers and sales of the Products and on the distribution of this Base Prospectus, see "Subscription and Sale" below.

The Products do not constitute a collective investment scheme as defined in the CISA and are not subject to authorisation by FINMA. Accordingly, Holders of the Product do not have the benefit of the specific investor protection provided under the CISA. Holders of the Product bear the issuer risk.

A subscription to or a purchase of Products may be subject to various costs for the Holders of the Products (cp. Condition 11 "*Costs (Expenses, Fees, Retrocessions and Taxation)*" of the Terms and Conditions). Holders of the Products must be aware that they waive any claims (if existing) with respect to the forwarding of any fees, Retrocessions, Distribution Remunerations, Trailer Fees, or similar payments, versus the Issuer, Lead Manager, Financial Intermediaries, or Distributors (as defined in Condition 4) to the benefit of such parties (unless any agreement (other than the Terms and Conditions) between the Holder of the Products and such parties explicitly stipulates a duty to forward such fees to the Holder of the Products) (cp. Condition 11 "*Costs (Expenses, Fees, Retrocessions and Taxation)*" of the Terms and Conditions).

Collateralisation, as further described in Section "Triparty Collateral Management Secured Structured Products (TCM)" herein, eliminates the credit risk of the Issuer only to the extent that the proceeds from the liquidation of collateral upon occurrence of a liquidation event (less the costs of liquidation and payout) meet the claims of the Holders of Products. The Holders of Products bears the following risk, among others: the market risk associated with the collateral results in insufficient liquidation proceeds or, in extreme circumstances, the collateral might lose its value entirely before the liquidation can take place. The costs for the TCM service provided by SIX SIS AG with respect to the collateralisation of the Products may be taken into

**account for the pricing of a specific Product and may therefore be borne by the Holders of Products. With regard to the payment of the pro-rata share of the net liquidation proceeds the Holders of Products shall bear the solvency risks of SIX Swiss Exchange resp. SIX SIS AG and the financial intermediaries along the payout chain. The payment to the Holders of Products may be delayed for factual or legal reasons. To the extent the calculation of the current value of Products proves to be incorrect, the collateralisation of the Products may be insufficient.**

**In this Base Prospectus all references to "CHF" and "Swiss Francs" are to the official currency of Switzerland, all references to "U.S.\$", "\$" and "U.S. dollars" are to United States dollars, all references to "British pounds", "Sterling", "GBP", "STG" and "£" are to the lawful currency of the United Kingdom, all references to "Swedish Krona" and "SEK" are to the lawful currency of Sweden, all references to "Japanese Yen", "JPY" and "¥" are to the lawful currency of Japan and all references to "Euro", "EUR" and "€" are to the lawful currency of the member states of the European Union that have adopted or adopt the single currency in accordance with the Treaty establishing the European Communities, as amended by the Treaty on European Union (the "Treaty").**

## TABLE OF CONTENTS

	Page
<b>SUMMARY .....</b>	<b>6</b>
<b>RISK FACTORS.....</b>	<b>8</b>
<b>TERMS AND CONDITIONS.....</b>	<b>19</b>
<b>FORM OF FINAL TERMS .....</b>	<b>55</b>
<b>USE OF PROCEEDS .....</b>	<b>66</b>
<b>INFORMATION ON THE ISSUER.....</b>	<b>67</b>
<b>TRIPARTY COLLATERAL MANAGEMENT SECURED PRODUCTS (TCM) .....</b>	<b>70</b>
<b>SUBSCRIPTION AND SALE .....</b>	<b>74</b>
<b>TAXATION.....</b>	<b>78</b>
<b>GENERAL INFORMATION.....</b>	<b>83</b>
<b>ANNEX 1: ANNUAL REPORT 2019 .....</b>	<b>85</b>
<b>ANNEX 2: ANNUAL REPORT 2018 .....</b>	<b>86</b>

## SUMMARY

The following summary of the Base Prospectus (the "**Summary**") contains the essential information required for a FinSA prospectus by Art. 40 para. 3 FinSA, Art. 43 FinSA, and Art. 54 FinSO.

<b>Part A – Introduction</b>		
A.1.	<b>Introduction and Warnings</b>	<b>The Summary is to be understood as a mere introduction to the Prospectus. This Summary shall facilitate a comparison of the Products with similar securities.</b>
A.2.	<b>Investment Decision</b>	<b>The investment decision of the Holders of the Products must not be based on the Summary but rather on the information contained in the entire Base Prospectus and the applicable Final Terms of a Product.</b>
A.3.	<b>Liability</b>	<b>The liability of the Issuer for the Summary is limited to cases where the information contained therein is misleading, inaccurate or inconsistent when read together with the other parts of the Prospectus.</b>
<b>Part B – Issuer</b>		
B.1.	<b>Company Name of the Issuer</b>	The legal company name of the Issuer is Helvetische Bank AG (the " <b>Issuer</b> ").
B.2.	<b>Domicile and Registered Office of the Issuer</b>	The domicile of the Issuer is Zurich, Switzerland.  The registered office of the Issuer is Helvetische Bank AG, Seefeldstrasse 215, 8008 Zurich, Switzerland.
B.3.	<b>Legal Form of the Issuer</b>	The Issuer is a company limited by shares ( <i>Aktiengesellschaft</i> ) registered in the Register of Commerce in Zurich, Switzerland, under the registration number CH-115.256.141 on December 3, 2009.
B.4.	<b>Auditor</b>	BDO AG (CHE-105.952.747), Schiffbaustrasse 2, 8031 Zurich.
B.5.	<b>Regulatory Status of the Issuer</b>	The Issuer has a banking licence in Switzerland pursuant to Art. 3 para. 1 Banking Act.
B.6.	<b>Principal Activities of the Issuer</b>	The principal activities of the Issuer comprise, inter alia, asset management for private and institutional customers, investment advisory and private banking services, corporate finance transactions, and financial products.
<b>Part C – Securities (Products)</b>		
C.1.	<b>Nature of the Products</b>	The Products described in the Base Prospectus are derivatives and structured products in accordance with the Swiss Derivative Map of the Swiss Structured Products Association and may be categorized, inter alia, as capital protection products, yield enhancement products, participation products, leverage products, or products with reference entities. Especially, the Products may be Actively-Managed Certificates (AMCs).

C.2.	<b>Products</b>	The key information on the Products for a specific public offer or a specific admission to trading of Products is supplemented in the applicable Final Terms.
C.3.	<b>Public Offer</b>	The key information on any specific public offer is supplemented in the applicable Final Terms.
C.4.	<b>Admission to Trading</b>	The key information on any admission to trading is supplemented in the applicable Final Terms.
C.5.	<b>Base Prospectus</b>	This Base Prospectus of August 3, 2020 was approved by the Reviewing Body (SIX Exchange Regulation AG) on August 3, 2020.
C.6.	<b>Final Terms</b>	<p>The applicable Final Terms for public offers or the admission to trading are to be published and filed with the Reviewing Body as soon as possible after the final information is available. In case of an admission to trading, this shall be by no later than the time that the Products in question are admitted to trading.</p> <p>The applicable Final Terms for exempt offers according to Art. 36 et seq. FinSA will not be filed with the Reviewing Body (e.g., in case of offers addressed exclusively to professional clients).</p>
C.6.	<b>Risik Factors</b>	<p><b>The Products and the Underlyings may involve a high degree of risk, including the risk of a total loss of all capital invested.</b></p> <p>Further reference is made to the Section "Risk Factors" of the Programme as well as to the risk factors (if any) set out in the applicable Final Terms.</p>
<b>Part D – Public Offer or Admission to Trading</b>		
D.1.	<b>Public Offers</b>	This Base Prospectus has been reviewed and approved as a FinSA prospectus in terms of Art. 35 para. 1 FinSA with the Reviewing Body and is valid as such for a period of 12 months after its approval. During this period, Products issued under this Programme may be publicly offered unless an offer of a Product is restricted in the applicable Final Terms (see "Exempt Offers" below).
D.2.	<b>Exempt Offers</b>	Certain Products issued under this Programme may be subject to an exempt offer under Art. 36 et seq. FinSA.
D.3.	<b>Admission to Trading</b>	Products issued under this Programme may be listed on SIX Swiss Exchange and traded on SIX Structured Products Exchange for a period of 12 months after the approval of the Base Prospectus by the Reviewing Body if such listing and admission to trading is provided for in the applicable Final Terms of a Product (and approved by SIX Exchange Regulation).

## RISK FACTORS

This Section does not describe all of the risks and other ramifications of an investment in the Products (or in relation to the Issuer), including risks resulting from the amounts payable or deliverable in respect thereof being determined by reference to one or more equity or fixed income securities, indices or other Underlyings or being dependent on the credit performance of one or more specified entities. The Issuer disclaims any responsibility to advise prospective investors of such risks as they exist at the date of this Base Prospectus or as they change from time to time. Prospective investors should consult their own financial and legal advisers about risks associated with an investment in the Products and the suitability and appropriateness of investing in the Products in light of their particular circumstances. In particular, Products where the amount payable or deliverable in respect thereof is determined by reference to one or more equity or fixed income securities, indices or other Underlyings which will be specified in the applicable Final Terms or Products which are dependent on the credit performance of one or more specified entities, may not be a suitable or appropriate investment for investors who are unsophisticated with respect to such transactions.

Investors should also refer to additional risk factors set out in the applicable Final Terms prepared in connection with the issue of Products. Such risk factors will complement or replace the risk factors set out below to the extent that (if any) they go beyond, respectively, conflict with them.

### General Considerations

Products involve a high degree of risk, which may include, among others, market risks such as interest rate risk or foreign exchange risk, credit risk, counterparty risk, time value or political risks. Prospective purchasers of Products should recognise that Products, other than any Products having a minimum expiration value, may expire worthless. Purchasers should therefore be prepared to sustain a total loss of the purchase price of the Products, except, if so indicated in the Final Terms, to the extent of any minimum expiration value attributable to such Products. This risk is *inter alia* reflected in the nature of Warrants which, other factors held constant, tend to decline in value over time and which may become worthless when they expire (except to the extent of any minimum expiration value). See "Certain Factors Affecting the Value and Trading Price of Products" below. Prospective purchasers of Products should be experienced with respect to derivatives and derivative transactions, should understand the risks of transactions involving the relevant Products and should reach an investment decision only after careful consideration, with their advisers, of the suitability and appropriateness of such Products in light of their particular financial circumstances, the information set forth herein and the information regarding the relevant Products and the basis of the Underlying to which the value of the relevant Products may relate, as specified in the applicable Final Terms.

The risk of the loss of some or all of the purchase price of certain Products upon expiration means that, in order to recover and realise a return upon his or her investment, a purchaser of certain Products must generally be correct about the direction, timing and magnitude of an anticipated change in the value of the Underlying specified in the applicable Final Terms. As regards Warrants assuming all other factors remain unchanged, the more they are "out-of-the-money" and the shorter their remaining term to expiration, the greater the risk that purchasers of such Warrants will lose all or part of their investment. With respect to certain European-style Products, the only means through which a Holder can realise value from such Products prior to the Exercise Date in relation to such Products is to sell them at their current market price in an available secondary market. See "Possible Illiquidity of the Secondary Market" below.

Fluctuations in the value of the relevant index or basket of indices will affect the value of Products relating thereto. Fluctuations in the price of the relevant equity security or value of the basket of equity securities will affect the value of Products relating thereto. Fluctuations in the price or yield of the relevant debt instrument or value of the basket of debt instruments will affect the value of Products relating thereto. Also, if a Product relates to a debt instrument as the Underlying, then, due to the character of the particular market on which a debt instrument is traded, the absence of last sale information and the limited availability of quotations for such debt instrument may make it difficult for many investors to obtain timely, accurate data for the price or yield of such debt instrument.



Fluctuations in the value of the relevant commodity or basket of commodities will affect the value of Products relating thereto. Fluctuations in the value of the relevant currency or basket of currencies will affect the value of Products relating thereto. Purchasers of certain Products risk losing their entire investment if the value of the Underlying(s) does not move in the anticipated direction.

If Products relating to particular Underlyings are subsequently issued, the supply of Products in the market will increase which could cause the price at which such Products trade in the secondary market to decline significantly.

### **Products are unsecured Obligations**

The Products and Coupons constitute direct, unconditional, unsecured and unsubordinated obligations of the Issuer and rank pari passu with all present and future, unsecured and unsubordinated obligations without any preference among themselves and without any preference one above the other by reason of priority of date of issue, currency of payment or otherwise, except for obligations given priority by law. The Issuer may issue several issues of Products relating to various Underlyings which will be specified in the applicable Final Terms. However, no assurance can be given that the Issuer will issue any Products other than the Products to which particular Final Terms relate. At any given time, the number of Products outstanding may be substantial.

Products provide opportunities for investment and pose risks to investors as a result of fluctuations in the value of the Underlying. In general, certain of the risks associated with the Products are similar to those generally applicable to other options, warrants, certificates or notes of private issuers. Warrants, Certificates and Notes relating to equity or debt securities are priced primarily on the basis of the value of the Underlying. The trading value of Products relating to currencies or commodities is likely to reflect primarily present and expected values of the reference currency (or basket of currencies) or commodity (or basket of commodities) specified in the applicable Final Terms.

### **Risks Associated with the Issuer**

The Issuer provides a comprehensive range of banking and related financial services and products and divides its principal activities into the segments asset management for private and institutional customers, investment advisory and private banking services, corporate finance transactions, and financial products. The activities of the issuer with respect to financial products comprise, inter alia, the offering and issuance of financial instruments (in particular, derivatives and structured products). Thus, the Issuer's financial stability depends significantly on the turnover and profitability of these business areas and the Issuer is subject to a general insolvency risk. Further, the Issuer is likely to be affected by global geopolitical trends, including the risk of government intervention. The financial information of the Issuer may vary due to revenue and earnings fluctuations, be inconsistent with past results in the future, or otherwise be unreliable.

In addition, the Issuer's operations are highly dependent on its information and technology systems. The Issuer remains susceptible to a wide range of cyber risks that impact and/or are facilitated by technology. The Issuer could incur losses or be required to hold additional capital as a result of model limitations or failure. Third parties may use the Issuer as a conduit for illegal activities without the Issuer's knowledge. The Issuer may suffer losses due to employee misconduct. The Issuer's data management policies and processes may not be sufficiently robust. The Issuer relies on recruiting, retaining and developing appropriate senior management and skilled personnel. Liquidity, or ready access to funds, is essential to the Issuer's businesses.

Further, the Issuer may not manage risks associated with the replacement of benchmarks (e.g., LIBOR) effectively. Moreover, the delivery of the Issuer's strategic actions is subject to execution risk. The Issuer is subject to unfavourable legislative or regulatory developments and changes in the policy of regulators or governments and the Issuer may fail to comply with all applicable regulations, particularly any changes thereto. Any reduction in the financial stability of the Issuer, any subsidiaries of the Issuer or any of their respective debt securities could increase the cost or decrease the availability of the Issuer's funding and materially adversely affect the Issuer's liquidity position and

net interest margin. Besides, the Issuer is subject to the risk of current and future legal, regulatory or administrative actions and investigations, the outcomes of which are inherently difficult to predict.

Holders of the Products bear the counterparty risk, respectively, the Issuer risk (see "Counterparty Risk" below).

### **Counterparty Risk**

Holders of Products bear the issuer risk or credit risk regarding the Issuer, i.e., the counterparty risk with respect to the Issuer. A Product's value is dependent not only on the development of its Underlying, but also on the creditworthiness of its Issuer, which may vary over the term of the Product. In case of the Issuer's insolvency, a Product may not be treated as an investor's asset, but as an investor's claim versus the Issuer. In the event of a default of the Issuer, such a claim will be uncertain. The Issuer is regulated under the Swiss Banking Law and stands under the prudential supervision of FINMA.

Collateralisation, as further described in Section "Triparty Collateral Management Secured Products (TCM)" herein, eliminates the counterparty risk regarding the Issuer only to the extent that the proceeds from the liquidation of collateral upon occurrence of a liquidation event (less the costs of liquidation and payout) meet the claims of the Holders of Products. The Holders of Products bear the following risks, among others: the market risk associated with the collateral results in insufficient liquidation proceeds or, in extreme circumstances, the collateral might lose its value entirely until the liquidation can take place. The costs for the TCM service provided by SIX SIS AG with respect to the collateralisation of the Products may be taken into account for the pricing of a specific Product and may therefore be borne by the Holders of Products, as the case may be. With regard to the payment of the pro-rata share of the net liquidation proceeds the Holders of Products shall bear the solvency risks of SIX Swiss Exchange resp. SIX SIS AG and the financial intermediaries along the payout chain. The payment to the Holders of Products may be delayed for factual or legal reasons. To the extent the calculation of the current value of Products proves to be incorrect, the collateralisation of the Products may be insufficient.

### **Independent Review and Advice**

Prior to entering into a transaction, Holders of Products should consult their own legal, regulatory, tax, financial and accounting advisors, as far as required by laws and regulations or as they consider necessary otherwise, and make their own investment, hedging, and trading decisions (including an assessment of the suitability and appropriateness of an investment in the Products, where required) based upon their own independent review and assessment and advice taken from those asset managers or investment advisers which are required by law or they consider necessary.

Furthermore, Holders of Products should conduct such independent investigation and analysis regarding the Issuer and all other relevant persons or entities and such market and economic factors as they deem appropriate to evaluate the merits and risks of the investment in the Products. As part of such independent investigation and analysis, Holders of Products should consider carefully all the information set forth in the Programme and the applicable Final Terms.

Investment in the Products may involve a loss of the capital invested by virtue of the Terms and Conditions even where there is no default or insolvency of the Issuer. Holders of Products will at all times be solely responsible for making their own independent appraisal of, and investigation into, the business, financial condition, prospects and creditworthiness, status, and course of business of the Issuer.

## **Suitability and Appropriateness**

Purchase of the Products involves substantial risks. Holders of Products should be familiar with financial instruments having the characteristics of the Products and should fully understand the terms and conditions set out in the Programme and the nature and extent of their exposure to risk of loss.

In addition, Holders of Products must evaluate, based on their own independent review and any legal, business, financial, tax and other advice as they deem necessary under the circumstances, that the acquisition of the Products (i) is fully consistent with their financial needs, objectives, and conditions, (ii) complies and is fully consistent with all corporate law documents, investment policies, guidelines, authorisations and restrictions (including in terms of their capacity) applicable to them, (iii) has been duly approved in accordance with all applicable laws and procedures and (iv) is an adequate, reasonable, appropriate and suitable investment for them.

Holders of Products should understand whether the Product constitutes a suitable and appropriate investment for them and whether they have sufficient knowledge and experience to invest in the Products. There is a risk that an appointed asset manager or investment advisor of a Holder of the Product does not conduct a suitability or appropriateness check in compliance with the FinSA.

## **No Supervision by the Swiss Financial Market Supervisory Authority**

The Products are derivative financial instruments and/or structured products. They do not qualify as units of a collective investment scheme according to the relevant provisions of the Federal Act on Collective Investment Schemes (CISA), as amended, and are not licenced or approved by the FINMA thereunder. Therefore, the Products are neither governed by the CISA nor supervised by the FINMA. Accordingly, Holders of Products do not have the benefit of the specific investor protection provided under the CISA. Holders of Products should be aware that they are exposed to the counterparty risk of the Issuer.

## **Certain Factors affecting the Value and Trading Price of Products**

The Cash Settlement Amount (in the case of Cash Settled Products) or the Entitlement (in the case of Physical Delivery Products) at any time prior to expiration is typically expected to be less than the trading price of such Products at that time. The difference between the trading price and the Cash Settlement Amount or the Entitlement, as the case may be, may reflect, among other things, a "**time value**" for the Products. The "**time value**" of the Products will depend partly upon the length of the period remaining to expiration and expectations concerning the value of the relevant security (or basket of securities), index (or basket of indices), currency (or basket of currencies), commodity (or basket of commodities) or other Underlyings as specified in the applicable Final Terms. Products offer hedging and investment diversification opportunities but also pose some additional risks with regard to their interim value. The interim value of Products varies with the price level of the Underlyings of the Products specified in the applicable Final Terms, as well as a number of other related factors, including, but not limited to, those specified herein.

Before exercising or selling Products, Holders of Products should carefully consider, among other things, (i) the trading price of the Products they wish to exercise or sell, (ii) the value and volatility of the Underlying specified, (iii) the time remaining to expiration, (iv) in the case of Cash Settled Products, the probable range of Cash Settlement Amounts, (v) any change(s) in interim interest rates and dividend yields, (vi) any change(s) in currency exchange rates, (vii) the depth of the market or liquidity of the Underlying specified, and (viii) any related transaction costs.

## **Limitations on Exercise**

If so indicated in the Final Terms, the Issuer will have the option to limit the number of Products exercisable on any date (other than the final exercise date) to the maximum number specified in the Final Terms and, in conjunction with such limitation, to limit the number of Products exercisable by any person or group of persons (whether or not acting in concert) on such date. In the event that the

total number of Products being exercised on any date (other than the final exercise date) exceeds such maximum number and the Issuer elects to limit the number of Products exercisable on such date, a Holder of Products may not be able to exercise on such date all Products that such Holder desires to exercise.

In any such case, the number of Products to be exercised on such date will be reduced until the total number of Products exercised on such date no longer exceeds such maximum, such Products being selected at the discretion of the Issuer or in any other manner specified in the applicable Final Terms.

### **Minimum Exercise Amount**

If so indicated in the Final Terms, a Holder of Products must tender a specified number of Products at any one time in order to exercise them. Thus, Holders of Products with fewer than the specified minimum number of Products will either have to sell their Products or purchase additional Products, incurring transaction costs in each case, in order to realise their investment. In such situations, also, Holders of that Product incur the risk that there may be differences between the trading price of that Product and the value of that Product.

### **Certain Considerations regarding Hedging**

Prospective purchasers intending to purchase Products to hedge against the market risk associated with investing in a Underlying specified in the applicable Final Terms should recognise the complexities of utilising Products in this manner. For example, the value of the Products may not exactly correlate with the value or movements of the Underlying specified in the applicable Final Terms. In addition, due to fluctuating supply and demand for the Products, there is no assurance that their value will correlate with movements of the Underlying specified in the applicable Final Terms. For these reasons, among others, it may not be possible for an investor to purchase or liquidate the Underlyings at prices used to calculate the value of the Underlyings.

In the case of Products relating to Underlyings, the Issuer may from time to time hedge the Issuer's obligations under such Products by taking positions, directly or indirectly, in the Underlyings. Although the Issuer has no reason to believe that such hedging activities will have a material impact on the price of the Underlyings, there can be no assurance that such hedging activities will not adversely affect the value of the Products to the detriment of the Holders of the Products. In particular, in case of larger redemptions of a product or when unwinding a hedge at or before the maturity of a Product, related sell orders regarding the Underlying may cause the price of the Underlying to decrease which could in extreme cases lead to changes of the value of the Product (e.g., due to a related breach of a barrier of the Product) to the detriment of the Holders of the Product.

### **Time Lag after Exercise**

Unless otherwise specified in the Final Terms, in the case of any exercise of Products, there will be a time lag between the time a Holder of Products gives instructions to exercise and the time the applicable Cash Settlement Amount (in the case of Cash Settled Products) relating to such exercise is determined. Any such delay between the time of exercise and the determination of the Cash Settlement Amount will be specified in the applicable Final Terms or the applicable Terms and Conditions. However, such delay could be significantly longer, particularly in the case of a delay in exercise of Products arising from any daily maximum exercise limitation, or the occurrence of a Market Disruption Event or failure to open of an exchange or related exchange (if applicable), or following the imposition of any exchange controls or other similar regulations affecting the ability to obtain or exchange any relevant currency (or basket of currencies) in the case of Products relating thereto. The applicable Cash Settlement Amount may change significantly during any such period, and such movement or movements could decrease the Cash Settlement Amount of the Products being exercised and may even result in such Cash Settlement Amount being zero.

## **Exchange Rates**

Prospective purchasers of Products should be aware that an investment in the Products may involve exchange rate risks. For example (i) the Underlying may be denominated in a currency other than that of the Products, (ii) the Products may be denominated in a currency other than the currency of the purchaser's home jurisdiction and/or (iii) the Products may be denominated in a currency other than the currency in which a purchaser wishes to receive funds.

Exchange rates between currencies are determined by factors of supply and demand in the international currency markets which are influenced by macro economic factors, complex political factors, speculation, central bank and government intervention (including the imposition of currency controls and restrictions) and other market forces. Fluctuations in exchange rates may affect the value of the Products.

Furthermore, the exchange of different currencies related to the Products or the Underlyings may cause transaction costs which can negatively impact the value of the Products and might not be seen as ideal exchange rates by the Holders of the Products. Fluctuations in exchange rates might also affect Products in the case of a conversion of gains or losses from the exercise or sale of such Products into the respective home currency of investors.

Where the calculation of any Cash Settlement Amount involves a currency conversion (for example between the currency of a share serving as Underlying to which the value of the Products may relate and the Settlement Currency) fluctuations in the relevant exchange rate will directly affect the value of the relevant Products.

### **Certain additional Risk Factors associated with Products relating to Currencies or Commodities**

Fluctuations in exchange rates of the relevant currency (or basket of currencies) will affect the value of Products relating thereto. Furthermore, investors who intend to convert gains or losses from the exercise or sale of Products into their home currency may be affected by fluctuations in exchange rates between their home currency and the relevant currency (or basket of currencies). Purchasers of certain Products relating to currencies or commodities risk losing their entire investment if exchange rates of the relevant currency (or basket of currencies) do not move in the anticipated direction.

### **Certain additional Risk Factors associated with Actively Managed Certificates ("AMCs")**

The risks of an investment in AMCs may be similar to the risks of a direct investment in the Underlying. The performance of an AMC depends on the performance of the Underlying(s), the quality of the decisions made by the Strategy-Manager, and the investment techniques applicable to a specific AMC (see Condition 17(F)). Past performance is not a guarantee for future developments and the performance is not foreseeable at the point in time of the investment decision. Furthermore, it is not certain that all Adjustments of the Strategy-Components intended by the Strategy-Manager may be implemented and its expectations regarding the development of the value of the Product will be fulfilled. A total loss of the investment may occur, if the Underlying(s) become worthless, respectively, the Strategy-Level decreases to zero.

## **Interest Rates**

Prospective purchasers of the Products should be aware that an investment in the Products may involve interest rate risk in the sense that the intrinsic value of a Product will be sensitive to fluctuations in interest rates.

Interest rates are determined by factors of supply and demand in the international money markets which are affected by macro economic factors, complex political factors, speculation, central bank and government intervention and other market forces. Fluctuations in short term and/or long term interest rates may affect the value of the Products. Fluctuations in interest rates of the currency in

which the Products are denominated and/or fluctuations in interest rates of the currency or currencies in which the Underlying is denominated may affect the value of the Products.

### **Option to vary Settlement**

Unless the applicable Final Terms in respect of any Products indicate otherwise, the Issuer has an option to vary settlement in respect of such Products. The Issuer may, at its sole and unfettered discretion, elect (1) not to pay the relevant Holders of Products the Cash Settlement Amount, but to deliver or procure delivery of the Entitlement or (2) not to deliver or procure delivery of the Entitlement, but to make payment of the Cash Settlement Amount on the Settlement Date to the relevant Holders of Products.

### **Possible Illiquidity or Restricted Tradability of the Products in the Secondary Market**

It is not possible to predict the price at which Products will trade in the secondary market or whether such market will be liquid or illiquid (or be subject to a restricted tradability). Pricing information for the Products may be difficult to obtain and the liquidity/tradability of the Products may be adversely affected. Also, to the extent Products of a particular issue are exercised, the number of Products of such issue outstanding will decrease, resulting in a diminished liquidity for the remaining Products of such issue. A decrease in the liquidity of an issue of Products may cause, in turn, an increase in the volatility associated with the price of such issue of Products.

The Issuer may, but is not obligated to, at any time purchase Products at any price in the open market or by tender or private treaty. Any Products so purchased may be held or resold or cancelled. The Issuer may, but is not obliged to, be a market maker for an issue of Products. Even if the Issuer acts as a market maker for an issue of Products, the secondary market for such Products may be limited. To the extent that an issue of Products becomes illiquid, an investor may have to exercise such Products to realise value.

### **Fluctuations in Market Volatility may affect the Value of certain Products**

Market volatility reflects the degree of instability and expected instability of the performance of a Underlying over time. The level of market volatility is not purely a measurement of the actual market volatility, but is largely determined by the prices for Products that offer investors protection against such market volatility. The prices of these instruments are determined by forces of supply and demand in the options and derivatives markets. These forces are, in turn, affected by factors such as actual market volatility, expected market volatility, other economic and financial conditions, and trading speculation.

### **The Issuer has not investigated the Underlyings to which the Value of the relevant Products may relate.**

The Underlyings are selected without regard for the value, price performance, volatility or investment merit of such reference instrument. In particular, the Issuer has not performed any investigation or review of any company issuing any reference security, including any public filings by such companies.

Investors should not conclude that the inclusion of the securities of any company is any form of investment recommendation by the Issuer. Consequently, there can be no assurance that all events occurring prior to the relevant issue date of the relevant Products (including events that would affect the accuracy or completeness of the publicly available documents described in this paragraph or in any annex (if applicable) to any applicable Final Terms) that would affect the trading price of the Underlying will have been publicly disclosed. Subsequent disclosure of any such events or the disclosure of or failure to disclose material future events concerning a company issuing any reference security could affect the trading price of the Underlying and therefore the trading price of the Products.

## **Risks related to Conflicts of Interest**

The Issuer may from time to time engage in transactions involving one or more of the Underlyings for its proprietary accounts and for other accounts under its management. The Issuer may also act as underwriter in connection with future offerings of shares or other securities to which Products relate or financial adviser to certain companies or companies whose shares or other securities serve as Underlyings or which are included in a basket of securities serving as Underlying or may otherwise act in a commercial banking capacity for such companies (including extending loans to, making equity investments in, or providing advisory services to such company). Furthermore, the Issuer or other parties involved in the launch or management of Products (e.g., a Strategy-Manager of AMCs) may act as Distributor or in other functions related to specific Products. In particular, conflicts of interest could arise if the Distributor of Products (and/or Strategy-Manager of AMCs) is at the same time the asset manager or investment advisor of the Holder of the Product. All these activities could cause certain potential or actual conflicts of interest, could influence the prices of shares or other securities, and could adversely affect the value of the Products.

No issuer of Underlyings is involved in the offering of Products related to itself in any way and has no obligation to consider the interests of the Holders of Products in taking any corporate actions that might affect the value of the Products. No proceeds from the offering of Products are received by a related issuer of Underlyings. On the other hand, it follows from this separation that the Issuer will also not be able to provide for the exercise of any voting rights, or delivery of rights or title to the shares serving as Underlying(s) of the relevant Product following any such corporate action or business engagement by the issuers of Underlyings and/or their affiliates.

## **Illegality or Disruption**

If the Issuer determines that its performance under any Products or that any arrangements made to hedge the Issuer's obligations under any Products have become illegal or disrupted in whole or in part for any reason, such Issuer may cancel such Products and pay the Holder of each such Products an amount equal to the fair market value of such Products notwithstanding such illegality or disruption less the cost to such Issuer and/or any of its agents of unwinding any Underlying related hedging arrangements plus, if already paid, the Exercise Price, if any, all as determined by the Calculation Agent in its sole and absolute discretion.

## **Market Disruption Event**

If an issue of Products includes provisions dealing with the occurrence of a Market Disruption Event or a failure to open of an exchange or related exchange on a Valuation Date or an Averaging Date and the Calculation Agent determines that a Market Disruption Event or such failure has occurred or exists on a Valuation Date or an Averaging Date, any consequential postponement of the Valuation Date or Averaging Date or any alternative provisions for valuation provided in any Products may have an adverse effect on the value of such Products.

## **Settlement Disruption Event**

In the case of Physical Delivery Products, if a Settlement Disruption Event occurs or exists on the Settlement Date, settlement will be postponed until the next Settlement Business Day on which no Settlement Disruption Event occurs. The Issuer in these circumstances also has the right to pay the Disruption Cash Settlement Price (as defined in the Terms and Conditions) in lieu of delivering the Entitlement. Such a determination may have an adverse effect on the value of the relevant Products.

## **Subprime Exposure**

Money market instruments such as treasury bills, certificates of deposit and short-term commercial debt, including money market funds, may serve as Underlyings of the Products. Although money market instruments used to be considered virtually risk-free, some of the largest money market funds have been putting part of their cash into collateralised debt obligations backed by subprime mortgage

loans. Since subprime debt must be considered far from safe, such an investment may create significant risks for investors.

### **Market Risk**

The Issuer's various businesses may be adversely impacted by global market conditions and economic conditions that may cause fluctuations in interest rates, exchange rates, equity, debt, commodity or other prices and credit spreads. The financial services industry and the global financial markets are influenced by numerous unpredictable factors including economic conditions, monetary and fiscal policies, the liquidity of global markets, availability and cost of capital, international and regional political events, acts of war or terrorism, pandemics, and investor sentiment. These factors or changes thereof may result in changes of the volatility in interest rates, exchange rates, prices of financial instruments (including, but not limited to, Products), and credit spreads. The Issuer has some trading and investment positions, which include proprietary trading positions in fixed income, currency and equity securities, as well as in other investments. The Issuer may incur losses as a result of increased market volatility, as these fluctuations may adversely impact the valuation of its trading and investment positions. Conversely, a decline in volatility may adversely affect the results in the Issuer's trading businesses, which depend on market volatility to create client and proprietary trading opportunities.

### **Credit Risk**

The Issuer may incur losses from its credit exposure related to trading, lending, and other business activities. The Issuer is exposed to the potential credit-related losses that can occur as a result of an individual, counterparty or issuer being unable or unwilling to honor its contractual obligations. These credit exposures exist within lending relationships, commitments, letters of credit, bonds, notes, derivatives, foreign exchange and other transactions. These exposures may arise, for example, from a decline in the financial condition of a counterparty, from a decrease in the value of securities of third parties held by the Issuer as collateral, from entering into swap or other derivative contracts under which counterparties have long-term obligations to make payments to the Issuer, and from extending credit to clients through loans or other arrangements. An increase in the Issuer's credit exposure could have an adverse effect on its business and profitability if credit losses exceed credit provisions.

### **Operational Risk**

The Issuer may incur losses from inadequate or failed internal processes, people and systems or from external events. The Issuer may incur losses arising from its exposure to operational risk. Financial services firms, including the Issuer, are exposed to the risk of loss resulting from inadequate or failed internal processes, people and systems or from external events. Such operational risks may include, for example, exposure to natural or man-made disasters, mistakes made in the confirmation or settlement of transactions or from improper recording, evaluating or accounting for transactions. The Issuer could suffer financial loss, disruption of its business, liability to clients, regulatory intervention or reputational damage, which would affect its business and financial condition.

### **Liquidity Risk**

The Issuer's business and financial condition may be adversely impacted by an inability to borrow funds or sell assets to meet maturing obligations. Financial services firms, including the Issuer, are exposed to liquidity risk, which is the potential inability to repay short-term borrowings with new borrowings or assets that can be quickly converted into cash while meeting other obligations and continuing to operate as a going concern. The Issuer's liquidity may be impaired due to circumstances that it may be unable to control, such as general market disruptions or an operational problem that affects its trading clients, third parties or itself. The Issuer's ability to sell assets may also be impaired if other market participants are seeking to sell similar assets at the same time. The inability of the Issuer to borrow funds or sell assets to meet maturing obligations, a negative change in its credit ratings, which would have an adverse effect on its ability to borrow funds, or regulatory capital restrictions imposed on the Issuer may have a negative effect on its business and financial condition.



## **Litigation Risk**

Legal proceedings could adversely affect the Issuer's operating results and financial condition for a particular period and impact its credit ratings.

## **Regulatory and Legislative Risks**

Many of the Issuer's businesses are highly regulated and could be adversely impacted by regulatory and legislative initiatives, revised laws or changing practices of courts or supervisory authorities around the world. Such regulatory changes could also negatively affect the Holders of the Products. In particular, the new Financial Services Act (FinSA) and the new Financial Institutions Act (FinIA) entered into force in Switzerland on 1 January 2020. These new regulations and their implementing ordinances will, inter alia, have an impact on the production and the point of sale of derivatives and structured products. Violation of applicable laws and regulations (including, but not limited to, tax laws) could result in legal, administrative and/or penal proceedings, which may impose censures, fines, cease-and-desist orders or suspension of a firm, its officers or employees. Supervision and regulation of the financial services industry has increased over the past several years, which has led to increased regulatory or other investigations and litigation against financial services firms.

Legislation and rules adopted both in Switzerland and around the world have imposed substantial new and more stringent regulations, internal practices, capital requirements, procedures and controls and disclosure requirements. This is in such areas as financial services and products regulation, financial reporting, corporate governance, auditor independence, equity compensation plans, restrictions on the interaction between equity research analysts and investment banking employees and anti-money laundering. The trend and scope of increased regulatory and compliance requirements may require the Issuer to invest in additional resources in related areas.

The Issuer's reputation is critical in maintaining their relationships with clients, investors, regulators and the general public and is a key focus in the Issuer's risk management efforts. However, the Issuer is or may become involved in a number of judicial, regulatory, arbitration, penal or other proceedings or investigations concerning matters arising in connection with the conduct of its business.

## **Competitive Environment**

Competitive pressures in the financial services industry in which the Issuer operates could adversely affect its business and results of operations. The Issuer competes for individual and institutional clients on the basis of prices, the range of products that it offers, the quality of its services, its financial resources, and product and service innovation. The financial services industry continues to be affected by an intensifying competitive environment, as demonstrated by the introduction of new technologies, technology platforms, consolidation through mergers, increased competition from new and established industry participants and diminishing margins in many mature products and services. The Issuer competes for investments by investors with mutual fund management companies, insurance companies, finance and investment advisory companies, banks, fintech companies, trust companies, and other competitors. In addition, the Issuer's business is substantially dependent on its continuing ability to compete effectively to attract and retain qualified employees, including successful financial advisers, investment bankers, trading professionals and other revenue-producing or support personnel.

## **Benchmark and Reference Rates related Risks**

Benchmarks and/or other reference rates (e.g. LIBOR, SARON, EURIBOR, ICE Swap rates, or other reference rates or prices) that may be relevant for the pricing of Products may be inaccurate or incorrect due to calculation errors, negligence or fraud and/or be subject to current or future regulation or reforms that may impact the calculation of such benchmarks. This may adversely affect the evaluation or the pricing of the Products and cause losses to Holders of Products. In addition, certain benchmarks and/or reference rates may be subject to reforms or be abolished and/or replaced entirely.

## **Risks related to Outbreaks of Infectious Diseases**

The business of the Issuer as well as the value of the Products are subject to risks related to pandemics (such as the Corona pandemic), epidemics, endemics, or other large-scale outbreaks of infectious diseases which may greatly increase morbidity and mortality over a geographic area or a particular group of people and cause significant economic, social, political, and market disruption. Such events may also cause a higher volatility of the Underlyings of the Products. The likelihood of such events has increased over the past century due to increased global travel and integration, urbanization as well as other trends. These trends as well as the risks related to outbreaks of infectious diseases may continue and intensify.

## **Changes in Tax Law**

Tax law and practice is subject to change, possibly with retrospective effect, and this could adversely affect the value of the Products to the Holder of the Products and/or the market value of the Products. Any such change may (i) cause the tax treatment of the relevant Products to change from what the Holder of the Product understood the position to be at the time of purchase; (ii) render the statements in this Programme concerning relevant tax law and practice in relation to Products under the Programme to be inaccurate or to be inapplicable in some or all respect to certain Products or to not include material tax considerations in relation to certain Products; or (iii) give the Issuer the right to amend the Terms and Conditions, or redeem the Products, if such change has the effect that the Issuer's performance under the Product is unlawful or impracticable.

***Prospective purchasers of any Products should consult their own tax advisers in relevant jurisdictions about the tax implications of holding any Product and of any transaction involving any Product.***

## **U.S. Investors in the Products are not permitted**

The Products may not at any time be offered, sold, pledged or otherwise transferred in the United States or to a person that is not a Permitted Transferee (as defined herein). Accordingly, any purported transferee of any legal or beneficial ownership interest in a Product in such a transaction will not be entitled to any rights as a legal or beneficial owner of such interest in such Product. The Issuer shall have the right at any time after becoming aware that any legal or beneficial ownership interest in a Product is held by a person other than a Permitted Transferee to require such person to sell such interest to (a) the Issuer (to the extent permitted by applicable law) or (b) a person who is a Permitted Transferee. The foregoing restrictions on the offer, sale, pledge or other transfer of Products to persons other than Permitted Transferees may adversely affect the ability of an investor in the Products to dispose of the Products in the secondary market, if any, and significantly reduce the liquidity of the Products. As a result, the value of the Products may be materially and adversely affected.

## **Swiss Bankers Association's Brochure "Special Risks in Securities Trading"**

Potential Holders of the Products should refer to the brochure "Risks Involved in Trading Financial Instruments" (see <https://www.swissbanking.org/en/services/library/guidelines>) of the Swiss Bankers Association, as amended from time to time, which shall be deemed to be incorporated in, and to form part of, the Base Prospectus, for a more detailed description of the risks associated with an investment in the Products. Holders of the Products are deemed to have read and understood and, if necessary discussed this brochure and the explanations contained therein with their legal, tax and financial advisers.

## TERMS AND CONDITIONS

**The following is the text of the general Terms and Conditions of the Products.**

Each issue of Products will, if not otherwise specified in the applicable Final Terms, be represented by a permanent global certificate according to Art. 973b Swiss Code of Obligations ("**CO**") (the "**Permanent Global Certificate**") which will be issued and deposited with SIX SIS AG, Olten ("**SIS**"). Definitive Products and coupons, if any, to which a Holder of Products is entitled according to the applicable Final Terms (each a "**Coupon**" and collectively the "**Coupons**") shall only be issued by the Issuer in the event of default by the Issuer or if SIS goes out of business without a successor. If issued, definitive Products and Coupons, if any, shall exclusively be issued in registered form. The Issuer shall arrange for the printing of the definitive Products and Coupons in registered form at their own cost and arrange for delivery of the definitive Products and Coupons to SIS, Euroclear Bank S.A./N.V., as operator of the Euroclear system ("**Euroclear**") or Clearstream Banking, société anonyme ("**Clearstream, Luxembourg**"), as the case may be, for distribution (free of charge) to the Holders of the Products and Coupons. The Holders of the definitive Products and Coupons, if any, shall be registered in the register of Holders of the definitive Products and Coupons, if any, kept by a registrar to be appointed by the Issuer at the time of issuance of the definitive Products and Coupons, if any, in registered form.

If specified in the applicable Final Terms, Products will be booked into the SIS system as uncertificated securities according to Art. 973c CO (*unverurkundete Wertrechte*) (the "**Uncertificated Securities**"). The integration of Uncertificated Securities into the SIS-giro-system is based on an agreement concluded between SIS and the Issuer. Once the Uncertificated Securities are registered in the Main Register of the Clearing System and entered into the accounts of one or more participants of the Clearing System, the Products will constitute Intermediated Securities (*Bucheffekten*) according to Art. 3 para. 1 of the Swiss Federal Intermediated Securities Act (*Bucheffektengesetz*) ("**FISA**") (the "**Intermediated Securities**"). The creation of a supply of Intermediated Securities is constitutive and replaces the issuance of individual security deeds or a global security deed. SIS may effect changes to the supply of Intermediated Securities (increase/decrease) in accordance with instructions given by HB. After the creation of the Intermediated Securities supply, transactions in Intermediated Securities will be effected through securities accounts in accordance with the general terms and conditions of SIS and the further body of rules and regulations pursuant to Art. 10 of the general terms and conditions of SIS. The rights arising from the terms of the Products exist vis-à-vis the Issuer and may be asserted against the Issuer with the respective supply disclosure statement issued by SIS. No legal claims with respect to Intermediated Securities, irrespective of their booking, may be asserted against SIS.

The applicable Final Terms for the Products supplement these general Terms and Conditions and may specify other terms and conditions which shall, to the extent so specified or to the extent inconsistent with these Terms and Conditions, supplement, replace or modify these Terms and Conditions for the purposes of the Products. References herein to the "**applicable Final Terms**" are to the Final Terms or several Final Terms (in the case of any further Products issued pursuant to Condition 12 and forming a single series with the Products). Words and expressions defined in the applicable Final Terms shall have the same meanings where used in these Terms and Conditions unless the context otherwise requires or unless otherwise stated. The Final Terms may be published in an indicative and/or final version. The final version of the Final Terms replaces the indicative version thereof. In case of discrepancies between the indicative version and the final version of the Final Terms only the final version thereof is binding. The Issuer may update the indicative or final version of the Final Terms of a Product from time to time at its own discretion. The Holders of the Products agree to such one-sided updates and related changes of the Final Terms by the Issuer by investing in the Products. Copies of the applicable Final Terms are available for inspection at the office of the Issuer in Zurich.

The Holders of Products (as defined in Condition 1(B)) are entitled to the benefit of, are deemed to have notice of, and are bound by all the provisions of the Programme (insofar as they relate to the Products) and the applicable Final Terms.

## 1. Type, Title and Transfer

### (A) *Type*

If the Products are booked into the SIS system as Intermediated Securities, the Products are issued in registered, dematerialised and uncertificated book-entry form and the Products will be booked into the SIS system as uncertificated securities (*unverurkundete Wertrechte*) according to Art. 973c CO and Art. 3 FISA and thereby become Intermediated Securities (*Bucheffekten*), and no physical document of title will be issued in respect of the Products.

The Products are derivatives and structured products, including, but not limited to, warrants of any kind, certificates and structured notes. Such Products may be, inter alia, any product type foreseen by the Swiss Structured Products Association's categorisation model. The Products will be linked, for example, to a specified index or a basket of indices ("**Index Warrants**", "**Index Certificates**" and "**Index-linked Notes**"), a specified share or a basket of shares ("**Share Warrants**", "**Share Certificates**" and "**Share-linked Notes**"), a specified debt instrument or a basket of debt instruments ("**Debt Warrants**", "**Debt Certificates**" and "**Debt-linked Notes**"), a specified currency or a basket of currencies ("**Currency Warrants**", "**Currency Certificates**" and "**Currency-linked Notes**") or a specified commodity or a basket of commodities ("**Commodity Warrants**", "**Commodity Certificates**" and "**Commodity-linked Notes**"), a strategy, or linked to any further assets meant to serve as Underlying(s) by the Issuer. Certain terms which will, unless otherwise varied in the applicable Final Terms, apply to Index Warrants, Share Warrants, Debt Warrants, Currency Warrants, Commodity Warrants, Share Certificates, Commodity Certificates, Currency Certificates, Debt Certificates, Index Certificates, Index-linked Notes, Share-linked Notes, Debt-linked Notes, Currency-linked Notes or Commodity-linked Notes are set out in Condition 17.

The applicable Final Terms will, if applicable, indicate whether the Products are American Style Products ("**American Style Products**") or European Style Products ("**European Style Products**") or such other type as may be specified in the applicable Final Terms, whether settlement can be by way of cash payment ("**Cash Settled Products**") or physical delivery ("**Physical Delivery Products**") or both and whether the Products are call Products ("**Call Products**"), put Products ("**Put Products**") or certificates ("**Certificates**"), whether the Products entitle to a Coupon, and whether Averaging ("**Averaging**") will apply to the Products. If Averaging is specified as applying in the applicable Final Terms the applicable Final Terms will state the relevant Averaging Dates and, in the case of a Market Disruption Event (as defined in Condition 17) occurring on an Averaging Date, whether Omission, Postponement or Modified Postponement (each as defined in Condition 3 below) applies.

References in these Terms and Conditions, unless the context otherwise requires, to Cash Settled Products shall be deemed to include references to Physical Delivery Products, which include an option (as set out in the applicable Final Terms) by the Issuer or the Holder of the Products to elect cash settlement of such Products. References in these Terms and Conditions, unless the context otherwise requires, to Physical Delivery Products shall be deemed to include references to Cash Settled Products, which include an option (as set out in the applicable Final Terms) by the Issuer or the Holder of the Products to elect physical delivery of the Underlying(s) in settlement of such Products. The rights of a Holder as described in this paragraph may be subject to the Issuer's right to vary settlement as indicated in the applicable Final Terms and accordingly, the interpretation rule as described just above, will apply to these Terms and Conditions.

### (B) *Title to Products*

As long as the title to Products is not printed, with respect to each Product and Coupon, the person shown in the records of SIS or, in the case of Products and Coupons held through

Clearstream Luxembourg or Euroclear (together with SIS, the "**Clearance Institutions**") the Swiss banking correspondent of such clearance institution shall be treated by the Issuer as the Holder of such amount of Products or Coupons for all purposes (and the expressions "**Holder of Products**", "**Couponholder**" and related expressions shall be construed accordingly).

If the Products are booked into the SIS system as Intermediated Securities, Holder of Products means the person in whose name a Product is registered in the register maintained at the SIS (the "**SIS Register**"), and the reference to a person in whose name a Product is registered shall also include any person whose Products are nominee-registered. Title to Products shall pass by transfer between accountholders at the SIS as evidenced by registration in the Swiss Register in accordance with the rules, regulations and procedures of the SIS (the "**SIS Rules**"). Except as ordered by a court of competent jurisdiction or as required by law, the Holder of any Product shall, to the extent permitted by law, be deemed to be and may be treated as its absolute owner for all purposes, whether or not it is overdue and regardless of any notice of ownership, trust or an interest in it, and no person shall be liable for so treating the Holder of Products. The Issuer shall be entitled to obtain information in respect of title to the Products from the SIS.

**Holders of the Products cannot demand the delivery of individual certificates for Products certificated in the form of one or more permanent global certificates or issued as uncertificated securities.**

(C) *Transfers of Products*

All transactions (including transfers of Products) in the open market or otherwise must be effected through the relevant Clearance Institution, subject to and in accordance with the rules and procedures for the time being of such Clearance Institution. Title will pass upon registration of the transfer in the books of the relevant Clearance Institution. Transfers of Products may not be effected after the exercise of such Products pursuant to Condition 5.

Any reference herein to the Clearance Institution shall, whenever the context so permits, be deemed to include a reference to any additional or alternative clearing system approved by the Issuer from time to time and notified to the Holders of Products in accordance with Condition 10.

If the Products are booked into the SIS system as Intermediated Securities, title to Products shall pass by transfer between accountholders at the SIS as evidenced by registration in the SIS Register in accordance with the SIS Rules.

**2. Status of the Products**

The Products and Coupons, if any, constitute direct, unconditional, unsecured and unsubordinated obligations of the Issuer and rank pari passu with all present and future, unsecured and unsubordinated obligations without any preference among themselves and without any preference one above the other by reason of priority of date of issue, currency of payment or otherwise, except for obligations given priority by law.

**3. Definitions**

For the purposes of these Terms and Conditions, the following general definitions shall apply:

**"Actual Exercise Date"** means the Exercise Date (in the case of European Style Products) or, in the case of American Style Products as more fully set out in Condition 4(A)(i) below, the date during the Exercise Period on which the Product is actually or deemed exercised (in accordance with Condition 6(A)(ii) below);

**"Averaging Date"** means, in respect of an Actual Exercise Date, each date specified as an Averaging Date in the applicable Final Terms or, if any such date is not a Trading Day, the immediately following Trading Day unless, in the opinion of the Issuer, a Market Disruption Event (as set out in Condition 17(A)(1)) has occurred on that day. If there is a Market Disruption Event on that day, then:

- (a) if **"Omission"** is specified as applying in the applicable Final Terms, then such date will be deemed not to be an Averaging Date for purposes of determining the relevant Settlement Price. Therefore, if through the operation of this provision there would not be an Averaging Date in respect of such Actual Exercise Date, then the provisions of the definition of **"Valuation Date"** will apply for purposes of determining the relevant level, price or amount on the final Averaging Date with respect to that Actual Exercise Date as if such Averaging Date were a Valuation Date on which a Market Disruption Event had not occurred;
- (b) if **"Postponement"** is specified as applying in the applicable Final Terms, then the provisions of the definition of **"Valuation Date"** will apply for purposes of determining the relevant level, price or amount on that Averaging Date as if such Averaging Date were a Valuation Date on which a Market Disruption Event had occurred irrespective of whether, pursuant to such determination, that deferred Averaging Date would fall on a day that already is or is deemed to be an Averaging Date;
- (c) if **"Modified Postponement"** is specified as applying in the applicable Final Terms,
  - (i) where the Products are Index Warrants, Index Certificates or Index-linked Notes relating to a single Index or Share Warrants, Share Certificates or Share-linked Notes relating to a single Share, the Averaging Date shall be the first succeeding Valid Date (as defined below). If the first succeeding Valid Date has not occurred as of the Valuation Time on the fifth Trading Day immediately following the original date that, but for the occurrence of another Averaging Date or Market Disruption Event, would have been the final Averaging Date in relation to such Actual Exercise Date, then (A) that fifth Trading Day shall be deemed the Averaging Date (irrespective of whether that fifth Trading Day is already an Averaging Date), and (B) the Issuer shall determine the relevant level or price for that Averaging Date in accordance with sub-paragraph (a)(ii) of the definition of **"Valuation Date"** below;
  - (ii) where the Products are Index Warrants, Index Certificates or Index-linked Notes relating to a Basket of Indices or Share Warrants, Share Certificates or Share-linked Notes relating to a Basket of Shares, the Averaging Date for each Index or Share not affected by a Market Disruption Event shall be the originally designated Averaging Date (the **"Scheduled Averaging Date"**) and the Averaging Date for an Index or Share affected by the Market Disruption Event shall be the first succeeding Valid Date (as defined below) in relation to such Index or Share. If the first succeeding Valid Date in relation to the affected Index or Share has not occurred as of the Valuation Time on the fifth Trading Day immediately following the original date that, but for the occurrence of another Averaging Date or Market Disruption Event, would have been the final Averaging Date in relation to such Actual Exercise Date, then (A) that fifth Trading Day shall be deemed the Averaging Date (irrespective of whether that fifth Trading Day is already an Averaging Date) in relation to the affected Index or Share, and (B) the Issuer shall determine the relevant Index or Share level or amount for that Averaging Date in accordance with sub-paragraph (b)(ii) of the definition of **"Valuation Date"** below; and

- (iii) where the Products are Debt Warrants, Debt Certificates, Debt-linked Notes, Currency Warrants, Currency Certificates, Currency-linked Notes, Commodity Warrants, Commodity Certificates or Commodity-linked Notes, provisions for determining the Averaging Date in the event of Modified Postponement applying will be set out in the applicable Final Terms;

for the purposes of these Terms and Conditions "**Valid Date**" means a Trading Day on which there is no Market Disruption Event and on which another Averaging Date in relation to the Actual Exercise Date does not or is not deemed to occur;

"**Business Day**" means (i) a day (other than a Saturday or Sunday) on which commercial banks are open for business (including dealings in foreign exchange and foreign currency deposits) in the relevant Business Day center(s) and the relevant Clearance System(s) is/are open for business and (ii) on which money transfers are permitted to be settled in accordance with generally recognised Swiss banking practice and (iii) for the purposes of payments in euro, a day on which the Trans-European Automated Real-Time Gross Settlement Express Transfer (TARGET) System is open;

"**Cash Settlement Amount**" means, in relation to a Cash Settled Product, the amount as specified in the applicable Final Terms to which the Holder of a Product is entitled to receive on the Settlement Date in the Settlement Currency in relation to each such Product, or, if a ratio of Products per unit of the Underlying(s) is specified in the applicable Final Terms, in relation to the specified number of Products per unit of the Underlying(s), as determined by the Issuer pursuant to Condition 4;

"**Entitlement**" means, in relation to a Physical Delivery Product, the quantity of the Underlying(s) or the Underlying(s) determined by the Issuer, which a Holder of a Product is entitled to receive (e.g. Call Products) or obliged to deliver (Put Products) on the Settlement Date in respect of each such Product or, if a ratio of Products per unit of the Underlying(s) is specified in the applicable Final Terms, in respect of the specified number of Products, following payment of the Exercise Price (and any other sums payable), if any, rounded down as provided in Condition 4(C)(i), and upon review of any documents evidencing the relevant Products;

"**Relevant Time**" means the time specified on the Valuation Date or an Averaging Date, as the case may be, for the calculation of the Settlement Price. It shall be, unless differently specified in the Final Terms:

- (a) where the Products are (i) European Style Products relating to Swiss Underlying(s) only or (ii) in case the Products are American Style Products relating to Swiss Underlying(s) and if automatically exercised in accordance with Condition 4(A)(i), at or around 2.15 p.m. (in Zurich);
- (b) in any other cases the closing of the relevant Exchange(s) or, as regards Products relating to a Basket of Underlying(s), reporting of the last selling prices of the Underlying(s) on the relevant Exchange(s);

"**Settlement Business Day**" means a day on which transfers of the Underlying(s) are permitted to be settled in accordance with generally recognised banking practice;

"**Settlement Date**" means:

- (a) in relation to Cash Settled Products:

in relation to each Actual Exercise Date, (i) where **Averaging** is not specified in the applicable Final Terms, the fifth Business Day following the Valuation Date.

However, if the Products are Index Warrants, Index Certificates or Index-linked Notes relating to a Basket of Indices, Share Warrants, Share Certificates or Share-linked Notes relating to a Basket of Shares, Debt Warrants, Debt Certificates or Debt-linked Notes relating to a Basket of Debt Certificates, Commodity Warrants, Commodity Certificates or Commodity-linked Notes relating to a Basket of Commodities, Currency Warrants, Currency Certificates or Currency-linked Notes relating to a Basket of Currencies and a Market Disruption Event (as set out in Condition 17) for one or more of the Indices, Shares, Debt Securities, Commodities or Currencies, as the case may be, has resulted in a Valuation Date being adjusted as set out in the definition of "**Valuation Date**" below, the Settlement Date shall be the fifth Business Day next following the last occurring Valuation Date in relation to any Index, Share, Debt Security, Commodity or Currency, as the case may be; or (ii) where Averaging is specified in the applicable Final Terms, the fifth Business Day following the last occurring Averaging Date. However, if the Products are Index Warrants, Index Certificates or Index-linked Notes relating to a Basket of Indices, Share Warrants, Share Certificates or Share-linked Notes relating to a Basket of Shares, Debt Warrants, Debt Certificates or Debt-linked Notes relating to a Basket of Debt Securities, Commodity Warrants, Commodity Certificates or Commodity-linked Notes relating to a Basket of Commodities, Currency Warrants, Currency Certificates or Currency-linked Notes relating to a Basket of Currencies and a Market Disruption Event (as set out in Condition 17) for one or more Indices, Shares, Debt Securities, Commodities or Currencies, as the case may be, has resulted in an Averaging Date being adjusted as set out in the definition of "**Averaging Date**" above, the Settlement Date shall be the fifth Business Day next following the last occurring Averaging Date in relation to any Index, Share, Debt Security, Commodity or Currency, as the case may be, or such other date as is specified in the applicable Final Terms; and

- (b) in relation to Physical Delivery Products:

the fifth Business Day following the Actual Exercise Date;

"**Settlement Price**" means, if not otherwise specified in the applicable Final Terms, in relation to each Cash Settled Product:

- (a) in respect of Index Warrants, Index Certificates or Index-linked Notes, subject to Condition 17(A) and as referred to in "**Valuation Date**" below or "**Averaging Date**" and "**Relevant Time**" above, as the case may be:
- (i) in the case of Index Warrants, Index Certificates or Index-linked Notes relating to a Basket of Indices, an amount (which shall be deemed to be a monetary value on the same basis as the Exercise Price) equal to the sum of the values calculated for each Index as the level of each Index determined by the Issuer at the Relevant Time on (A) if **Averaging** is not specified in the applicable Final Terms, the Valuation Date or (B) if Averaging is specified in the applicable Final Terms, an Averaging Date and, in either case, without regard to any subsequently published correction, multiplied by the relevant Multiplier; and
- (ii) in the case of Index Warrants, Index Certificates or Index-linked Notes relating to a single Index, an amount (which shall be deemed to be a monetary value on the same basis as the Exercise Price) equal to the level of the Index determined by the Issuer at the Relevant Time on (A) if Averaging is not specified in the applicable Final Terms, the Valuation Date or (B) if Averaging is specified in the applicable Final Terms, an Averaging Date and, in either case, without regard to any subsequently published correction. In the case of Index Warrants, Index Certificates or Index-linked Notes relating to a Swiss index which are exercised on the Expiration Date, the amount shall be



equal to the official closing price or settlement price, as the case may be, of the relevant index on the Expiration Date;

- (b) in respect of Share Warrants, Share Certificates or Share-linked Notes, subject to Condition 17(B) and as referred to in "**Valuation Date**" below or "**Averaging Date**" and "**Relevant Time**" above, as the case may be:
- (i) in the case of Share Warrants, Share Certificates or Share-linked Notes relating to a Basket of Shares, an amount equal to the sum of the values calculated for each Share at the price at the Relevant Time for such Share (as defined in Condition 17(B)) on (A) if **Averaging** is not specified in the applicable Final Terms, the Valuation Date or (B) if Averaging is specified in the applicable Final Terms, an Averaging Date, multiplied by the relevant Multiplier, each such value to be converted, if so specified in the applicable Final Terms, into the Settlement Currency at the Exchange Rate and the sum of such converted amounts to be the Settlement Price, all as determined by or on behalf of the Issuer; and
  - (ii) in the case of Share Warrants, Share Certificates or Share-linked Notes relating to a single Share, an amount equal to the price at the Relevant Time for such Share (as defined in Condition 17(B)) on (A) if Averaging is not specified in the applicable Final Terms, the Valuation Date or (B) if Averaging is specified in the applicable Final Terms, an Averaging Date, such amount to be converted, if so specified in the applicable Final Terms, into the Settlement Currency at the Exchange Rate and such converted amount to be the Settlement Price, all as determined by or on behalf of the Issuer;

If, in the opinion of the Issuer, no price of such Share at the Relevant Time can be so determined and no Market Disruption Event has occurred and is continuing, the Settlement Price will be an amount determined by the Issuer in good faith to be equal to the arithmetic mean of the fair market buying price at the Relevant Time and the fair market selling price at the Relevant Time. For the relevant Share whose price at the Relevant Time cannot be determined, the fair market buying price and fair market selling price shall be based, at the Issuer's discretion, either on the arithmetic mean of the prices observed before the Market Disruption occurred, on middle market quotations provided to it by two or more financial institutions (as selected by the Issuer) engaged in the trading of the relevant Share or on such other factors as the Issuer shall decide;

- (c) in respect of Debt Warrants, Debt Certificates or Debt-linked Notes, subject as referred to in "**Valuation Date**" below or "**Averaging Date**" above:
- (i) in the case of Debt Warrants, Debt Certificates or Debt-linked Notes relating to a Basket of Debt Securities, an amount equal to the sum of the values calculated for each Debt Security at the closing price for such Debt Security as determined by or on behalf of the Issuer by reference to the closing price for such Debt Security appearing on the Relevant Screen Page at the Relevant Time on (A) if **Averaging** is not specified in the applicable Final Terms, the Valuation Date or (B) if Averaging is specified in the applicable Final Terms, an Averaging Date, such closing prices to be expressed as a percentage of the nominal amount of such Debt Security, multiplied by the relevant Multiplier;
  - (ii) in the case of Debt Warrants, Debt Certificates or Debt-linked Notes relating to a single Debt Security, an amount equal to the closing price for the Debt Security as determined by or on behalf of the Issuer by reference to the closing price for such Debt Security appearing on the Relevant Screen Page

at the Relevant Time on (A) if Averaging is not specified in the applicable Final Terms, the Valuation Date or (B) if Averaging is specified in the applicable Final Terms, an Averaging Date, such closing prices to be expressed as a percentage of the nominal amount of the Debt Security;

If such price of the Debt Security is not available, the Settlement Price will be an amount determined by the Issuer in good faith to be equal to the arithmetic mean of the closing prices for such Debt Security at the Relevant Time on the Valuation Date or the Averaging Date, as the case may be, as received by it from two or more market makers in such Debt Security selected by the Issuer;

- (d) in respect of Currency Warrants, Currency Certificates or Currency-linked Notes, the provisions relating to the calculation of the Settlement Price will be set out in the applicable Final Terms;
- (e) in respect of Commodity Warrants, Commodity Certificates or Commodity-linked Notes, the provisions relating to the calculation of the Settlement Price will be set out in the applicable Final Terms;

**"Trading Day"** means any day that is (or, but for the occurrence of a Market Disruption Event (as set out in Condition 17), would have been) a trading day on the Exchange(s) other than a day on which trading on any such Exchange is scheduled to close prior to its regular weekday closing time;

**"Valuation Date"** means, unless differently specified in the Final Terms,

- (a) where the Products relate to Swiss Underlying(s) only, the Actual Exercise Date of the relevant Products, and,
- (b) where the Products relate (also) to non-Swiss Underlying(s), the first Trading Day following the Actual Exercise Date of the relevant Products,

and unless, in the opinion of the Issuer, a Market Disruption Event (as set out in Condition 17) has occurred on that day.

If there is a Market Disruption Event on that day, then:

- (a) where the Products are Index Warrants, Index Certificates or Index-linked Notes relating to a single Index, Share Warrants, Share Certificates, Share-linked Notes relating to a single Share, Debt Warrants, Debt Certificates, Debt-linked Notes relating to a single Debt Security, Commodity Warrants, Commodity Certificates or Commodity-linked Notes relating to a single Commodity, Currency Warrants, Currency Certificates or Currency-linked Notes relating to a single Currency, the Valuation Date shall be the first succeeding Trading Day on which there is no Market Disruption Event, unless there is a Market Disruption Event occurring on each of the five Trading Days immediately following the original date that (but for the Market Disruption Event) would have been the Valuation Date. In that case, (i) the fifth Trading Day shall be deemed to be the Valuation Date (notwithstanding the Market Disruption Event) and (ii) the Issuer acting in good faith, shall determine the Settlement Price in the manner set out in the applicable Final Terms or, if not so set out or if not practicable, determine the Settlement Price:
  - (i) in the case of Index Warrants, Index Certificates or Index-linked Notes, by determining the level of the Index as of the Valuation Time on that fifth Trading Day in accordance with (subject to Condition 17(A)(2)) the formula for and method of calculating the Index last in effect prior to the commencement of the Market Disruption Event using the Exchange traded

price (or if trading in the relevant security/commodity has been materially suspended or materially limited, its good faith estimate of the Exchange traded price that would have prevailed but for that suspension or limitation) as of the Valuation Time on that fifth Trading Day of each security/commodity comprised in the Index; or

- (ii) in the case of Share Warrants, Share Certificates, Share-linked Notes, Debt Warrants, Debt Certificates, Debt-linked Notes, Commodity Warrants, Commodity Certificates, Commodity-linked Notes, Currency Warrants, Currency Certificates or Currency-linked Notes, in accordance with its good faith estimate of the Settlement Price that would have prevailed but for the Market Disruption Event as of the Valuation Time on that fifth Trading Day; or
- (b) where the Products are Index Warrants, Index Certificates or Index-linked Notes relating to a Basket of Indices, Share Warrants, Share Certificates or Share-linked Notes relating to a Basket of Shares, Debt Warrants, Debt Certificates or Debt-linked Notes relating to a Basket of Debt Securities, Commodity Warrants, Commodity Certificates or Commodity-linked Notes relating to a Basket of Commodities or Currency Warrants, Currency Certificates or Currency-linked Notes relating to a Basket of Currencies, the Valuation Date for each Index, Share, Debt Security, Commodity or Currency, as the case may be, not affected by a Market Disruption Event shall be the originally designated Valuation Date and the Valuation Date for each Index, Share, Debt Security, Commodity or Currency, as the case may be, affected (each an "**Affected Item**") by a Market Disruption Event shall be the first succeeding Trading Day on which there is no Market Disruption Event relating to the Affected Item, unless there is a Market Disruption Event relating to the Affected Item occurring on each of the five Trading Days immediately following the original date which (but for the Market Disruption Event) would have been the Valuation Date. In that case, (i) the fifth Trading Day shall be deemed to be the Valuation Date for the Affected Item (notwithstanding the Market Disruption Event) and (ii) the Issuer, acting in good faith, shall determine the Settlement Price using, in relation to the Affected Item, in the case of an Index, the level of that Index determined in the manner set out in the applicable Final Terms, and, in the case of a Share, Debt Security, Commodity or Currency, a price determined in the manner set out in the applicable Final Terms or, if not set out or if not practicable, using:
- (i) in the case of an Index, the level of that Index as of the Valuation Time on that fifth Trading Day determined by reference to the formula for and method of calculating that Index last in effect prior to the commencement of the Market Disruption Event using the Exchange traded price (or, if trading in the relevant security/commodity has been materially suspended or materially limited, its good faith estimate of the Exchange traded price that would have prevailed but for that suspension or limitation) as of the Valuation Time on that fifth Trading Day of each security/commodity comprised in that Index; or
  - (ii) in the case of a Share, Debt Security, Commodity or Currency, its good faith estimate of the price for the Affected Item that would have prevailed but for the Market Disruption Event as of the Valuation Time on that fifth Trading Day;

and otherwise in accordance with the above provisions; and

**"Valuation Time"** means the Relevant Time.

#### 4. **Exercise Rights**

##### (A) *Exercise Period*

##### (i) **American Style Products**

American Style Products are exercisable on any Business Day as defined in the applicable Final Terms during the Exercise Period.

The Business Day during the Exercise Period on which an Exercise Notice is delivered (together with all unmatured Coupons, if any) prior to 12.00 noon, Zurich time (or at any other time as defined in the Final Terms), in the manner as set out in Condition 5 is referred to herein as the "**Actual Exercise Date**". If any Exercise Notice which is delivered, in the manner as set out in Condition 5, after 12.00 noon, Zurich time (or at any other time as defined in the Final Terms), on any Business Day during the Exercise Period, such Exercise Notice will be deemed to have been delivered on the next following Business Day, which Business Day shall be deemed to be the Actual Exercise Date, provided that only such Products in respect of which an Exercise Notice has been delivered in the manner set out in Condition 5 at or prior to 12.00 noon Zurich time (or at any other time as defined in the Final Terms) prior to the last Business Day of the Exercise Period (the "**Expiration Date**") shall be exercised and entitle the Holder of such Product to receive as soon as practicable the Cash Settlement Amount or the Entitlement (as determined in the Final Terms, less any taxes or duties of whatever nature).

##### (ii) **European Style Products**

European Style Products are only exercisable on the Exercise Date as defined in the applicable Final Terms.

Any European Style Product shall, if such Product is "in the money", automatically be exercised and entitle the Holder of such Product to receive as soon as practicable the Cash Settlement Amount or the Entitlement (as determined in the Final Terms, less any taxes or duties of whatever nature).

##### (B) *Cash Settlement*

If the Products are Cash Settled Products, or if the Cash Settlement Amount becomes applicable by function of automatic exercise or otherwise, each such Product or, if a ratio of Products per Underlying(s) is specified in the applicable Final Terms, the specified number of Products per unit of the Underlying(s) entitles its Holder, upon due exercise and subject to certification as to non-U.S. beneficial ownership, to receive from the Issuer on the Settlement Date a Cash Settlement Amount calculated by the Issuer (which shall not be less than zero) equal to:

##### (i) where **Averaging** is not specified in the applicable Final Terms:

##### (a) if such Products are Call Products,

(Settlement Price less Exercise Price) multiplied by, in the case of Debt Warrants only, the Nominal Amount;

##### (b) if such Products are Put Products,

(Exercise Price less Settlement Price) multiplied by, in the case of Debt Warrants only, the Nominal Amount; and

- (c) if such Products are neither Call Products nor Put Products settlement will be as specified in the applicable Final Terms;
- (ii) where **Averaging** is specified in the applicable Final Terms:
- (a) if such Products are Call Products,
 

(the arithmetic mean of the Settlement Prices for all the Averaging Dates less Exercise Price) multiplied by, in the case of Debt Warrants only, the Nominal Amount;
  - (b) if such Products are Put Products,
 

(Exercise Price less the arithmetic mean of the Settlement Prices for all the Averaging Dates) multiplied by, in the case of Debt Warrants only, the Nominal Amount; and
  - (c) if such Products are neither Call Products nor Put Products, settlement will be as specified in the applicable Final Terms.

Any amount determined pursuant to the above, if not an amount in the Settlement Currency, will be converted into the Settlement Currency at the Exchange Rate specified in the applicable Final Terms. The Cash Settlement Amount will be rounded to the nearest two decimal places (or, in the case of Japanese Yen, the nearest whole unit) in the relevant Settlement Currency, 0.005 (or, in the case of Japanese Yen, half a unit) being rounded upwards, with Products exercised at the same time by the same Holder of a Product being aggregated for the purpose of determining the aggregate Cash Settlement Amounts payable in respect of such Products.

(C) *Physical Settlement*

(i) Exercise Rights in relation to Physical Delivery Products

If the Products are Physical Delivery Products, each such Product or, if a ratio of Products per Underlying(s) is specified in the applicable Final Terms, the specified number of Products per unit of the Underlying(s), entitles its Holder, upon due exercise and subject to certification as to non-U.S. beneficial ownership, to receive from the Issuer on the Settlement Date the Entitlement subject to payment of the relevant Exercise Price, if any, any unmaturing Coupons, if any, and any other sums payable.

Products exercised at the same time by the same Holder of a Product will be aggregated for the purpose of determining the aggregate Entitlements in respect of such Products, provided that the aggregate Entitlements in respect of the same Holder of a Product will be rounded down to the nearest whole unit of the Underlying(s) or each of the Underlying(s), as the case may be, in accordance with the ratio specified. Therefore, fractions of the Underlying(s) or of each of the Underlying(s), as the case may be, will not be delivered and no cash adjustment will be made in respect thereof.

Following the exercise of a Share Warrant, Share Certificate or Share-linked Note which is a Physical Delivery Product, all dividends on the relevant Shares to be delivered will be payable to the party that would receive such dividend according to market practice for a sale of the Shares executed on the relevant Actual Exercise Date and to be delivered in the same manner as such relevant Shares. Any such dividends to be paid to a Holder of a Product will be paid to the account specified by the Holder of a Product in the relevant Exercise Notice as referred to in Condition 5(A)(2)(vi).

(ii) Settlement Disruption

If, following the exercise of Physical Delivery Products, in the opinion of the Issuer, delivery of the Entitlement is not practicable by reason of a **Settlement Disruption Event** (as defined below) having occurred and continuing on any Settlement Date, then such Settlement Date for such Products shall be postponed to the first following Settlement Business Day in respect of which there is no such Settlement Disruption Event. The Issuer may elect in its sole discretion to satisfy its obligations in respect of the relevant Product by delivering the Entitlement using such other commercially reasonable manner as it may select and in such event the Settlement Date shall be such day as the Issuer deems appropriate in connection with delivery of the Entitlement in a commercially reasonable manner and that manner of delivery provides for. For the avoidance of doubt, where a Settlement Disruption Event affects some but not all of the Underlying(s) comprising the Entitlement, the Settlement Date for the Underlying(s) not affected by the Settlement Disruption Event will be the originally designated Settlement Date.

In the event that a Settlement Disruption Event will result in the delivery on a Settlement Date of some but not all of the Underlying(s) comprising the Entitlement, the Issuer shall determine in its discretion the appropriate *pro rata* portion of the Exercise Price to be paid by the relevant Holder of a Product in respect of that partial settlement.

For so long as delivery of the Entitlement is not practicable by reason of a Settlement Disruption Event, then in lieu of physical settlement and notwithstanding any other provision hereof, the Issuer may elect in its sole discretion to satisfy and discharge its obligations in respect of the relevant Product by payment to the relevant Holder of a Product of the Disruption Cash Settlement Price (as defined below).

The Issuer shall give notice of such election as soon as practicable in accordance with Condition 10. The Disruption Cash Settlement Price shall be paid on the third Business Day following such notice.

No Holder of a Product shall be entitled to any payment in respect of the relevant Product in the event of any delay in the delivery of the Entitlement due to the occurrence of a Settlement Disruption Event and no liability in respect thereof shall attach to the Issuer.

For the purposes hereof:

**"Disruption Cash Settlement Price"** in respect of any relevant Product shall be the fair market value of such Products (taking into account, where the Settlement Disruption Event affected some but not all of the Underlying(s) comprising the Entitlement and the non-affected Underlying(s) have been duly delivered as provided above, the value of such Underlying(s)), less the cost to the Issuer of unwinding any Underlyings related hedging arrangements, all as determined by the Issuer in its sole and absolute discretion, plus, if and already paid, the Exercise Price (or, where as provided above some Underlying(s) have been delivered, and a *pro rata* portion thereof has been paid, such *pro rata* portion); and

**"Settlement Disruption Event"** means, in the opinion of the Issuer, an event beyond the control of the Issuer as a result of which the Issuer cannot make delivery of the Underlying(s) using the method specified in the applicable Final Terms.

(D) *General*

The purchase of Products does not confer on any Holder of such Products any rights (whether in respect of voting, distributions or otherwise) attaching to any of the Underlying(s).

## 5. Exercise Procedure

### (A) Exercise Notice

If automatic exercise is not specified in the applicable Final Terms, Products may – subject to Condition 4(A) – only be exercised by the delivery, or the sending by confirmed facsimile transmission, of a duly completed exercise notice (an "**Exercise Notice**") to the Issuer in accordance with the provisions set out in Condition 4 and this Condition 5.

(1) In the case of Cash Settled Products entitling as of the Valuation Date to a cash payment, the Exercise Notice shall:

- (i) specify the securities number (Valoren number) or ISIN number of the Products and the number of Products being exercised;
- (ii) specify the securities account of the Holder exercising the Products to be debited;
- (iii) irrevocably instruct the Issuer to instruct the Clearance Institution to debit on or before the Settlement Date the securities account of that Holder of the Product. In case of Euroclear and Clearstream, Luxembourg, such instruction might be directly sent to Euroclear or Clearstream, Luxembourg, in accordance with the then applicable rules of Euroclear and Clearstream, Luxembourg; or

if the Products are booked into the SIS system as Intermediated Securities, irrevocably instruct the Issuer to debit on or before the Settlement Date the securities account of that Holder of the Product being exercised;

- (iv) specify the cash account of the Holder of the Product to be credited with the Cash Settlement Amount (if any); or

if the Products are booked into the SIS system as Intermediated Securities, specify the number of Holder of the Product's account at the SIS to be credited with the Cash Settlement Amount (if any) for each Product being exercised;

and it shall be understood to:

- (v) include an undertaking to pay all taxes, duties and/or expenses, including any applicable depository charges, transaction or exercise charges, stamp duty, stamp duty reserve tax, issue, registration, securities transfer and/or other taxes or duties arising in connection with the exercise of such Product ("**Exercise Expenses**"); or

if the Products are booked into the SIS system as Intermediated Securities, include an undertaking to pay all taxes, duties and/or expenses, including any applicable Exercise Expenses arising in connection with the exercise of such Product and an authority to the SIS to deduct an amount in respect thereof from any Cash Settlement Amount due to such Holder exercising the Products and/or to debit a specified account of the Holder exercising the Products at the SIS in respect thereof and to pay such Exercise Expenses;

- (vi) certify, *inter alia*, that the beneficial owner of each Product being exercised is a Permitted Transferee (as defined in the Base Prospectus); and

- (vii) authorise the production of such certification in any applicable administrative or legal proceedings.

(2) In the case of Physical Delivery Products, the Exercise Notice shall:

- (i) specify the securities number (Valoren number) or ISIN of the Products and the number of Products being exercised;
- (ii) specify the number of the Holders' of the Products account to be debited with the Products being exercised;
- (iii) irrevocably instruct the Issuer to instruct the Clearance Institution to debit on or before the Settlement Date the securities account of the Holder of a Product with the Products being exercised. In case of Euroclear and Clearstream, Luxembourg, such instruction might be directly sent to Euroclear or Clearstream, Luxembourg, in accordance with the then applicable rules of Euroclear and Clearstream, Luxembourg; or

if the Products are booked into the SIS system as Intermediated Securities, irrevocably instruct the Issuer to debit on or before the Settlement Date the account of the Holder of a Product with the Products being exercised;

- (iv) irrevocably instruct the Issuer to instruct the Clearance Institution to debit on the Actual Exercise Date a specified cash account (Call Products) or securities account (Put Products) of the Holder of the Products with the aggregate Exercise Prices (Call Products) or Entitlement (Put Products) in respect of such Products, (together with any other amounts payable); or

if the Products are booked into the SIS system as Intermediated Securities, irrevocably instruct the SIS to debit on the Actual Exercise Date a specified cash account (Call Products) or securities account (Put Products) of the Holder of the Products with the aggregate Exercise Prices (Call Products) or Entitlement (Put Products) in respect of such Products, (together with any other amounts payable);

- (v) include such details as are required by the applicable Final Terms for delivery of the Entitlement, which may include account details and/or the name and address of any person(s) into whose name evidence of the Entitlement is to be registered and/or any bank, broker or agent to whom documents evidencing the Entitlement are to be delivered and specify the name and the number of the account of the Holder of Products with the SIS to be credited with any cash payable by the Issuer, either in respect of any cash amount constituting the Entitlement or any dividends relating to the Entitlement or as a result of the occurrence of a Settlement Disruption Event and the Issuer electing to pay the Disruption Cash Settlement Price, as applicable;
- (vi) in the case of Currency Warrants or Certificates only, specify the account of the Holder of a Product to be credited with the amount due upon exercise of the Products;

and it shall be understood to:

- (vii) include an undertaking to pay all taxes, duties and/or expenses, including any applicable Exercise Expenses arising from the exercise of such Products and/or the delivery or transfer of the Entitlement pursuant to the terms of such Products and the bank of the Holder of Product to debit a specified



account of the Holder of a Product at its bank in respect thereof and to pay such Exercise Expenses; or

if the Products are booked into the SIS system as Intermediated Securities, include an undertaking to pay all Exercise Expenses arising from the exercise of such Products and/or the delivery or transfer of the Entitlement pursuant to the terms of such Products and an authority to the SIS to debit a specified account of the Holder of a Product at the SIS in respect thereof and to pay such Exercise Expenses;

- (viii) certify, *inter alia*, that the beneficial owner of each Product being exercised is a Permitted Transferee (as defined in the Exercise Notice); and
- (ix) authorise the production of such certification in any applicable administrative or legal proceedings.

(B) *Instruction of the Clearance Institution by the Issuer and the Holder of the Products*

Upon receipt of an Exercise Notice, both, the Issuer and the Holder of the Products, shall instruct the Clearance Institution of the exercise and the relevant details. Such instruction will be made in accordance with the then applicable rules and procedures of the relevant Clearance Institution. If the instructions of the Issuer and the Holder of the Products are identical (or within a tolerance tolerated by the Clearance Institution) and the Holder of the Products or its custodian bank is recorded as the Holder of the Products by the Clearance Institution, the Clearance Institution will on the Settlement Date debit the account of the Holder of the Products with the Products being exercised against, (a) in the case of Put Products, (i) payment of the Cash Settlement Amount or (ii) payment of the aggregate Exercise Prices (subject to the delivery of the Entitlement by the Holder of the Products) or, (b) in the case of Products which are not Put Products, (i) payment of the Cash Settlement Amount (if any) or (ii) delivery of the Entitlement (subject to the payment of the aggregate Exercise Prices, if any, by the Holder of the Products).

Upon maturity of a Product, the Issuer will cause the automatic exercise of the Products in accordance with Condition 4 and the applicable Final Terms.

(C) *Verification of the Holder of a Product*

If the Products are booked into the SIS system as Intermediated Securities, verification of the Holder of a Product and debiting of the relevant securities accounts shall be done pursuant to the then applicable SIS Rules. Cash Settlement and, to the extent applicable, settlement of Physical Delivery Products will occur in accordance with the SIS Rules and payments will be effected to the Holder as may be stipulated in the SIS Rules (the payment date being the "**Record Date**") unless otherwise set out in the Final Terms.

(D) *Settlement*

(i) *Cash Settled Products*

The Issuer shall on the Settlement Date pay or cause to be paid the Cash Settlement Amount (if any) for each duly exercised Product or (if a ratio of Products per Underlying(s) was specified in the applicable Final Terms), for each exercised number of Products, to the cash account of the Holders of the Products specified in the relevant Exercise Notice for value on the Settlement Date, less any Exercise Expenses not already paid.

(ii) Physical Delivery Products

Subject to payment of the aggregate Exercise Prices (Call Products), if any, or delivery of the Entitlement (Put Products) with regard to the relevant Products or (if a ratio of Products per Underlying(s) was specified in the applicable Final Terms), for each exercised number of Products, the Issuer shall on the Settlement Date deliver, or procure the delivery of, the Entitlement (e.g. Call Warrants) or aggregate Exercise Prices (Put Products) for each duly exercised number of Products, pursuant to the details specified in the Exercise Notice in accordance with Condition 4(C).

(E) *Determinations*

Any determination as to whether an Exercise Notice is duly completed and in proper form shall be made by the Issuer (or, in case of Euroclear and Clearstream, Luxembourg, by the Clearance Institution) and shall be conclusive and binding on the Issuer and the relevant Holder of the Products. Subject as set out below, any Exercise Notice so determined to be incomplete or not in proper form shall be null and void.

If such Exercise Notice is subsequently corrected to the satisfaction of the Issuer, it shall be deemed to be a new Exercise Notice submitted at the time such correction was delivered to the Issuer.

**Any Products with respect to which the Exercise Notice has not been duly completed and delivered by the cut-off time specified in Condition 4(A)(i), in the case of American Style Products, or Condition 4(A)(ii), in the case of European Style Products, in the manner set out above shall be considered as not being delivered, subject to the automatic exercise provided in Conditions 4 (A)(i) and 4 (A)(ii).**

The Issuer or, if appropriate the Clearance Institution, shall use its best efforts promptly to notify the Holder of Products submitting an Exercise Notice if it has determined that such Exercise Notice is incomplete or not in proper form. In the absence of negligence or wilful misconduct on its part, the Issuer shall not be liable to any person with respect to any action taken or omitted to be taken by it in connection with such determination or the notification of such determination to a Holder of a Product.

(F) *Delivery of an Exercise Notice*

Delivery of an Exercise Notice shall constitute an irrevocable election by the relevant Holder of a Product to exercise the Products specified. After the delivery of the Exercise Notice, the exercising Holder of a Product may not transfer the exercised Products.

(G) *Exercise Risk*

Exercise of the Products is subject to all applicable laws, regulations and practices in force on the relevant Exercise Date and the Issuer shall not incur any liability whatsoever if it is unable to effect the transactions contemplated, after using all reasonable efforts, as a result of any such laws, regulations or practices. The Issuer shall under no circumstances be liable for any acts or defaults of the relevant Clearance Institution in relation to the performance of its duties in relation to the Products.

**6. Minimum and Maximum Number of Products Exercisable (where applicable)**

(A) *American Style Products*

This paragraph (A) applies only to American Style Products.

- (i) The number of Products exercisable by any Holder of a Product on any Actual Exercise Date, as determined by the Issuer, must not be less than the Minimum Exercise Number specified in the applicable Final Terms or any integral multiple in excess thereof. Any Exercise Notice which purports to exercise Products in an amount less than the Minimum Exercise Number shall be void and of no effect.
- (ii) If the Issuer determines that the number of Products being exercised on any Actual Exercise Date by any Holder of a Product or a group of Holders of Products (whether or not acting in concert) exceeds the Maximum Exercise Number, the Issuer may deem the Actual Exercise Date for the Maximum Exercise Number of such Products, selected at the discretion of the Issuer, to be the day the Holder communicated the Exercise Notice and the Actual Exercise Date for each additional Maximum Exercise Number of such Products (and any remaining number thereof) to be each of the succeeding Business Days until all such Products have been attributed with an Actual Exercise Date, provided, however, that the deemed Actual Exercise Date for any such Products which would thereby fall after the Expiration Date shall fall on the Expiration Date. In any case where more than the Maximum Exercise Number of Products are exercised on the same day by Holder(s) of Products, the order of settlement in respect of such Products shall be at the sole discretion of the Issuer.

*(B) European Style Products*

This paragraph (B) applies only to European Style Products.

The number of Products exercisable by any Holder of a Product on any Exercise Date must be equal to the Minimum Exercise Number specified in the applicable Final Terms, or any integral multiple in excess thereof. Any Exercise Notice which purports to exercise Products in breach of this provision shall be void and be of no effect.

**7. Illegality**

If the Issuer determines that the performance of its obligations under the Products has become illegal in whole or in part for any reason, the Issuer may cancel the Products by giving notice to Holders of a Product in accordance with Condition 10.

Should any one or more of the provisions contained in these Terms and Conditions be or become invalid, the validity of the remaining provisions shall not in any way be affected thereby.

If the Issuer cancels the Products, then the Issuer will, if and to the extent permitted by applicable law, pay to each Holder of a Product in respect of each Product or, if a ratio of Products per Underlying(s) was specified in the applicable Final Terms, for each number of Products per Underlying(s), held by such Holder, the following amount:

The fair market value of a Product, less the cost to the Issuer of unwinding any Underlyings related hedging arrangements plus, if any and already paid by or on behalf of the Holder of a Product, the Exercise Price, all as determined by the Issuer in its sole and absolute discretion. Payment will be made in such manner as shall be notified to the Holders of a Product in accordance with Condition 10.

**8. Purchases**

The Issuer may at any time, but is not obliged to, purchase Products at any price in the open market or by tender or private contract. Any Products so purchased may be held or resold or cancelled.

## **9. Agents, Determinations and Modifications**

### *(A) Products Agents*

The Issuer shall initially act as sole Products Agent.

The Issuer reserves the right at any time to appoint further or additional Products Agents, provided that no termination of the appointment of a qualified Swiss agent shall become effective until a replacement Products Agent shall have been appointed. Notice of any termination of appointment and of any changes in the specified office of any Products Agent will be given to Holders of a Product in accordance with Condition 10. In acting under the Programme, a Products Agent acts solely as agent of the Issuer and does not assume any obligation or duty to, or any relationship of agency or trust for or with, the Holders of a Product and any Products Agent's determinations and calculations in respect of the Products shall (save in the case of manifest error) be final, conclusive and binding on the Issuer and the Holders of a Product.

The Programme may be amended by the Issuer, but without the consent of the Holders of a Product, for the purpose of curing any ambiguity or of curing, correcting or supplementing any defective provision contained therein or in any manner which the Issuer may deem necessary or desirable and which shall not be materially prejudicial to the interests of the Holders of a Product.

### *(B) Calculation Agent*

If the applicable Final Terms indicate that a Calculation Agent (other than the Issuer) is appointed in respect of the Products, it acts solely as agent of the Issuer and does not assume any obligation or duty to, or any relationship of agency or trust for or with, the Holders of Products. All calculations and determinations made in respect of the Products by the Calculation Agent shall (save in the case of manifest error) be final, conclusive and binding on the Issuer and the Holders of Products.

The Calculation Agent may, with the consent of the Issuer, delegate any of its obligations and functions to a third party as it deems appropriate.

### *(C) Determinations by the Issuer*

Any determination made by the Issuer pursuant to these Terms and Conditions shall (save in the case of manifest error) be final, conclusive and binding on the Issuer and the Holders of Products.

### *(D) Modifications*

The Issuer may modify these Terms and Conditions without the consent of the Holders of Products in any manner which the Issuer may deem necessary or desirable provided that such modification is not prejudicial to the interests of the Holders of Products, or such modification is of a formal, minor or technical nature, or to correct a manifest error or to cure, correct or supplement any defective provision contained herein and/or therein. Notice of any such modification will be given to the Holders of Products in accordance with Condition 10 but failure to give, or non-receipt of, such notice will not affect the validity of any such modification.

## **10. Notices**

Notices to Holders of listed Products shall be valid and binding if published on the website of SIX Swiss Exchange ([http://www.six-swiss-exchange.com/news/official\\_notices](http://www.six-swiss-exchange.com/news/official_notices)), or SIX Structured Products Exchange, or in newspapers or on a website, to the extent and in the form

and language required and/or permitted by the applicable rules and regulations of the SIX Swiss Exchange. If permitted by such rules and regulations, notices will be published in English language only.

Notices to Holders of non listed Products shall be valid and binding if published on the website of the Issuer (<http://www.helvetischebank.ch>) or as otherwise specified in the applicable Final Terms (e.g. in newspapers, on a website different than <http://www.helvetischebank.ch> or otherwise).

## 11. Costs (Expenses, Fees, Retrocessions and Taxation)

- (A) A Holder of Products must pay all Exercise Expenses relating to such provided above.
- (B) For certain services rendered and in order to increase quality and services relating to Products the Issuer and/or the Lead Manager may from time to time pay trailer fees (the "**Trailer Fees**"), distribution remunerations (the "**Distribution Fees**"), or commissions, fees, expenses, retrocessions, kickbacks, or similar fees (the "**Retrocessions**") to distribution partners (the "**Distributors**") or pay or charge structuring fees (the "**Structuring Fees**"), discounts, placement fees or any other fees (the "**Other Fees**"). The applicable ranges of these fees will typically be specified in the Final Terms.

If and to the extent such Trailer Fees, Distribution Fees, Retrocessions, Structuring Fees, or Other Fees on the basis of statutory law, would have to be forwarded to the Holder of the Product by the Distributor, the Issuer and/or the Lead Manager, each Holder of a Product hereby (and under consideration of the Final Terms) takes note and unconditionally accepts to the benefit of the Distributor, the Issuer and/or the Lead Manager that the latter may retain and keep such fees. This waiver of claims of the Holders of Products shall be valid and binding regardless of whether any other agreements (in particular, but not limited to, asset management agreements, investment advisory agreement or execution only agreement) exist between the Distributors on one side and the Holders of the Products on the other side (unless such agreements explicitly stipulate a duty to forward such fees to the Holder of the Products).

Potential Holders of the Products should be aware that any such fees may, depending on the circumstances, cause potential or actual conflicts of interests of the Distributor, the Issuer and/or the Lead Manager. They are obliged, however, to implement organisational measures designed to prevent that such potential or actual conflicts of interest may adversely affect the interests of their clients. Further information is available from the Issuer, the Lead Manager or the Distributors.

- (C) The Issuer, and/or the Lead Manager may charge and/or receive Distribution Fees, Structuring Fees, Retrocessions (in a range which will typically be between 0 and 2% of the invested amount, unless stipulated differently in the Final Terms), or Other Fees from the Issuer of the Products, or from the issuer, managers or lead managers of securities, financial products or indexes that serve as Underlyings, or the respective custodian banks.

If and to the extent such fees, on the basis of statutory law, would have to be credited to the Product or forwarded to the Holder of the Products, each Holder of a Product hereby (and under consideration of the Final Terms) takes note and unconditionally accepts to the benefit of the Issuer, the Lead Manager and/or the Distributors that they will retain and keep such Distribution Fees, Structuring Fees, Retrocessions, or Other Fees. This waiver of claims of Holders of Products shall be valid and binding regardless of whether any other agreements (in particular, but not limited to, asset management agreements, investment advisory agreements or execution only agreements) exist between the Issuer, the Lead Manager and/or the Distributors on one side and the Holders of the Products on the other side (unless such agreements explicitly stipulate a duty to forward fees to the Holder of the Products).

Potential Holders of the Products should be aware that such fees may cause conflicts of interests of the Issuer, and/or the Lead Manager, and that there are organisational measures in place, designed to reduce the risk that such conflicts of interest adversely affect the interests of the Holders of the Products. Further information is available from the Issuer or the Lead Manager.

- (D) The Issuer shall not be liable for, or otherwise obliged to, pay any tax, duty, withholding or other payment which may arise as a result of the ownership, transfer, exercise or enforcement of any Products by any person and all payments made by the Issuer shall be made subject to any such tax, duty, withholding or other payment which may be required to be made, paid, withheld or deducted.

## 12. Further Issues

The Issuer shall be at liberty from time to time without the consent of Holders of Products to create and issue further Products so as to be consolidated with and form a single series with the outstanding Products.

## 13. Early Termination of Products and Compulsory Redemption

- (A) If the Issuer determines that any arrangements made to hedge the Issuer's obligations under any Products have become illegal or disrupted in whole or in part for any reason, the Issuer may cancel such Products and pay the Holder of such Products an amount equal to the fair market value of such Products notwithstanding such illegality or disruption, and less the cost to the Issuer and/or any of its agents of unwinding any Underlyings related hedging arrangements plus, if any and already paid, the Exercise Price, all as determined by the Calculation Agent in its sole and absolute discretion.
- (B) Subject to a period of 60 days prior notice, the Issuer reserves the right to redeem the Product at any time after the payment date and prior to the Settlement Date in whole, but not in part, at an amount determined by the Calculation Agent in consultation with leading market makers to be the fair market value of the Products on the date of such termination, provided 95% or more of the initially issued Products have been redeemed or purchased and cancelled at the time of such notice.
- (C) The Issuer shall have the right to terminate the Products if it shall have determined that the Underlying(s) of the Products has ceased to be liquid or that compliance by the Issuer with the obligations under the Products or that any arrangements made to hedge the Issuer's obligations shall have become unlawful or impossible in whole or in part, in particular as a result of compliance by the Issuer with any applicable present or future law, rule, regulation, judgment, order, underlying markets or directive of any governmental, administrative, legislative or judicial authority or power or controlling authority or of the relevant competent market authorities or due to Increased Cost of Hedging, Hedging Disruption or Increased Cost of Collateralisation in case of collateralised Products, including TCM-Products.

**"Increased Cost of Hedging"** means that the Hedging Entity would incur a materially increased (as compared with circumstances existing on the issue date) amount of tax, duty, expense, fee or other cost (other than brokerage commissions) to (i) acquire, establish, re-establish, substitute, maintain, unwind or dispose of any transaction(s) or asset(s) the Hedging Entity deems necessary to hedge the risk in respect of entering into and performing its obligations under the relevant Products, or (ii) realise, recover or remit the proceeds of any such transaction(s) or asset(s).

**"Hedging Entity"** means the Issuer or any affiliate(s) of the Issuer or any entity (or entities) acting on behalf of the Issuer engaged in any underlying or hedging transactions in respect of the Issuer's obligations arising from the Products.

**"Hedging Disruption"** means that the Hedging Entity is unable, after using commercially reasonable efforts, to (i) acquire, establish, re-establish, substitute, maintain, unwind or dispose of any transaction(s) or asset(s) the Issuer deems necessary to hedge the risk of entering into and performing its obligations arising from the Products, or (ii) realise, recover or remit the proceeds of any such transaction(s) or asset(s).

**"Increased Cost of Collateralisation"** means that the Borrowing Entity would incur a materially increased (as compared with circumstances existing on the Issue Date) amount of tax, duty, expense, fee or other cost (other than brokerage commissions) to acquire, hold, substitute, maintain of any transaction(s) or asset(s) the Borrowing Entity deems necessary to borrow in order to collateralise the Products (including TCM-Products) provided such collateralisation is applicable.

**"Borrowing Entity"** means the Issuer or Collateral Provider or any affiliate(s) of the Issuer or Collateral Provider or any entity (or entities) acting on behalf of the Issuer or Collateral Provider engaged in any underlying or borrowing transactions in respect of the Issuer's obligations arising from the Products.

In such circumstances, the Issuer may cancel/terminate the Products by providing notice to Holders of the Products in accordance with Condition 10.

If the Issuer terminates Products the Issuer will, if and to the extent permitted by applicable law, pay to each Investor in respect of such Products held by it an amount determined by the Calculation Agent in its duly executed discretion (*billiges Ermessen*), but in accordance with established market practice, as representing the fair market value of such Products immediately prior to such cancellation/termination (notwithstanding any illegality or impossibility). Payment will be made as soon as reasonably possible in such manner as shall be notified to the Holders of the Products within a period of not less than ten (10) nor more than thirty (30) Business Days in accordance with Condition 10. Instead of paying a cash amount corresponding to the Fair Market Value of a Product, the Issuer may – in its duly executed discretion – deliver the Underlying(s) of such Product.

#### 14. Substitution of the Issuer

The Issuer, or any previous substituted company may, at any time, without the consent of the Holders of Products, substitute for itself as principal obligor under the Products any company (the "**Substitute**"), subject to:

- (a) the Issuer unconditionally and irrevocably guaranteeing in favor of each Holder of Products the performance of all obligations by the Substitute under the Products;
- (b) all actions, conditions and things required to be taken, fulfilled and done (including the obtaining of any necessary consents) to ensure that the Products represent legal, valid and binding obligations of the Substitute having been taken, fulfilled and done and are in full force and effect;
- (c) the Substitute shall execute an updated version of the Programme containing the identical Terms and Conditions as set forth in the Programme, with any appropriate consequential amendments, as if it had executed the Programme;
- (d) the Substitute and the Issuer shall have obtained legal opinions, from independent legal advisers of recognised standing in the country of incorporation of the Substitute and Switzerland, that the obligations of the Substitute are legal, valid and binding obligations and that all consents and approvals as aforesaid have been obtained;
- (e) the Issuer shall have given at least 30 days prior notice of the date of such substitution to the Holders of Products in accordance with Condition 10;

and

- (f) if appropriate, the Substitute shall have appointed a process agent as its agent in Switzerland to receive service of process on its behalf in relation to any legal action or proceedings arising out of or in connection with the Products.

## 15. Prescription and Statute of Limitations

Claims of any kind against the Issuer in connection with the Products for, *inter alia*, payment of any amount, or, if applicable, delivery of any Underlying(s) in respect of the Products will be prescribed 10 years after the earlier of (i) the due date thereof resulting from (a) the exercise of the Products by the Holder of the Products or (b) the early repayment of the Products, or (ii) the Maturity Date. Coupons will be prescribed after a period of five years from their due date.

## 16. Governing Law and Jurisdiction

The Products and the Programme (including the Terms and Conditions) are governed by and shall be construed in accordance with Swiss law.

In relation to any legal action or proceedings arising out of or in connection with the Products ("**Proceedings**"), the Issuer irrevocably submits to the exclusive jurisdiction of the courts of the Canton of Zurich, venue being in Zurich, with the right to appeal to the Swiss Federal Court of Justice in Lausanne.

## 17. Terms for Index Warrants, Share Warrants, Debt Warrants, Commodity Warrants, Currency Warrants, Index Certificates, Share Certificates, Debt Certificates, Commodity Certificates, Currency Certificates, Index-linked Notes, Share-linked Notes, Debt-linked Notes, Commodity-linked Notes, Currency-linked Notes, and Actively Managed Certificates

(A) *Index Warrants, Index Certificates, Index-linked Notes*

### (1) Market Disruption

"**Market Disruption Event**" shall mean, in respect of an Index, the occurrence or existence on any Trading Day during the one-half hour period that ends at the relevant Valuation Time:

- (i) on the Exchange: a suspension of, or limitation imposed on, trading (by reason of movements in price exceeding limits permitted by the Exchange or otherwise) in securities/commodities that comprise 20 per cent. or more of the level of that Index; or
- (ii) on any exchange on which options contracts or futures contracts on that Index are traded: a suspension of, or limitation imposed on, trading (by reason of movements in price exceeding limits permitted by the relevant exchange or otherwise) in options contracts or futures contracts on that Index;

if, in the determination of the Issuer, in any such case the suspension or limitation is material.

For the purpose of determining whether a Market Disruption Event exists in relation to an Index at any time, if trading in a security/commodity included in that Index is materially suspended or materially limited at that time, then the relevant percentage contribution of that security/commodity to the level of that Index shall be based on a comparison of (i) the portion of the level of that Index attributable to that security/commodity relative to (ii) the overall level of that Index, in each case immediately before that suspension or limitation.



The Issuer shall give notice that a Market Disruption Event has occurred as soon as practicable to the Holders of Products in accordance with Condition 10.

**(2) Adjustments to an Index**

**(a) Successor Sponsor Calculates and Reports Index**

If a relevant Index is (i) not calculated and announced by the agreed sponsor (the "**Sponsor**") but is calculated and announced by a successor to the Sponsor (the "**Successor Sponsor**") acceptable to the Issuer or (ii) replaced by a successor index using, in the determination of the Issuer, the same or a substantially similar formula for and method of calculation as used in the calculation of that Index, then that Index will be deemed to be the index so calculated and announced by the Successor Sponsor or that successor index, as the case may be.

**(b) Modification and Cessation of Calculation of an Index**

If (i) on or prior to any Valuation Date or Averaging Date the Sponsor or (if applicable) the Successor Sponsor makes a material change in the formula or the method of calculating a relevant Index, or in any other way materially modifies that Index (other than a modification prescribed in that formula or method to maintain that Index in the event of changes in constituent stock, capitalisation, contracts or commodities and other routine events), or (ii) on a Valuation Date or an Averaging Date the Sponsor or (if applicable) the Successor Sponsor fails to calculate and announce a relevant Index, then the Issuer shall determine the Settlement Price using, in lieu of a published level for that Index, the level for that Index as at the Valuation Time on that Valuation Date or that Averaging Date, as the case may be, in accordance with the formula for and method of calculating that Index last in effect prior to that change or failure, but using only those securities/commodities that comprised that Index immediately prior to that change or failure (other than those securities that have since ceased to be listed on the Exchange).

**(c) Notice**

The Issuer shall, as soon as practicable after receipt of any written request to do so, advise a Holder of Products of any determination made by it pursuant to paragraph (b) above, as at the date of receipt of such request. The Issuer shall make available for inspection by Holders of Products copies of any such determinations.

**(B) *Share Warrants, Share Certificates, Share-linked Notes***

For the purposes of this Condition 17(B):

**"Basket Company"** means a Company whose shares are included in the Basket of Shares and **"Basket Companies"** means all such companies;

**"Shares"** and **"Share"** mean, subject to adjustment in accordance with this Condition 17(B), the shares or a share of the relevant Basket Company and, in the case of an issue of Products relating to a single Share, such share and related expressions shall be construed accordingly; and

**"Share Company"** means, in the case of an issue of Products relating to a single share, the company that has issued such share.

**(1) Market Disruption**

**"Market Disruption Event"** shall mean in respect of a Share, the occurrence or existence on any Trading Day during the one-half hour period that ends at the relevant Valuation Time:

- (a) on the Exchange: a suspension of or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the Exchange or otherwise) of the Share; or
- (b) on any related exchange on which options or futures contracts on the Share are traded: a suspension of or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the related exchange or otherwise) of any options contracts or futures contracts relating to the Share;

if in the determination of the Issuer, in any such case the suspension or limitation is material.

The Issuer shall give notice that a Market Disruption Event has occurred as soon as practicable to the Holders of Products in accordance with Condition 10.

**(2) Potential Adjustment Events, Merger Event, Nationalisation and Insolvency**

- (a) **"Potential Adjustment Event"** means any of the following:
  - (i) a subdivision, consolidation or reclassification of relevant Shares (unless a Merger Event) or a free distribution or dividend of any such Shares to existing Holders by way of bonus, capitalisation or similar issue;
  - (ii) a distribution or dividend to existing Holders of relevant Shares of (a) such Shares or (b) other share capital or securities granting the right to payment of dividends and/or the proceeds of liquidation of the Basket Company or Share Company equally or proportionately with such payments to Holders of such Shares or (c) any other type of securities, rights or warrants or other assets, in any case for payment (in cash or otherwise) at less than the prevailing market price as determined by the Issuer;
  - (iii) an extraordinary dividend;
  - (iv) a call by the Basket Company or Share Company, as the case may be, in respect of relevant Shares that are not fully paid;
  - (v) a repurchase by the Basket Company or Share Company, as the case may be, of relevant Shares whether out of profits or capital and whether the consideration for such repurchase is cash, securities or otherwise;
  - (vi) unforeseen changes in the Underlyings, as the case may be, such as an exchange of securities or similar transactions; or
  - (vii) any other event having, in the opinion of the Issuer, a diluting or concentrative effect on the theoretical value of the relevant Shares or the Products.

Following the declaration by the **Basket Company** or Share Company of the terms of any Potential Adjustment Event, the Issuer will, in its sole and absolute discretion, determine whether such Potential Adjustment Event has a diluting or concentrative effect on the theoretical value of the Shares. If so, the Issuer will (i) make the corresponding adjustment to any one or more of any Underlying(s) and/or the Entitlement and/or the Exercise Price and/or the Multiplier and/or redemption and/or

any of the other terms of these Terms and Conditions and/or the applicable Final Terms as the Issuer in its sole and absolute discretion determines appropriate to account for that diluting or concentrative effect and (ii) determine the effective date of that adjustment. The Issuer may, but need not, determine the appropriate adjustment by reference to the adjustment in respect of such Potential Adjustment Event made by an options exchange to options on the Shares traded on that options exchange.

Upon making any such adjustment, the Issuer shall give notice as soon as practicable to the Holders of Products in accordance with Condition 10, stating the adjustment to any Underlying(s) and/or the Entitlement and/or the Exercise Price and/or the Multiplier and/or redemption and/or any of the other terms of these Terms and Conditions and/or the applicable Final Terms and giving brief details of the Potential Adjustment Event.

- (b) **"Insolvency"** means that by reason of the voluntary or involuntary liquidation, bankruptcy or insolvency of or any analogous proceeding affecting the Basket Company or Share Company (i) all the Shares of that Basket Company or that Share Company are required to be transferred to a trustee, liquidator or other similar official or (ii) holders of the Shares of that Basket Company or that Share Company become legally prohibited from transferring them.

**"Merger Date"** means, in respect of a Merger Event, the date upon which all holders of the relevant Shares (other than, in the case of a takeover offer, Shares owned or controlled by the offeror) have agreed or have irrevocably become obliged to transfer their Shares.

**"Merger Event"** means, in respect of any relevant Shares, any (i) reclassification or change of such Shares that results in a transfer of or an irrevocable commitment to transfer all such Shares outstanding, (ii) consolidation, amalgamation or merger of the Basket Company or Share Company, as the case may be, with or into another entity (other than a consolidation, amalgamation or merger in which such Basket Company or Share Company, as the case may be, is the continuing entity and which does not result in any such reclassification or change of all such Shares outstanding) or (iii) other takeover offer for such Shares that results in a transfer of or an irrevocable commitment to transfer all such Shares (other than the Shares owned or controlled by the offeror), in each case if the Merger Date is on or before, in the case of Physical Delivery Products, the relevant Actual Exercise Date or, in any other case, the final Valuation Date or where **Averaging** is specified in the applicable Final Terms, the final **Averaging Date** in respect of the relevant Products.

**"Nationalisation"** means that all the Shares or all the assets or substantially all the assets of the Basket Company or Share Company, as the case may be, are nationalised, expropriated or are otherwise required to be transferred to any governmental agency, authority or entity.

If a Merger Event, Nationalisation or Insolvency occurs in relation to a Share, the Issuer in its sole and absolute discretion may take the action described in (i), (ii) or (iii) below:

- (i) determine in its sole and absolute discretion the appropriate adjustment, if any, to be made to any one or more of any Underlying(s) and/or the Entitlement and/or the Exercise Price and/or the Multiplier and/or redemption and/or any of the other terms of these Terms and Conditions and/or the applicable Final Terms to account for the Merger Event, Nationalisation or Insolvency, as the case may be, and determine the effective date of that adjustment; or

- (ii) cancel the Products by giving notice to Holders of Products in accordance with Condition 10. If the Products are so cancelled the Issuer will pay an amount to each Holder of Products which shall be the fair market value of a Product or, if a ratio of Products per Underlying(s) is specified in the Final Terms, the fair market value of that number of Products, taking into account the Merger Event, Nationalisation or Insolvency, less the cost to the Issuer of unwinding any Underlyings related hedging arrangements plus, if any and already paid, the Exercise Price, all as determined by or on behalf of the Issuer in its sole and absolute discretion. Payments will be made in such manner as shall be notified to the Holders of Products in accordance with Condition 10; or
  - (iii) follow such adjustment to the settlement terms of options on the Shares traded on such exchange(s) or quotation system(s) as the Issuer in its sole discretion shall select (the "**Options Exchange**") and make a corresponding adjustment to any one or more of any Underlying(s) and/or the Entitlement and/or the Exercise Price and/or the Multiplier and/or redemption and/or any of the other terms of these Terms and Conditions and/or the applicable Final Terms, which adjustment will be effective as of the date determined by the Issuer to be the effective date of the corresponding adjustment made by the Options Exchange. If options on the Shares are not traded on an options exchange or quotation system, the Issuer will make such adjustment, if any, to any one or more of any Underlying(s) and/or the Entitlement and/or the Exercise Price and/or the Multiplier and/or redemption and/or any of the other terms of these Terms and Conditions and/or the applicable Final Terms as the Issuer in its sole and absolute discretion determines appropriate, with reference to the rules and precedents (if any) set by the options exchange or quotation system selected by the Issuer to account for the Merger Event, Nationalisation or Insolvency, as the case may be, that in the determination of the Issuer would have given rise to an adjustment by the options exchange or quotation system if such options were so traded.
- (c) Upon the occurrence of a Merger Event, Nationalisation or Insolvency, the Issuer shall give notice in accordance with Condition 10 as soon as practicable to the Holders of Products, stating the occurrence of the Merger Event, Nationalisation or Insolvency, as the case may be, giving details thereof and the action proposed to be taken in relation thereto.
  - (d) Exchange of Shares for other securities of the relevant Basket Company or Share Company:

In the event that the relevant Share Company or Basket Company should grant its Holders of relevant Shares the right on a discretionary basis to exchange the relevant Shares for other securities of the relevant Share Company or Basket Company, the Holders of Products shall be duly notified thereof in accordance with Condition 10. Such notification shall include the date after which the Issuer in its absolute discretion, shall have the right to replace the relevant Shares deliverable under the Products by such new securities of the relevant Share Company or Basket Company and such decision shall be binding upon all Holders of unexercised Products.

(C) *Debt Warrants, Debt Certificates, Debt-linked Notes*

**(1) Market Disruption**

"**Market Disruption Event**" in relation to Debt Warrants, Debt Certificates and Debt-linked Notes shall mean the suspension of or limitation imposed on trading of one or more (in the

case of a Basket of Debt Securities) Debt Securities specified as Underlying(s), either on the exchange on which the relevant Debt Securities are traded or on any exchange on which options contracts or futures contracts with respect to the Debt Securities are traded if, in the determination of the Issuer, such suspension or limitation is material.

The Issuer shall give notice that a Market Disruption Event has occurred as soon as practicable to the Holders of Products in accordance with Condition 10.

**(2) Adjustments**

If any action is taken in accordance with the terms of one or more (in the case of a Basket of Debt Securities) Debt Securities specified as Underlying(s) which has had a dilutive or concentrative effect on the theoretical value of the relevant Debt Securities or otherwise affects or would affect the rights and entitlements of the Holders of such relevant Debt Securities, the Issuer (i) shall make such adjustment(s) to the redemption, settlement or payment terms of the Products which relate to such relevant Debt Securities as the Issuer determines in its sole and absolute discretion appropriate to account for the effect of such action and (ii) shall determine the effective date(s) of such adjustment(s).

If the Issuer determines in its sole and absolute discretion that on or prior to any Valuation Date, the Settlement Price of the Underlying(s) is not or will not be available anymore, the Issuer may elect to terminate the Products by giving notice to the Holders of Products in accordance with Condition 10 of such situation and the fair market value, as determined by the Issuer in its sole and absolute discretion, of such Products and the fair market value so determined to be payable in respect of a Product shall be payable on the date specified in such notice.

The applicable Final Terms may include provisions specifying adjustments for Underlying(s) not addressed in these Terms and Conditions or amending the adjustments for Underlying(s) specified in these Terms and Conditions.

*(D) Commodity Warrants, Commodity Certificates, Commodity-linked Notes*

**(1) Market Disruption**

**"Market Disruption Event"** in relation to Commodity Warrants, Commodity Certificates and Commodity-linked Notes shall mean the suspension of or limitation imposed on trading of the Commodity or any of the Commodities (in the case of a Basket of Commodities) on either the exchange on which the relevant Commodity/Commodities are traded or on any exchange on which options contracts or commodity futures contracts specified as Underlying(s) are traded if, in the determination of the Issuer, such suspension or limitation is material.

The Issuer shall give notice as soon as practicable to the Holders of Products in accordance with Condition 10 that a Market Disruption Event has occurred.

**(2) Adjustments/Termination**

In respect of Commodity Warrants, Commodity Certificates or Commodity-linked Notes relating to one, or a basket of, commodity futures or options contracts it shall be provided that if any action is taken in accordance with the terms of one or more (in the case of a Basket of commodity futures contracts) futures contracts specified as Underlying(s) which has had a dilutive or concentrative effect on the theoretical value of such relevant contracts or otherwise affects or would affect the rights and entitlements under such relevant contracts, the Issuer (i) shall make such adjustment(s) to the redemption, settlement or payment terms of the Products which relate to such relevant contracts as the Issuer determines in its sole and

absolute discretion appropriate to account for the effect of such action and (ii) shall determine the effective date(s) of such adjustment(s).

If the Issuer determines in its sole and absolute discretion that on or prior to any Valuation Date, the Settlement Price of the Underlying(s) is not or will not be available anymore, the Issuer may elect to terminate the Products by giving notice to the Holders of Products in accordance with Condition 10 of such situation and the fair market value, as determined by the Issuer in its sole and absolute discretion, of such Products and the fair market value so determined to be payable in respect of a Product shall be payable on the date specified in such notice.

The applicable Final Terms may include further provisions specifying adjustments for Underlying(s) not addressed in these Terms and Conditions or amending the adjustments for Underlying(s) specified in these Terms and Conditions.

(E) *Currency Warrants, Currency Certificates, Currency-linked Notes*

**(1) Market Disruption**

"**Market Disruption Event**" in relation to Currency Warrants, Currency Certificates and Currency-linked Notes shall mean (i) the suspension of or limitation imposed on trading of one or more (in the case of a Basket of Currencies) of the currencies specified as Underlying(s) generally or (ii) the impossibility for the Issuer to obtain the currencies or exchange rates to which the Products relate if, in the determination of the Issuer, such suspension or limitation is material.

The Issuer shall give notice as soon as practicable to the Holders of Products in accordance with Condition 10 that a Market Disruption Event has occurred.

**(2) Adjustments/Termination**

Unless otherwise specified in these Terms and Conditions, the relevant currency/exchange rate to which the Products relate shall be defined in the applicable Final Terms. If, on or prior to any Valuation Date, the Issuer is or will be unable to obtain the Settlement Price of one or more (in the case of a Basket of Currencies) of the currencies or (ii) the Settlement Price with respect to the exchange rates specified as Underlying(s), the Issuer may rebase the Products against such other currencies/exchange rates determined by the Issuer, in its sole and absolute discretion, to be comparable currencies/exchange rates.

If the Issuer determines in its sole and absolute discretion that there are no such comparable currencies/exchange rates, the Issuer may elect to terminate the Products by giving notice to the Holders of Products in accordance with Condition 10 of such situation and the fair market value, as determined by the Issuer in its sole and absolute discretion, of such Products and the fair market value so determined to be payable in respect of a Product shall be payable on the date specified in such notice.

The applicable Final Terms may include further provisions specifying adjustments for Underlying(s) not addressed in these Terms and Conditions or amending the adjustments for Underlying(s) specified in these Terms and Conditions.

(F) *Additional Terms for Actively Managed Certificates ("AMCs")*

(1) **Definitions**

In this Condition, the following expressions have the following meanings:

**"Actively Managed Certificates"** ("AMCs") means Products whose Underlying consists of a notional Strategy (or tailor-made index) which is fully or partially adjusted at the discretion of a Strategy-Manager and allows the Holders of the Product to participate in a positive performance of the Strategy-Level in an unrestricted manner, and on the other hand, may reflect a negative performance of the Strategy-Level.

**"Adjustments of the Strategy-Components"** means the rebalancing of the weight of Strategy-Components or the replacement of Strategy-Components.

**"Dynamic Products"** are Products whose Underlying(s) may be subject to adjustments according to actively or passively determined and objectively comprehensible rules during the term of the Product.

**"Investment Restrictions"** means the applicable framework for the selection of, and adjustments to, the Strategy-Components, as specified in the applicable Final Terms.

**"Investment Universe"** contains all underlyings which may be selected as Strategy-Components as defined in the applicable Final Terms of a specific Product.

**"Potential Adjustment Event"** has the meaning stated in Condition 17(A) or (B), where applicable.

**"Strategy"** means the precise definitions and specifications regarding the investment strategy of an AMC as set out in the applicable Final Terms. The Strategy must be clear and comprehensible and be determined in a manner such that the Holders of the Products can clearly understand the investment strategy and orientation of the Product.

**"Strategy-Component"** means an Underlying which is part of the Strategy-Composition.

**"Strategy-Composition"** means the specific applicable composition, structure and weighting of the Strategy-Components of an AMC, created, maintained and/or adjusted by the Strategy-Manager.

**"Strategy-Guidelines"** means the guidelines that are specified in the applicable Final Terms and are applicable to the selection of, and adjustments to, the Strategy-Components by the Strategy-Manager.

**"Strategy-Level"** means the theoretical value of the synthetical Strategy which is based on the value of the notional Strategy-Components and calculated as specified in the applicable Final Terms.

**"Strategy-Manager"** is the provider which is responsible for the selection of, and adjustments to, the Strategy-Composition, respectively, the Strategy-Components, and the compliance of a Product with the Strategy-Guidelines and Investment Restrictions.

(2) **Terms**

The Terms and Conditions are generally applicable for AMCs, unless stated differently as follows or in the Final Terms or if they are not feasible for AMCs.

Dynamic Products may be listed on the SIX Swiss Exchange provided that the criteria that result in a change to the Final Terms (e.g. the exercise price) and/or the Underlyings (e.g. rebalancing of individual components of a basket or roll-over in the underlying future) can be defined in advance and described in objective terms (e.g. historical returns, P/E ratio, etc.) in the listing prospectus. These criteria must remain unchanged for the term of the certificate.

Pursuant to the Strategy-Guidelines only the selection of assets contained in the Investment Universe (as defined in the Final Terms) are permitted as Strategy-Components. The Strategy-Guidelines and the Investment Universe must be respected upon Fixing and upon Adjustment of the Strategy-Components.

The Strategy-Manager is free to correct infringements of the Strategy-Guidelines or the Investment Universe which might possibly occur. No liabilities are assumed by the Strategy-Manager or the Issuer for such infringements.

Each Holder of Products has the right to receive a redemption of an amount in the currency of the Product according to the Strategy-Level of the Product, which has been calculated by the Calculation Agent based on the Final Terms.

If the Issuer, the Lead Manager or a Distributor is acting as Strategy-Manager, potential or actual conflicts of interests may arise. Holders of AMCs should be aware of such conflicts of interests. However, the Issuer, the Lead Manager and/or the Strategy-Manager will take appropriate measures to deal with potential or actual conflicts of interests.

If the applicable Final Terms indicate that a Strategy-Manager (other than the Issuer) is appointed in respect of the Products, it acts solely as Strategy-Manager and does not assume any obligation or duty to, or any relationship of agency or trust for or with, the Holders of Products. All Adjustments of the Strategy-Components made by the Strategy-Manager shall (save in the case of manifest error) be final, conclusive and binding on the Issuer and the Holders of Products.

The Strategy-Manager may, with the consent of the Issuer, delegate any of its obligations and functions to a third party as it deems appropriate.

In case of differences, inconsistencies or other deviations of the Terms and Conditions and the Final Terms, the Final Terms shall have priority.

### **(3) Adjustments of the Strategy-Components**

With respect to Potential Adjustment Events Condition 17(A) or (B), are applicable, depending on the Underlying.

The following additional provisions apply for Adjustments of the Strategy-Components of AMCs:

- (a) AMCs are subject to an active management of the Strategy-Components. The Strategy-Manager selects and adjusts the Strategy-Components in its sole and absolute discretion and thereby selects and adjusts the Strategy-Components in compliance with the Investment Universe, the Strategy, the Strategy-Guidelines, and the Investment Restrictions.
- (b) The applicable Final Terms shall include provisions specifying details concerning changes of the Terms and Conditions and/or the Strategy-Components. Such changes may occur on a regular basis and are regarded as changes of the Terms and Conditions and must be made public in accordance with the Terms and Conditions.



- (c) The Adjustments of the Strategy-Components will be made during the respective Trading Day. Breaches of the Strategy-Guidelines or the Investment Universe shall be corrected within one day after detection. The value of the Product will not be adjusted retrospectively. Neither the Issuer nor the Strategy-Manager shall be held responsible for obligations arising from such breaches.
- (d) The Strategy-Manager (if different from the Issuer) is responsible for Adjustments of the Strategy-Components in case of events with a dilution or concentration effect or similar events. If the Strategy-Manager does not decide within reasonable time, the Issuer will decide independently.
- (e) The Issuer and the Strategy-Manager each reserve the right to terminate the strategy-management agreement. If the strategy-management agreement is terminated by either party, the Issuer may replace the former Strategy-Manager and become the new Strategy-Manager of the relevant AMC. Alternatively, the Issuer may terminate the AMC in accordance with Condition 17(F)(4).

**(4) Termination of AMCs**

AMCs may be open-end, i.e., not have a final due date (expiry). Open-end AMCs shall entail a redemption or termination right of the Issuer and the Holder of the Product as follows:

- (a) The Issuer has the right to terminate the AMC within one month after notification without a specific reason to the last trading day of a month.
- (b) The Holder of the AMC may redeem or terminate his position in the AMC within one month after written notification of the Issuer to the last trading day of the month.

**18. Adjustments for European Monetary Union**

The Issuer may, without the consent of the Holders of Products, on giving notice to the Holders of Products in accordance with Condition 10:

- (i) elect that, with effect from the Adjustment Date specified in the notice, certain terms of the Products shall be redenominated in Euro;

The election will have effect as follows:

- (A) where the Settlement Currency of the Products is the National Currency Unit of a country which is participating in the third stage of European Economic and Monetary Union, such Settlement Currency shall be deemed to be an amount of Euro converted from the original Settlement Currency into Euro at the Established Rate, subject to such provisions (if any) as to rounding as the Issuer may decide and as may be specified in the notice, and after the Adjustment Date, all payments of the Cash Settlement Amount in respect of the Products will be made solely in Euro as though references in the Products to the Settlement Currency were to Euro;
- (B) where the Exchange Rate and/or any other terms of these Terms and Conditions are expressed in or, in the case of the Exchange Rate, contemplate the exchange from or into, the currency (the "**Original Currency**") of a country which is participating in the third stage of European Economic and Monetary Union, such Exchange Rate and/or any other terms of these Terms and Conditions shall be deemed to be expressed in or, in the case of the Exchange Rate, converted for or, as the case may be into, Euro at the Established Rate; and

- (C) such other changes shall be made to these Terms and Conditions as the Issuer may decide, in its sole and absolute discretion to conform them to conventions then applicable to instruments expressed in Euro; and/or
- (ii) make such adjustments to the Multiplier and/or the Settlement Price and/or the Exercise Price and/or any other terms of these Terms and Conditions and/or the Final Terms as the Issuer, in its sole discretion, may determine to be appropriate to account for the effect of the third stage of European Economic and Monetary Union on the Multiplier and/or the Settlement Price and/or the Exercise Price and/or such other terms of these Terms and Conditions and/or the applicable Final Terms.

Notwithstanding the foregoing, neither the Issuer nor any Agent shall be liable to any Holder of Products or other person for any commissions, costs, losses or expenses in relation to or resulting from the transfer of euro or any currency conversion or rounding effected in connection therewith.

In this Condition, the following expressions have the following meanings:

**"Adjustment Date"** means a date specified by the Issuer in the notice given to the Holders of Products pursuant to this Condition which falls on or after the date on which the country of the Original Currency first participates in the third stage of European Economic and Monetary Union pursuant to the Treaty;

**"Established Rate"** means the rate for the conversion of the Original Currency (including compliance with rules relating to rounding in accordance with applicable European Community regulations) into euro established by the Council of the European Union pursuant to first sentence of Art. 1091(4) of the Treaty;

**"Euro"** means the currency introduced at the start of the third stage of European Economic and Monetary Union pursuant to the Treaty;

**"National Currency Unit"** means the unit of the currency of a country, as those units are defined on the date on which the country of the Original Currency first participates in European Economic and Monetary Union; and

**"Treaty"** means the treaty establishing the European Community, as amended by the treaty on the European Union.

## 19. Currency Indemnity

Any amount received or recovered in a currency other than the currency in which payment under the relevant Product or Coupon is due (whether as a result of, or of the enforcement of, a judgment or order of a court of any jurisdiction, in the winding-up or dissolution of the Issuer or otherwise) by any Holder of Product or Couponholder in respect of any sum expressed to be due to it from the Issuer shall only constitute a discharge to the Issuer, as the case may be, to the extent of the amount in the currency of payment under the relevant Product or Coupon that the recipient is able to purchase with the amount so received or recovered in that other currency on the date of that receipt or recovery (or, if it is not practicable to make that purchase on that date, on the first date on which it is practicable to do so). If the amount received or recovered is less than the amount expressed to be due to the recipient under any Product or Coupon, the Issuer shall indemnify it against any loss sustained by it as a result. In any event, the Issuer shall indemnify the recipient against the cost of making any such purchase. For the purposes of this Condition, it shall be sufficient for the Holder of Product or Couponholder, as the case may be, to demonstrate that it would have suffered a loss had an actual purchase been made. These indemnities constitute a separate and independent obligation from the Issuer's other obligations, shall give rise to a separate and independent cause of action, shall apply irrespective of any indulgence granted by any Holder

of Product or Couponholder and shall continue in full force and effect despite any other judgment, order, claim or proof for a liquidated amount in respect of any sum due under any Product or Coupon or any other judgment or order.

**20. Terms for Share-linked Notes, Index-linked Notes, Debt-linked Notes, Commodity-linked Notes, Currency-linked Notes**

**(A) Coupon (interest)**

The Products shall, if applicable, entitle to a Coupon (interest payments) as set forth in the applicable Final Terms. The calculation of the interest amount payable shall be made as set forth in the applicable Final Terms.

**(B) Events of Default**

If one or more of the following events (herein referred to as "**Events of Default**") shall have occurred and be continuing for a tranche of Products, each Holder of Products shall have the right to declare all the outstanding Products of such tranche held by such Holder of Products, to be immediately due and payable at an amount determined by the Calculation Agent which shall have the effect of preserving for the Holders of Products of such tranche the economic equivalent of the obligation of the Issuer to pay or transfer the Cash Settlement Amount or the Entitlement on the Settlement Date, or to take any other measures to protect the interests of the Holders of Products of such tranche:

- (a) failure on the part of the Issuer to pay when due the Cash Settlement Amount or the Entitlement of any of the Derivatives and Structured Products for such tranche as and when the same shall become due and payable, whether upon redemption or otherwise;
- (b) failure on the part of the Issuer to pay when due any instalment of interest upon any Products for such tranche as and when the same shall become due and payable, and such failure shall have continued for a period of 30 days;
- (c) failure on the part of the Issuer to perform or comply with any one or more of its other material obligations under the Products for such tranche which default is not remedied within 90 days;
- (d) either the Issuer is (or is deemed by law or a court to be) insolvent or bankrupt or unable to pay its debts, stops, suspends or threatens to stop or suspend payment of all or a material part of its debts, proposes or makes a general assignment or an arrangement or composition with or for the benefit of the relevant creditors in respect of any of such debts or a moratorium is agreed or declared in respect of or affecting all or any part of the debts of the Issuer;
- (e) an order is made by any competent court or an effective resolution passed for the winding-up or dissolution of the Issuer, or the Issuer ceases or threatens to cease to carry on all or a substantial part of its business or operations, in each case except for the purpose of and followed by a reconstruction, amalgamation, reorganisation, merger or consolidation on terms approved by an Extraordinary Resolution (as defined in Subcondition (C) hereinafter) of the Holders of Products.

**21. Productholders' Meeting**

- (1) A meeting of the Holders of Products (a "**Productholders' Meeting**") may be convened by the Issuer or shall be convened by the Issuer, if so requested by Holders of Products representing not less than 10% of the aggregate principal amount of all Products outstanding, but in each case only in the event of the occurrence of an Event of Default under these Conditions such Productholders' Meeting may consider any amendment or waiver of these Conditions.

- (2) Notice of the Productholders' Meeting specifying the place, day and hour of meeting shall be given at least 10 days prior to the proposed date thereof (exclusive of the day on which the notice is given and the day on which the meeting is held) by way of one announcement in the newspapers referred to in Condition 10. Such notice shall state generally the nature of the business to be transacted at the meeting thereby convened but (except for an Extraordinary Resolution) it shall not be necessary to specify in such notice the terms of any resolution to be proposed.
- (3) The Productholders' Meeting shall be held in Zurich and shall be chaired by a representative of the Issuer or if such representative of the Issuer shall not be present within thirty minutes after the time appointed for holding the meeting the Holders of Products present shall choose one of their members to be chairman.
- (4) Resolutions shall only be passed if a quorum of two or more persons holding 25% or more of the aggregate principal amount of all Products outstanding are present. The quorum at any meeting for passing an Extraordinary Resolution shall be two or more persons holding two thirds or more of the aggregate principal amount of all Products outstanding. Resolutions shall be passed if approved by the absolute majority of votes cast save that an Extraordinary Resolution shall be passed only if approved by three-fourths of votes cast.
- (5) If within thirty minutes after the time appointed for any such meeting a quorum is not present the meeting shall, if convened upon the requisition of Holders of Products, be dissolved. In any other case it shall stand adjourned for such period being not less than 14 days nor more than 28 days, and at such place as may be appointed by the Issuer. At such adjourned meeting two or more persons present holding 10% or more of the aggregate principal amount of all Products outstanding shall form a quorum, provided that if the business of such adjourned meeting includes consideration of a proposed Extraordinary Resolution, the quorum shall be two or more persons present holding one-third or more of the aggregate principal amount of all Products for the time being outstanding.
- (6) If within thirty minutes after the time appointed for any such adjourned meeting the respective quorum is not present the meeting shall stand further adjourned for such period being not less than 14 days nor more than 28 days, and at such place as may be appointed by the Issuer and at such further adjourned meeting two or more persons present holding Products (whatever the principal amount of the Products so held by them) shall form a quorum, provided that if the business of such further adjourned meeting includes consideration of a proposed Extraordinary Resolution, the quorum shall be two or more persons present holding one-third or more of the aggregate principal amount of all Products for the time being outstanding.
- (7) Notice of any adjourned meeting or further adjourned meeting shall be given in the same manner as notice of an original meeting and such notice shall state, in the case of an adjourned meeting, that two or more persons present holding 10% (or in the case of a meeting the business of which includes consideration of a proposed Extraordinary Resolution one-third) or more of the aggregate principal amount of all Products for the time being outstanding will form a quorum, or, in the case of a further adjourned meeting, that two or more persons present (or in the case of a meeting the business of which includes the consideration of a proposed Extraordinary Resolution one-third or more of the aggregate principal amount of all Products for the time being outstanding), shall form a quorum.
- (8) In the absence of a quorum at any such further adjourned meeting, the Issuer shall have the right but not the obligation on behalf of Holders of Products to decide any or all the matters on the agenda of such meeting and such decision shall for all purposes be deemed a valid resolution of such meeting.
- (9) Voting rights of Holders of Products shall be determined according to the principal amount of Products held, each Product giving the right to one vote. Products held by or on behalf of the Issuer or a subsidiary of the Issuer shall have no voting rights and shall be disregarded for the purpose of this Condition 20, save that the Issuer shall be entitled to vote in respect of Products held by it for the benefit of and at the direction of an independent third party.

- (10) Any officer of the Issuer and its lawyers and any other person authorised in that behalf by it may attend and speak at any meeting.
- (11) A meeting of the Holders of Products shall have the following powers exercisable by Extraordinary Resolution:
- to postpone the maturity beyond the stated maturity of the Products, or
  - to reduce the amount of principal payable on any Products, or
  - to take any decision affecting the Coupons, if any, or the method of computation of the interest payable on any Products, or
  - to change any provision for, or the place of, payment contained in the Conditions of the Products or the Settlement Currency of any Products, or
  - to amend or modify or waive the whole or any parts of Conditions 2, 3, 4, 17 and 20, or
  - to waive an Event of Default.
- (12) Any amendments or waivers consented to or approved at a Productholders' Meeting will be conclusive and binding on all Holders of the Products whether or not they have given such consent or were present at such meeting, and on all future Holders of Products whether or not notation of such amendments or waivers is made upon the Products. Any instrument given by or on behalf of any Holder of a Products in connection with any consent to any such amendment or waiver will be irrevocable once given and will be conclusive and binding on all subsequent Holders of such Products.
- (13) Any reference in the Terms to an "Extraordinary Resolution" of the Holders of Products shall be construed as references to resolutions of the Holders of Products passed in accordance with the foregoing provisions of this Condition 20 as regards a matter stated in Subcondition (11) above.

**22. Further Adjustments, Updates, Modifications, or Supplements of the Terms and Conditions and Final Terms**

The Issuer has the possibility to conduct subsequent adjustments, updates, modifications, or supplements to the Base Prospectus, the Terms and Conditions or the Final Terms of the Products independently of unforeseeable changes regarding the Underlyings. This will primarily, but not exclusively, be required with respect to the updating of the information contained in these documents. However, the Issuer may also implement other (material) changes of the Terms and Conditions or the Final Terms deemed necessary by the Issuer in good faith and at its own discretion. In particular, such adjustments, updates, modifications or supplements may be necessary with respect to Products which have a term which is longer than one year or are open-ended (such as certain AMCs).

**23. Forced Transfer at Option of the Issuers Upon Void Transfer or Other Disposition**

No person other than a Permitted Transferee (as defined below) may at any time trade or maintain a position in the Products. Accordingly, any purported transferee of any legal or beneficial ownership interest in a Product in such a transaction will not be entitled to any rights as a legal or beneficial owner of such interest in such Product.

A "**Permitted Transferee**" means a person:

- (A) that is not a U.S. person as defined in Rule 902(k)(1) of Regulation S of the Securities Act; and
- (B) that is not a person who comes within any definition of U.S. person for the purposes of the CEA, as amended, or any rule, guidance or order proposed or issued by the

CFTC thereunder (including but not limited to any person who is not a "Non-United States person" under CFTC Rule 4.7(a)(1)(iv) (excluding for purposes of CFTC Rule 4.7(a)(1)(iv)(D) the exception for qualified eligible persons who are not "Non-United States persons"))).

**"Non-Permitted Transferee"** means a person that is not a Permitted Transferee.

Notwithstanding any other provision of these Conditions, the Issuer shall have the right, at any time after becoming aware that any legal or beneficial ownership interest in this Product is held or purported to be held by a Non-Permitted Transferee, to require such Non-Permitted Transferee to sell such interest to a person who is not a Non-Permitted Transferee at a price equal to the lesser of (i) the purchase price paid for such interest by such Non-Permitted Transferee, (ii) the principal amount of such interest and (iii) the fair market value of such interest, less any costs or expenses incurred by or on behalf of the Issuer in connection with such sale, all as determined by the Issuer in its sole and absolute discretion.

## FORM OF FINAL TERMS

### Derivative and Structured Product Programme

# [Product Name]

[Series No. [ ]]

These Final Terms shall form an integral part of the

Programme dated [ ], 2020

of

**Helvetische Bank AG**  
Zurich, Switzerland



(as "**Issuer**" and "**Lead-Manager**")]

---

Terms, words and expressions defined in the Base Prospectus shall bear the same meaning in these Final Terms (the "**Final Terms**"). This Product (the "**Product**") will be issued on the terms of these Final Terms to be read together with the Base Prospectus. A copy of the Base Prospectus is available free of charge from the registered office of the Issuer.

The Final Terms do not constitute, and may not be used for the purpose of, an offer or solicitation by anyone in any jurisdiction in which such offer or solicitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation, and no action is being taken to permit an offering of the Product or the distribution of these Final Terms in any jurisdiction where such action is required.

The Products, or interests therein, may not at any time be offered or distributed unless compliant with the applicable Selling Restrictions (see "Subscription and Sale" in the Base Prospectus as well as the Final Terms).

**[The Products do not constitute a collective investment scheme as defined in the Federal Collective Investment Schemes Act ("CISA") and are therefore neither governed by the CISA nor subject to supervision by the Swiss Financial Market Supervisory Authority (FINMA). Accordingly, Holders of the Product do not have the benefit of the specific investor protection provided under the CISA. Holders of the Product bear the issuer risk.]**

**or, for AMCs**

**[Actively Managed Certificates ("AMCs") are not collective investment schemes as defined in the Federal Collective Investment Schemes Act ("CISA") and are therefore neither governed by the CISA nor subject to supervision by the Swiss Financial Market Supervisory Authority (FINMA). Accordingly, Holders of the Product do not have the benefit of the specific investor protection provided under the CISA. Holders of the Product bear the issuer risk.]**

[Furthermore, investors should be aware that AMCs have a dynamic, discretionary structure, which may result in changes to the Product terms and/or the Strategy-Components.]

**[PROHIBITION OF SALES TO EEA AND UK RETAIL INVESTORS – The Products are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (EEA) or in the United Kingdom. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, MiFID II); or (ii) a customer within the meaning of Directive 2002/92/EC (as amended or superseded, the IMD), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Regulation (EU) 2017/1129 (the Prospectus Regulation). Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended, the PRIIPs Regulation) for offering or selling the Products or otherwise making them available to retail investors in the EEA or in the United Kingdom has been prepared and therefore offering or selling the Products or otherwise making them available to any retail investor in the EEA or in the United Kingdom may be unlawful under the PRIIPS Regulation.]**

**[MIFID II product governance / Professional investors and ECPs only target market – Solely for the purposes of [the/each] manufacturer's product approval process, the target market assessment in respect of the Products has led to the conclusion that: (i) the target market for the Products is eligible counterparties and professional clients only, each as defined in [Directive 2014/65/EU (as amended, "MiFID II")][MiFID II]; and (ii) all channels for distribution of the Products to eligible counterparties and professional clients are appropriate. [*Consider any negative target market*]. Any person subsequently offering, selling or recommending the Products (a "distributor") should take into consideration the manufacturer['s/s'] target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the Products (by either adopting or refining the manufacturer['s/s'] target market assessment) and determining appropriate distribution channels.**

or

**MIFID II product governance / Retail investors, professional investors and ECPs – Solely for the purposes of [the/each] manufacturer's product approval process, the target market assessment in respect of the Products has led to the conclusion that: (i) the target market for the Products is eligible counterparties, professional clients and retail clients, each as defined in MiFID II; EITHER [and (ii) all channels for distribution of the Products are appropriate, including investment advice, portfolio management, non-advised sales and pure execution services] OR [(ii) all channels for distribution to eligible counterparties and professional clients are appropriate; and (iii) the following channels for distribution of the Products to retail clients are appropriate - investment advice[,/ and] portfolio management[,/ and][ non-advised sales] [and pure execution services]], subject to the distributor's suitability and appropriateness obligations under MiFID II, as applicable]]. [*Consider any negative target market*]. Any person subsequently offering, selling or recommending the Products (a distributor) should take into consideration the manufacturer['s/s'] target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the Products (by either adopting or refining the manufacturer['s/s'] target market assessment) and**



determining appropriate distribution channels[, subject to the distributor's suitability and appropriateness obligations under MiFID II, as applicable].]

[Indicative Version / Final Version] of [Date]

[This Indicative Version of the Final Terms will be replaced by the Final Version thereof.] / [This Final Version of the Final Terms replaces the [Indicative / Final] Version of the Final Terms of [date].]

[In case of discrepancies between the Indicative Version and the Final Version of the Final Terms only the (latest) Final Version shall be binding. Holders of the Products must be aware that the Indicative Version and the Final Version of the Final Terms (or updates thereof) might not be identical with respect to certain terms, conditions, or other parameters thereof.]

1. Issuer Helvetische Bank AG, Seefeldstrasse 215, 8008 Zurich, Switzerland
2. Lead Manager, Paying Agent, Calculation Agent, Exchange Agent, Exercise Agent Helvetische Bank AG, Seefeldstrasse 215, 8008 Zurich, Switzerland
3. Method of Distribution [Syndicated or non-syndicated (including, if syndicated, the names of the Managers)]
4. Underlying [Details of the **Underlying or Underlying(s)** to which the Products relate and of the Entitlement (as defined in Condition 3) (in the case of Physical Delivery Products) and in the case of Cash Settled Products relating to a Basket, the multiplier (the "**Multiplier**", each such Multiplier shall be subject to adjustment in accordance with Condition 17(B) in the case of Share(s) as Underlying(s) or as otherwise provided in the Final Terms) to be applied to each item comprising the Basket in order to ascertain the Settlement Price]
5. General Information on the Underlying(s) [General Designation or Description of the Underlying(s) and in particular:
  - (a) details of the "**Basket of Shares**" (including, but not limited to, the number and type of each Share comprising the Basket) and of the Basket Companies or the single "**Share**" and the issuer of the Share;
  - (b) details of the "**Basket of Debt Securities**" or the single "**Debt Security**";
  - (c) details of the "**Basket of Indices**" or the single "**Index**";
  - (d) details of the "**Basket of Commodities**" or "**Commodity**";
  - (e) details of the "**Basket of Currencies**" or "**Currency**";
  - (f) details of any combination of the above, or other; and
  - (g) further details of the **Underlying(s)** to which the Products relate (if any).]
6. Company Name and Domicile of the issuers of the Underlying(s) [where applicable]
7. ISIN [If available, the **ISIN** of the Underlying(s); otherwise an alternative unique identifier]
8. Valoren Number [Where applicable, the relevant **Valoren Number** of the Products]

9. Common Code	[Where applicable, the relevant <b>Common Code</b> of the Products]
10. Source of the Underlying(s) Price	[Information on what <b>Source of the Underlying(s) Price</b> is used as a basis for the price of the Product. If the Underlyings are trading on a stock exchange, the name of this exchange must be given. Information must otherwise be given on where the price-setting mechanism for the Underlying(s) is available to the public.]
11. Price	[Information on which <b>Price</b> for the Underlying(s) (e.g. closing price, arithmetical mean price over a specific period) is material in establishing the price of the Product.]
12. Information on the Past Performance of the Underlying	[Details of where <b>Information on the Past Performance</b> of the Underlying(s) can be obtained.]
13. Additional Information on the Underlying(s) for Products on equity or debt securities, where applicable	[Note if a delivery of the Underlying is planned and transferability of the Underlying is restricted, if applicable]  [Information on where the current annual reports for the issuers of the Underlyings may be obtained free of charge for the term of the securities, provided they are not available on the website of the issuer of the Underlying or cannot be obtained via the latter.]
14. Additional Information on the Underlying(s) for Products on collective investment schemes, where applicable	[In the case of collective investment schemes, information on the fund management or issuing company, and details of the composition or investment universe of the collective investment scheme in question]  [Confirmation that the collective investment scheme has been authorised by FINMA for sale in or from Switzerland. Otherwise, a special statement must be made that the collective investment scheme has not been authorised for sale by FINMA.]
15. Additional Information on the Underlying(s) for Products on indices, where applicable:	[Name of the agency that calculates and publishes the index (index sponsor), as well as details of where information on the method of calculation is available to the public]  [Details of where information on the securities universe and any modifications to composition are available to the public (specifically where and when such adjustments are announced)]  [Whether the index in question is a price or performance (total return) index]
16. Additional Information on the Underlying(s) for Products on standardised options and futures contracts, where applicable	[Contract months, including the duration and the expiry, or information on the roll-over mechanism (e.g. roll-over to the corresponding front end future contract)]  [Contract unit and price quotation]
17. Additional Information on the Underlying(s) for Products on baskets of Underlying(s), where applicable:	[Initial fixing plus the percentage and, where appropriate, shares of the initial weighting of basket securities]  [If the composition of the basket is subject to predefined or discretionary modifications, then the permitted investment universe must be defined]
18. Additional Information on Actively Managed Certificates, where applicable:	[ <b>Statement regarding AMCs:</b> The Issuer must include the following statement on the cover sheet of the Final Terms:  <b>[Actively Managed Certificates ("AMCs") are not collective investment schemes as defined in the Federal Collective Investment Schemes Act ("CISA") and are therefore neither</b>

**governed by the CISA nor subject to supervision by the Swiss Financial Market Supervisory Authority (FINMA). Accordingly, Holders of the Product do not have the benefit of the specific investor protection provided under the CISA. Holders of the Product bear the issuer risk.]**

[Statement regarding Dynamic Structure: The Issuer must include the following statement on the cover sheet of the Final Terms:

**"The Product in question is a product with a dynamic structure, which may result in changes to the Product terms and/or to the Strategy-Components.".]**

[For Products with a dynamic structure: indication of how the price-related parameters in the product conditions, such as the composition of Underlying, may be modified during the term and an indication of whether the issuer may make modifications and, if so, which modifications.]]

(a) Investment Strategy

AMCs are subject to an active management.

[Details regarding the Investment Strategy]

[Information on investment universe, criteria for selecting securities]

[Information on how income from Underlying is treated]

[The Strategy-Guidelines and the related Investment Universe of AMCs must be specified at the time of issuance and may – in case of listed Products – not be altered at any later date without the approval of all investors.]

[The Strategy-Guidelines and the Investment Universe must be attached to the Final Terms.]

[The [Issuer / the Strategy-Manager], must continuously monitor compliance with the Strategy-Guidelines and the Investment Universe.]

[Note on where further information on the Investment Strategy can be obtained free of charge, where applicable.]

[Note on where the monthly updated percentage-weighted composition of the Underlying is accessible.]

(b) Investment Universe

[Details regarding the **Investment Universe**]

[if the composition of the Strategy-Components is subject to predefined or discretionary modifications, then the permitted Investment Universe must be defined]

(c) Initial Fixing / Initial Weighting of the Strategy-Level

[**Initial Fixing** plus the percentage and, where appropriate, shares of the **Initial Weighting** of the Strategy-Components]

(d) Strategy-Level

[Details regarding the Strategy-Level]

(e) Strategy-Manager

[Name or **company name** and **place of residence** or registered office of the Strategy-Manager of the Investment Strategy as well as information on the supervisory authority or, if applicable, a declaration that the manager is not prudentially supervised]

[Details regarding the **responsibilities of the Strategy-Manager**]

(f) Strategy-Guidelines	[Details regarding the <b>Strategy-Guidelines</b> [such information may be provided in the form of an annex to the Final Terms]
(g) Strategy-Components	[Details regarding the initial weighted <b>Strategy-Components</b> ]
(h) Investment Restrictions	[Details regarding Investment Restrictions for the Strategy-Manager, where applicable]
(i) Selection / Adjustments / Rebalancing of the Strategy-Components	[Details regarding <b>Adjustments of the Strategy-Components</b> [active or passive adjustments by the Strategy-Manager/detailed description of the adjustments ("roll-over")]  [Indication must be given as to the criteria according to which the <b>rebalancing</b> of the Strategy-Components is accomplished]
(j) Fees	[Details regarding the <b>Fees</b> ]  [Details of all compensation paid, such as, in particular, management fees for the Strategy-Manager of the Product]
(k) Reinvestment of Returns	[Details regarding <b>reinvestments of the returns</b> ]
(l) Redemption Amount	[Details on the redemption amount]
(m) Termination Rights	[Details regarding <b>termination rights</b> ]
19. Symbol	[Relevant Symbol of the Products]
20. Type	[The <b>Type</b> of Products admitted under this Programme, including, but not limited to, all products contained in the Swiss Derivative Map <sup>®</sup> , as amended from time to time by the Swiss Structured Products Association ( <a href="http://www.svsp-verband.ch">www.svsp-verband.ch</a> )]
21. Form	[Products to be represented by a Permanent Global Certificate or as Intermediated Securities ( <i>Bucheffekten</i> )]
22. Option Type, where applicable	[If applicable, whether the Products are <b>Call Products or Put Products</b> ]
23. Option Style, where applicable	[If applicable, whether the Products are <b>American Style Products, European Style Products</b> or other]
24. Exercise Date, where applicable	[If applicable, the exercise date, including the time the Product has to be exercised the latest on such date (the " <b>Exercise Date</b> ") for the Products (in the case of European Style Products) provided that, if such date is not a Business Day, the Exercise Date shall be the immediately preceding Business Day]
25. Exercise Period, where applicable	[If applicable, the exercise period, including the time the Product has to be exercised the latest on the last Business Day of such period (the " <b>Exercise Period</b> ") in respect of the Products (in the case of American Style Products)]
26. Settlement Date or Redemption Date, where applicable	[The settlement date (the day on which investors become entitled to the Cash Settlement Amount/Entitlement; the " <b>Settlement Date</b> " or " <b>Redemption Date</b> ") for the Products (if different from the definition in Condition 3)]
27. Minimum Exercise Number or Maximum Exercise Number, where applicable	[If applicable, whether, in addition to any requirements relating to " <b>Minimum Exercise Number</b> " or " <b>Maximum Exercise Number</b> " as set out below, Products must be exercised in units and the number of Products constituting a unit (the " <b>Ratio</b> "), and the Relevant Time and the Valuation Date if different from the definition in the Base Prospectus]
28. Ratio, where applicable	[In case of Share Warrants, Index Warrants, Share Certificates or

	Index Certificates, the <b>Ratio</b> ]
29. Nominal Amount	[If applicable, in the case of Cash Settled Products relating to Debt Securities, the nominal amount of the relevant Debt Securities to which the Products relate (the " <b>Nominal Amount</b> ") which is to be used to determine the Cash Settlement Amount pursuant to Condition 3 and details of the relevant screen page (" <b>Relevant Screen Page</b> ")]
30. Coupon, where applicable	[If applicable, whether the Products entitle to a <b>Coupon</b> and all provisions relating thereto including but not limited to, the method of calculation of the amount of interest payable and the interest payment dates; [N.B. interest portion and premium to be separately outlined for tax purposes; please specify all details as to the calculation of the interest payable, including but not limited to day-count-fraction, denomination (not the same as " <b>Nominal Amount</b> " as defined in Point 29 above).]
31. Total Amount	[The <b>Total Amount</b> and possible increase]
32. Number of Products / Issue Size	[The <b>number of Products</b> being issued/ <b>Issue Size</b> ]
33. Issue Price	[Issue Price per Product, be it in a currency amount, be it in a percentage]
34. Denomination	[Denominations of the Product, where applicable]
35. Issue Date	[Issue Date of the Products]
36. Payment Date	[Payment Date, where applicable]
37. Exercise Price	[If applicable, the exercise price or strike price (the " <b>Exercise Price</b> ") per Product (which may be subject to adjustment in accordance with Condition 17(B) in the case of Share Certificates and Share Warrants relating to shares) [N.B. This should take into account any relevant multiplier and, in the case of Index Warrants or Index Certificates, must be expressed as a monetary value]
38. [Issuer Cover, where applicable]	[In case of writers' warrants ( <i>Stillhalter-Optionen</i> ): declaration that the corresponding number of Underlyings has been pledged to or deposited with the Issuer or the holder of the warrants, so that the Issuer is able at all times to fulfil its obligation to deliver the instruments.]
39. Maturity Date	[ <b>Maturity Date</b> (the date on which the Product expires) and <b>Time</b> of stop trading of the Products]
40. Early Termination	[If the Issuer reserves the right to redeem the Product at any time after the payment date and prior to the Settlement Date in whole, but not in part, at an amount determined by the Calculation Agent in consultation with leading market makers to be the fair market value of the Products on the date of such termination (" <b>Early Termination</b> ")]
41. Redemption Details	[Details regarding redemption]  [If the Redemption Amount must be calculated on the basis of a formula, then the applicable formula(e) must be given.]
42. Level of Capital Protection, where applicable	[The Final Terms must contain information on how the level of capital protection is calculated.]  [If the capital protection is tied to conditions, such as reaching, exceeding or falling below certain thresholds, then this fact must

	be stated.]
43. Collateral Details, where applicable	[Details on collateral]
44. Interest Rate/Distributions, where applicable	[For interest-bearing Products and those with planned distributions of investment returns: interest rate and/or planned distribution; in the case of interest-bearing Products and those with planned distributions which have variable interest rates and/or variable distributions, details must also be provided on the interest or distribution periods, as well as the conditions for setting the interest rate or amount to be distributed.]
45. Interest Due Dates, where applicable	[For interest-bearing Products and those with planned distributions of investment returns: date from which interest becomes payable or the date on which the calculation period begins, as well as dates for the payment of interest or distributions, in addition to the "ex" date on which interest or distributions will be paid out.]
46. Settlement	[Whether settlement will be by way of cash payment (in case of <b>Cash Settled Products</b> ) and/or physical delivery (in case of an <b>Entitlement</b> )]
47. Option to vary settlement	[Whether the Issuer has the <b>Option to vary settlement</b> in respect of the Products, if any, and if different from 2.00 p.m. Zurich time on the second Business Day following the Actual Exercise Date]
48. Settlement Currency	[The settlement currency (the " <b>Settlement Currency</b> ") for the payment of the Cash Settlement Amount (in the case of Cash Settled Products) or the Disruption Cash Settlement Amount (in the case of Entitlement)]
49. Exchange Rate	[The applicable rate of exchange (the " <b>Exchange Rate</b> ") for conversion of any amount into the relevant settlement currency for the purposes of determining the Settlement Price (as defined in Condition 3) or the Cash Settlement Amount (as defined in Condition 3) and details of how and when such rate is to be ascertained]
50. Minimum Trading Volume	[Information on the minimum trading volume of the Products, if only multiple denominations can be traded (the " <b>Minimum Trading Volume</b> ")]
51. Minimum Exercise Number	[If applicable, the minimum number of Products (the " <b>Minimum Exercise Number</b> ") and any integral multiple of Products in excess thereof that can be exercised on any day by a Holder of Products]
52. Maximum Exercise Number	[If applicable, the maximum number of Products (the " <b>Maximum Exercise Number</b> ") that can be exercised on any day by a Holder of Products or group of Holders of Products (whether or not acting in concert) [N.B. not applicable for European Style Products]]
53. Listing	[Whether the Products will be listed on SIX Swiss Exchange and traded on SIX Structured Products Exchange (where applicable)]
54. Secondary Market / Market Maker	[Whether there will be a <b>Secondary Market / Market Maker</b> ]

55. Selling Restrictions [Details of any special **Selling Restrictions**]  
[**Highlighted information on any Selling Restrictions according to foreign law.**]
56. Details of the relevant Exchange(s), where applicable [If applicable, for the purposes of Condition 3 and Condition 17(B) (terms for Share Warrants and Share Certificates), details of the relevant Exchange(s) (the "**Exchange(s)**")]
57. Further information, where applicable [If applicable, for the purposes of Condition 17(A) (terms for Index Warrants and Index Certificates): (i) details of the relevant Exchange(s) (the "**Exchange(s)**"); and (ii) details of the relevant **Sponsor.**]  
[If applicable, in relation to Debt Warrants or Debt Certificates, provisions dealing with the situation where one or more of the relevant Debt Securities is redeemed (or otherwise ceases to exist) before the expiration of the relevant warrants or certificates]  
[If applicable, in relation to Commodity Warrants or Commodity Certificates, the **provisions for the calculation of the Settlement Price** [N.B.: Please distinguish between Settlement Price and Cash Settlement Amount]]  
[If applicable, in relation to Currency Warrants or Currency Certificates, details of the Relevant Screen Page, the relevant base currency (meaning the currency in which the Currency Warrants or the Currency Certificates will be issued and traded) (the "**Base Currency**") and the relevant subject currency or currencies (meaning the Currency representing the Underlying(s) in the Currency Warrants or the Currency Certificates) (each a "**Subject Currency**")]  
[Provisions for **calculating the Settlement Price** when a Market Disruption Event (if applicable and as defined in Condition 17) occurs on the Valuation Date (as defined in Condition 3) or on an Averaging Date (as defined in Condition 3), as the case may be if different from those outlined in Condition 3]  
[The applicable definition of **Trading Day** (if different from the definition in Condition 3)]  
[The applicable Business Day center(s) for the purposes of the definition of "**Business Day**" in Condition 3]
58. [Averaging, where applicable] Whether **Averaging** applies to the Products and if so the relevant Averaging Dates and whether in the event of a Market Disruption Event (as defined in Condition 17) occurring on an Averaging Date Omission, Postponement or Modified Postponement (each as defined in Condition 3) will apply (in the case of Debt Warrants, Debt Certificates, Currency Warrants, Currency Certificates or Commodity Warrants and Commodity Certificates, provisions for determining the Averaging Date in the event of Modified Postponement applying will be set out in the applicable Final Terms).
59. [Calculation, Paying and Exchange Agent] [Details of the **Calculation, Paying and Exchange Agent** (if other than the Issuer)]
60. No Material Adverse Change [Statement that either (i) except as disclosed in the Base Prospectus (including any document incorporated by reference therein) there has been no material adverse change in the

financial position of the Issuer since the date of the most recently published audited annual financial statements of the Issuer or (ii) gives details of any such material adverse change.]

[Except as disclosed in the Base Prospectus (including any document incorporated by reference therein) there has been no material adverse change in the financial position of the Issuer since the date of the most recently published audited annual financial statements of the Issuer.]

[Except as disclosed in the Base Prospectus (including any document incorporated by reference therein), the Issuer is not involved in any litigation or arbitration proceedings (nor to the knowledge of the Issuer are any such proceedings pending or threatened) relating to claims or amounts, the resolution of which, in the opinion of the management of the Issuer would have a material adverse effect on its financial position.]

61. [Use of Proceeds] [Use of Proceeds, if different than stipulated in this Base Prospectus]
62. [Series Number] [The series number of the Products]
- [Whether or not the Products are to be consolidated and form a single series with the Products of an existing series]
63. Applicable Law/Place of Jurisdiction Swiss Law/Zurich
64. Responsibility The Issuer accepts responsibility for the information contained in the Final Terms and has taken all reasonable care to ensure that the facts stated in the Final Terms are true and accurate in all material respects as of the date of the Final Terms and that as of such date there are no other material facts whose omission would render misleading any statement herein, whether of fact or opinion.
65. Risks **[Investments in the Product are subject to high risks. In a worst case scenario Holders of the Product may lose their total investment. Furthermore, depending on the specific circumstances the Product may not be suitable or appropriate for an investor.]**
- [Description of the main risks with regard to the Products (to the extent they are not already included in the Base Prospectus), in the form of an outline description of the loss potential of the Products in words or a graph showing the performance of the derivatives as a function of the Underlying.]
- [Additional information, if any, on the **Risks** for an investor to buy a Product]
66. Further Conditions [Specific conditions for Products]
- [Any other special conditions, in respect of, and any modification to the Terms and Conditions]
67. Information on Admission to Trading [The key information on any admission to trading is supplemented in the applicable Final Terms.]
- [Duration of trading: The planned duration for which the Products will be traded, stating the last trading day and time if trading does not continue until the close of trading]



- |   |   |
|---|---|
| 68. [Additional key information related to the Summary of the Base Prospectus, if required] | [The key information on the Products for a specific public offer or a specific admission to trading of Products is supplemented in the applicable Final Terms]<br><br>[The key information on any specific (public) offer is supplemented in the applicable Final Terms (if any)] |
| 69. Type of Quoting   | [Type of quoting: For Products with an interest component, such as reverse convertibles: information on whether the Products will be traded or quoted including accrued interest or whether the accrued interest will be shown separately (flat/dirty trading or clean trading)]  |
| 70. Fees  | [Details on Fees in percentage ranges]  |
| 71. Common Depositary   | [SIX SIS AG]  |
| 72. Tax   | [Details on taxation]   |

## **SIGNATURES**

Zurich, \_\_\_\_\_

Helvetische Bank AG

\_\_\_\_\_

\_\_\_\_\_

## **USE OF PROCEEDS**

The Issuer intends to use the net proceeds from each issue of Products for general corporate purposes. All or part of the proceeds may be used to maintain positions in certain options or forward contracts or hedging instruments relating to payment obligations resulting from the issuance of the Products.

## INFORMATION ON THE ISSUER

<b>1.</b>	<b>RISKS RELATING TO THE ISSUER</b>
	A description of the risk factors relating to the Issuer that may affect the ability of the Issuer to fulfil its obligations under the Products are set out in the Section entitled "Risk Factors" on pages 8 to 19 of the Base Prospectus.
<b>2.</b>	<b>GENERAL INFORMATION</b>
<b>2.1.</b>	<b>Name, Registered Office, Location</b>
	Helvetische Bank AG, Seefeldstrasse 215, 8008 Zurich, Switzerland
<b>2.2.</b>	<b>System of Law, Legal Form</b>
	The Issuer has been created as a company limited by shares according to the Art. 620 and following of the Swiss Code of Obligations (CO) and is subject to the Swiss Federal Law governing Banks and Savings Institutions.
<b>2.3.</b>	<b>Incorporation, Duration</b>
	The Issuer was incorporated in the Register of Commerce of Zurich on December 3, 2009. Its duration is unlimited.
<b>2.4.</b>	<b>Purpose</b>
	<p><i>"The company purposes in particular the activity of the following bank transactions:</i></p> <ul style="list-style-type: none"> <li><i>a) the asset and wealth advisory;</i></li> <li><i>b) the wealth management;</i></li> <li><i>c) the provision of family office services;</i></li> <li><i>d) the granting of covered and uncovered credits of all kinds, particularly lombard loans, overdraft credits and loans;</i></li> <li><i>e) acceptance of moneys in all customary banking forms, except saving deposits;</i></li> <li><i>f) the delivery of suretyships, bails and guarantees;</i></li> <li><i>g) purchase and sale of and trading with foreign currencies and foreign treasury notes, precious metals for own and third-party account;</i></li> <li><i>h) purchase and sale of and trading with securities for own and third-party account;</i></li> <li><i>i) handling of payment transactions;</i></li> <li><i>j) handling of the letter of credit business and the debt-collecting business;</i></li> <li><i>k) handling of trust transactions;</i></li> <li><i>l) consulting in the field of company financings, corporate mergers as well as company takeovers (corporate finance, mergers &amp; acquisitions);</i></li> <li><i>m) issue of securities, particularly transactions on the capital market.</i></li> </ul> <p><i>The corporation may set up subsidiaries, branches and agencies at home and abroad, hold participations in other companies, and acquire, exploit, administer and dispose of real estate and carry out all acts implicated by its business purpose.</i></p> <p><i>The geographical business circle extends over Switzerland particularly."</i></p> <p>(Art. 2 of the Issuer's company by-laws dated April 5, 2018)</p>
<b>2.5.</b>	<b>Register, Date of Registration, Company No.</b>
	Register of Commerce in Zurich / December 3, 2009 / CH-115.256.141

<b>2.6.</b>	<b>Group</b>  NA
-------------	------------------------

<b>3.</b>	<b>INFORMATION ON ADMINISTRATIVE, MANAGEMENT AND AUDIT BODIES</b>
-----------	---

<b>3.1.</b>	<p><b>Board of Directors and Management (as of June 1, 2020) / Business Address</b></p> <p><i>Board of Directors</i></p> <p>Thomas Matter, Chairman François M. Bianchi Marcel Rohner Arno G. Zanetti</p> <p><i>Management</i></p> <p>Daniel Hefti, Chief Executive Officer Thomas Maag Thomas Della Casa Rolf Weilenmann Stefan Renold</p> <p><i>Founders</i></p> <p>Matter Group AG (with Thomas Matter as sole shareholder) Tödi Holding AG (with Daniel Hefti as sole shareholder)</p> <p><i>Business address</i></p> <p>For the purposes of this Programme the business address of the members of the board of directors and the management is the registered office of the Issuer.</p>
-------------	--

<b>3.2.</b>	<p><b>Auditor</b></p> <p>BDO AG (CHE-105.952.747), Schiffbaustrasse 2, 8031 Zurich.</p>
-------------	---

<b>4.</b>	<b>BUSINESS ACTIVITIES</b>
-----------	----------------------------

<b>4.1.</b>	<p><b>Principal Activities</b></p> <p>The Issuer is a Swiss bank licenced by FINMA. The Issuer's principal activities are asset management for private and institutional customers, investment advisory and private banking services, corporate finance transactions, and financial products.</p> <p>The asset management services have a focus on discretionary mandates for private clients, entrepreneurs or former entrepreneurs and family offices, tailor-made individual mandates, and activities closely related to it such as investment funds and structured products.</p> <p>The corporate finance services in the Swiss capital market are primarily designed to meet the needs of SMEs and exchange-listed small and mid-cap companies. The Issuer offers a broad spectrum of services, such as equity capital (IPO, public to private, capital increases, share block transactions, share buybacks, stock splits, par value reductions, private placements, etc.), debt capital (bond and convertible bond issues, private placements, etc.), M&amp;A (private and public takeovers, MBOs/LBOs, succession planning, etc.), and further services (participation management, employee participation, market-making mandates, etc.).</p> <p>The advisory services offer an efficient securities trading service in the fixed income, equities, currencies, derivatives and futures segments. HB is a member of SIX Swiss Exchange and is linked to other important financial centers by way of electronic trading systems or third-party banks. It provides access to all of the investment instruments available on the market. The advisory services focus on the Swiss capital market.</p> <p>The activities of the issuer with respect to financial products comprise, inter alia, the offering and issuance of financial instruments (in particular, derivatives and structured products).</p>
-------------	---

<b>4.2.</b>	<b>Business Outlook</b>  The Issuer intends to strengthen its business and, subject to market conditions, the Issuer plans to further extend its issuance of structured products. However, the main prospects of the Issuer are uncertain.
<b>4.3.</b>	<b>Court, Arbitral and Administrative Proceedings</b>  The Issuer is not involved in any pending or threatened court, arbitral and administrative proceedings which are of material importance to the Issuer's assets and liabilities or profits and losses.
<b>4.4.</b>	<b>Recognised Representative of the Issuer</b>  Niederer Kraft Frey Ltd., Zurich, Switzerland, has been appointed as recognised representation pursuant to Art. 58a LR.
<b>5.</b>	<b>CAPITAL</b>
<b>5.1.</b>	<b>Capital Structure</b>  (see annexed annual report)
<b>5.2.</b>	<b>Outstanding Conversion and Option Rights and Bonds</b>  (see annexed annual report)
<b>5.3.</b>	<b>Own Equity Securities</b>  None
<b>6.</b>	<b>ANNUAL FINANCIAL STATEMENTS</b>
<b>6.1.</b>	<b>Annual Financial Statements</b>  (see annexed annual reports)
<b>6.2.</b>	<b>Audit of the Annual Financial Statements</b>  (see annexed annual report)
<b>6.3.</b>	<b>Balance Sheet Date</b>  (see annexed annual report)
<b>6.4.</b>	<b>Information on the Issuer's most recent Business Performance</b>  (see annexed annual report)
<b>6.5.</b>	<b>Material Changes since the most recent Annual Financial Statements</b>  There has been no material adverse change in the financial position or prospects of the Issuer and its subsidiaries taken as a whole, and no significant change in the financial or trading position of the Issuer since the date of the most recently published audited financial statements.

## TRIPARTY COLLATERAL MANAGEMENT SECURED PRODUCTS (TCM)

### Collateralisation of Products

A TCM-Product is secured in accordance with the terms of the Security Agreement (as defined below). Helvetische Bank AG ("**Collateral Provider**") undertakes to secure the value of the TCM-Product at any given time. Capitalised terms used but not otherwise defined herein shall have the meaning ascribed to them in the Final Terms of the TCM-Product or the Security Agreement respectively.

The owner of the Product ("**Collateral Taker**") has a surety right to the collateral. Security must be provided to the Collateral Taker in the form of a regular right of lien. The collateral is booked to an account of the Collateral Provider with SIX SIS AG. The TCM-Product and the collateral shall be valued on each Business Day. The TCM-Product will be valued by the Calculation Agent and such calculation will be published by the Calculation Agent on the respective webpage of SIX Financial Information AG. The Collateral Provider shall be obliged to adjust the collateral to any changes in value. Permitted forms of collateral shall be selected by SIX SIS AG on an ongoing basis from various categories of security, among others also the securities that are the direct or indirect underlying's of the TCM-Product. The Collateral Provider shall, upon inquiry, inform the Holders of the TCM-Products about the collateral that is eligible as security for the TCM-Product at any given time.

### Documentation

The collateralisation in favor of the Collateral Takers is based on the "TCM Security Agreement" between the Collateral Provider, the Collateral Taker, represented by SIX SAG AG (the "**Collateral Agent**"), and SIX SIS AG dated February 18, 2015 ("**Security Agreement**"). The Security Agreement is incorporated by reference to this Base Prospectus and constitutes an integral part thereof. In the event of any contradiction between the Base Prospectus and the Security Agreement, the Security Agreement takes precedence. The Issuer shall, upon request, provide the Security Agreement to investors free of charge. The Security Agreement may be obtained from Helvetische Bank AG, Seefeldstrasse 215, 8008 Zurich, Switzerland, via telephone (+41 44 204 56 78), fax (+41 44 204 56 99) or via e-mail ([products@helvetischebank.ch](mailto:products@helvetischebank.ch)), or on the website of the Issuer (<http://www.helvetischebank.ch>).

### Collateralisation Method

The collateral that must be furnished by the Collateral Provider is determined by the value of the TCM-Product at any given time ("**Current Value**"). The Current Value of the TCM-Product is calculated exclusively by, and with full responsibility of, the Collateral Provider in accordance with acknowledged accounting principles but without any independent review. Neither the Collateral Agent, nor SIX SIS AG nor SIX Financial Information AG recalculates or otherwise reviews the calculation of the Current Value. The Current Value is communicated by the Collateral Provider to SIX Financial Information AG which publishes it. SIX SIS AG calculates whether the coverage requirements for the collateral on the basis of the Current Value as published by SIX Financial Information AG are met. Neither the Collateral Agent, nor SIX SIS AG nor SIX Financial Information AG shall be liable for any losses or damages suffered by any Collateral Taker as a consequence of an inaccurate calculation of the Current Value or of an inaccurate communication of such value to SIX Financial Information AG. The Collateral Provider can act as the Calculation Agent. The Calculation Agent shall provide upon demand the method used to calculate the Current Value. The calculation method shall be determined for each TCM-Product upon its issuance and shall remain unchanged for its entire term. The collateral provided for a TCM-Product will be earmarked for this specific TCM-Product and will not secure any other TCM-Product.

## **Distribution and Market Making**

The distribution of the TCM-Product shall be the responsibility of the Issuer. The bid price published by the Calculation Agent on the respective page of SIX Financial Information AG does neither constitute an offer nor an invitation for an offer to purchase the TCM-Product.

## **Risks**

Collateralisation eliminates the Issuer default risk only to the extent that the proceeds from the liquidation of collateral upon occurrence of a Realisation Event – as defined below under "Liquidation of Collateral" – (less the costs of liquidation and payout) are able to meet the claims of the Holders of the TCM-Products. The Holders of the TCM-Products bear the following risks, among others: (i) the Collateral Provider is unable to supply the additionally required collateral if the value of the TCM-Product rises or the value of the collateral decreases; (ii) in a Realisation Event, the collateral cannot be liquidated immediately by the Collateral Agent because of factual hindrances or because the collateral must be handed over to the executory authorities for liquidation; (iii) the market risk associated with the collateral results in insufficient liquidation proceeds or, in extreme circumstances, the collateral might lose its value entirely until the liquidation can take place; (iv) the maturity of the TCM-Product in a foreign currency according to the Security Agreement may result in losses for the Holders of the TCM-Products because the Current Value (determinant for the claims of the Holders of the TCM-Products against the Issuer) is set in the foreign currency, while payment of the pro-rata share of net liquidation proceeds (determinant for the extent to which the claims of the Holders of the TCM-Products against the Issuer are satisfied) may be made in a different currency; (v) the collateralisation is challenged according to the laws governing debt enforcement and bankruptcy, so that the collateral cannot be liquidated according to the terms of the Security Agreement. The collateralisation does not eliminate the risk that there might not be a buyer for the TCM-Product during its lifetime and that the Holders of the TCM-Product might have to hold the TCM-Product until maturity.

## **Liquidation of Collateral**

If the Collateral Provider fails to fulfill its obligations, the collateral will be liquidated by the Collateral Agent or a liquidator under the terms of the applicable legal regulations. Collateral may be liquidated ("**Realisation Events**") in particular if (i) the Collateral Provider fails to furnish the required collateral or fails to do so in due time, unless this is remedied within five (5) Business Days; (ii) the Issuer fails to fulfill a payment or delivery obligation under the TCM-Product upon maturity according to the issuing conditions or fails to do so in due time, unless this is remedied within five (5) Business Days; (iii) FINMA orders protective measures with regard to the Issuer or the Collateral Provider under Art. 26 para. 1 lit. f or h of the Federal Act on Banks and Savings Banks ("**Banking Act**"), or restructuring proceedings under Art. 28 et seq. of Banking Act or liquidation (winding-up proceedings) under Art. 33 et seq. of the Banking Act. The Security Agreement provides for the exact time at which each Realisation Event occurs. The remedy of a Realisation Event is not possible.

## **Determination of a Realisation Event**

The Collateral Agent is not required to undertake investigations with regard to the occurrence of a Realisation Event. In determining the occurrence of a Realisation Event, it bases its decision on reliable sources of information only. The Collateral Agent determines with binding effect for the Holders of the TCM-Products whether an incident qualifies as a Realisation Event and at what point in time the Realisation Event occurred.

## **Procedure in case of a Realisation Event**

If a Realisation Event occurs, the Collateral Agent is at its discretion entitled: (i) to make public the occurrence of a Realisation Event immediately or at a later stage in suitable form; as well as (ii) to liquidate immediately or at a later stage – without regard to the amount of unsatisfied claims – all existing collateral on a private basis, provided the applicable legal regulations or regulatory orders do not prohibit such private liquidation (and, if a private liquidation is not possible, hand the collateral over to the competent person for liquidation).

## **Maturity of the TCM-Product / Claims of the Holders of the TCM-Product against the Issuer**

The Realisation Event with regard to a specific TCM-Product does not trigger the Realisation Event of other TCM-Products of the Issuer. The Collateral Agent will communicate the due date of the Realisation Event of a TCM-Product. The Holders of the TCM-Products shall have a security interest in accordance with Art. 25 para. 2 lit. b FISA over the securities and a pledge according to Art. 899 et seq. of the Swiss Civil Code ("CC") over the cash provided as collateral to secure the TCM-Product. The acquisition of a TCM-Product by a Holder of the TCM-Product automatically entails the declaration vis-à-vis the Collateral Agent to accept the Collateral Agent as its representative regarding the Security Agreement and that he wishes to enforce his right under the Security Agreement in the Realisation Events mentioned therein. In dealings with the Collateral Agent and SIX SIS AG, Holders of the TCM-Products are bound by the provisions of the Security Agreement, specifically the choice of Swiss law and the exclusive jurisdiction of the Courts of Zurich (Switzerland). If a Realisation Event with regard to a TCM-Product has occurred, the Collateral Agent will determine the liquidation value of such TCM-Product to the last Current Value available prior to the occurrence of the Realisation Event. This value shall be binding on the Collateral Provider and the Holders of the TCM-Products. Claims of the Holders of the TCM-Products against the Issuer will be based on these Current Values when the TCM-Products mature in accordance with the Security Agreement.

## **Costs of Liquidation and Payout for the Benefit of the Holders of the TCM-Products**

Any costs of the Collateral Agent and in connection with the liquidation of the collateral (including fees, taxes and duties) shall, in advance, be covered out of the proceeds of the liquidation of the collateral. In addition, the Collateral Agent shall be entitled to satisfy, in advance out of the proceeds of the liquidation of the collateral, any outstanding claims it holds against the Collateral Provider under the terms of the Security Agreement. The remaining liquidation proceeds are available for payout to the Holders of the TCM-Products. The pro-rata share of net liquidation proceeds due to Holders of the TCM-Products will be transferred to SIX SIS AG participants on a delivery versus payment basis. In doing so the Collateral Agent is released from all further obligations. The claim of the Holders of the TCM-Products is non-interest-bearing. The payments to the Holders of the TCM-Products may be delayed for factual or legal reasons. The Collateral Agent and SIX SIS AG are not liable to pay either default interest or damages should the payout be delayed for any reason. The maximum claim of the Holder of a TCM-Product to satisfaction from the net liquidation proceeds of the collateral earmarked for the TCM-Product is determined by its Current Value. Each TCM-Product will only be secured by its earmarked collateral. The claims of the Holders of the TCM-Products against the Issuer arising from the TCM-Product are reduced by the amount of the payment of the net liquidation proceeds. No further claims of the Holders of the TCM-Products exist against the Collateral Agent, SIX SIS AG or other persons which are involved in the collateralisation service for the TCM-Product under the terms of the Security Agreement.

## **Liability**

The liability of the parties to the Security Agreement to pay damages exists only in cases of gross negligence or intentional misconduct. Further liability is excluded.



**No Authorisation**

TCM-Products do not constitute collective investment schemes pursuant to the CISA. They do not require authorisation or supervision by FINMA.

**Congruence with the Programme**

The provisions of this Section "Triparty Collateral Management Secured Products (TCM)" take precedence in the event of contradiction between this Section and the other content of the Programme.

## SUBSCRIPTION AND SALE

The Issuer may from time to time agree to issue and place Products. Any such undertaking will extend to those matters stated under the relevant "Form of Final Terms" and "Terms and Conditions" above.

**No action has been or will be taken by the Issuer that would permit a public offering of any Products or possession or distribution of any offering material in relation to any Products in any jurisdiction where action for that purpose is required. No offers, sales, resales or deliveries of any Products, or distribution of any offering material relating to any Products, may be made in or from any jurisdiction except in circumstances which will result in compliance with any applicable laws and regulations and which will not impose any obligation on the Issuer.**

### United States of America, US Persons

The Products have not been and will not be registered under the Securities Act or under the securities law of any state or political sub-division of the United States. The Products are being offered and sold in reliance on an exemption from the registration requirements of the Securities Act pursuant to Regulation S.

Accordingly, the Products may not be offered, sold, pledged or otherwise transferred except in an "Offshore Transaction" (as such term is defined under Regulation S) to or for the account or benefit of a Permitted Transferee.

The following definitions shall apply for the purposes of this transfer restriction:

**"Permitted Transferee"** means any person:

- (a) that is not a U.S. person as defined in Rule 902(k)(1) of Regulation S; and
- (b) that is not a person who comes within any definition of U.S. person for the purposes of the CEA or any CFTC Rule, guidance or order proposed or issued under the CEA (for the avoidance of doubt, any person who is not a "Non-United States person" as such term is defined under CFTC Rule 4.7(a)(1)(iv), but excluding, for purposes of Subsection (D) thereof, the exception for qualified eligible persons who are not "Non-United States persons", shall be considered a U.S. person).

**"Non-Permitted Transferee"** means a person that is not a Permitted Transferee.

Transfers of Products within the United States or to any person other than a Permitted Transferee are prohibited. Accordingly, any purported transferee of any legal or beneficial ownership interest in a Product in such a transaction will not be entitled to any rights as a legal or beneficial owner of such interest in such Product. The Issuer shall have the right at any time after becoming aware that any legal or beneficial ownership interest in a Product is held by a person other than a Permitted Transferee to require such Non-Permitted Transferee to sell such interest to (i) the Issuer (to the extent permitted by applicable law); or (ii) a person who is a Permitted Transferee.

The Products have not been approved or disapproved by the United States Securities and Exchange Commission (the "SEC") or any other regulatory agency in the United States, nor has the SEC or any other regulatory agency in the United States passed upon the accuracy or adequacy of this document or the merits of the Products. Any representation to the contrary is a criminal offence. Furthermore, the Products do not constitute, and have not been marketed as, contracts for the sale of a commodity for future delivery (or options thereon) subject to the CEA and neither trading in the Products nor this document has been approved by the CFTC under the CEA, and no person other than a Permitted Transferee may at any time trade or maintain a position in the Products.

### European Economic Area

Unless the Final Terms in respect of any Products specifies "Prohibition of sales to EEA and UK Retail Investors" as "Not Applicable", each Dealer has represented and agreed, and each further

Dealer appointed under the Programme will be required to represent and agree, that it has not offered, sold or otherwise made available and will not offer, sell or otherwise make available any Products which are the subject of the offering contemplated by this Base Prospectus as completed by the Final Terms in relation thereto to any retail investor in any Member State of the European Economic Area and the United Kingdom (each a **Relevant State**). For the purposes of this provision:

- (a) the expression retail investor means a person who is one (or more) of the following:
  - (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, **MiFID II**); or
  - (ii) a customer within the meaning of Directive 2002/92/EC (as amended or superseded, the **Insurance Mediation Directive**), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or
  - (iii) not a qualified investor as defined in the Prospectus Regulation; and
- (b) the expression an offer includes the communication in any form and by any means of sufficient information on the terms of the offer and the Products to be offered so as to enable an investor to decide to purchase or subscribe the Products.

If the Final Terms in respect of any Products specifies "Prohibition of sales to EEA and UK Retail Investors" as "Not Applicable", in relation to each Relevant State, each Dealer has represented and agreed, and each further Dealer appointed subsequently under the Programme will be required to represent and agree, that it has not made and will not make an offer of Products which are the subject of the offering contemplated by this Base Prospectus as completed by the Final Terms in relation thereto to the public in that Relevant State, except that it may make an offer of such Products to the public in that Relevant State:

- (a) if the Final Terms in relation to the Products specify that an offer of those Products may be made other than pursuant to Articles 1(4) and/or 3(2) of the Prospectus Regulation in that Relevant State (a "**Public Offer**"), following the date of publication of a prospectus in relation to such Products which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, provided that any such prospectus has subsequently been completed by the Final Terms contemplating such Public Offer, in accordance with the Prospectus Regulation, in the period beginning and ending on the dates specified in such prospectus or Final Terms, as applicable, and the relevant Issuer has consented in writing to its use for the purpose of that Public Offer;
- (b) at any time to any legal entity which is a qualified investor as defined in the Prospectus Regulation;
- (c) at any time to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation) subject to obtaining the prior consent of the relevant Dealer or Dealers nominated by the relevant Issuer for any such offer; or
- (d) at any time in any other circumstances falling within Article 1(4) of the Prospectus Regulation,

provided that no such offer of Products referred to in paragraphs (b) to (d) above shall require the relevant Issuer or any Dealer to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.

For the purposes of this provision, the expression an "offer of Products to the public" in relation to any Products in any Relevant State means the communication in any form and by any means of

sufficient information on the terms of the offer and the Products to be offered so as to enable an investor to decide to purchase or subscribe for the Products.

## France

This Base Prospectus prepared in connection with the Products has not been submitted to the *Autorité des marchés financiers* (the "AMF").

Each of the Managers has represented and agreed that it undertakes to comply with applicable French laws and regulations in force regarding the offer, the placement or the sale of the Products and the distribution in France of this Base Prospectus or any other offering material relating to the Products.

## United Kingdom

All applicable provisions of the Financial Services and Markets Act 2000 (the "FSMA") must be complied with in respect to anything done in relation to any Products in, from or otherwise involving the United Kingdom.

Each Manager of an issue of Products has represented and agreed that:

- (1) it is a person whose ordinary activities involve them in acquiring, holding, managing or disposing of investments (as principal or agent) for the purposes of their businesses and it has not offered or sold and will not offer or sell the Products other than to persons whose ordinary activities involve them in acquiring, holding, managing or disposing of investments (as principal or agent) for the purposes of their businesses or who it is reasonable to expect will acquire, hold, manage or dispose of investments (as principal or agent) for the purposes of their businesses where the issue of the Products would otherwise constitute a contravention of Section 19 of the FSMA by the Issuer;
- (2) it has only communicated or caused to be communicated and will only communicate or cause to be communicated any invitation or inducement to engage in investment activity (within the meaning of Section 21 of the FSMA) received by it in connection with the issue or sale of any Products in circumstances in which Section 21(1) of the FSMA does not apply to the Issuer; and
- (3) it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to such Products in, from or otherwise involving the United Kingdom.

## Switzerland

**The Products do not constitute a collective investment scheme as defined in the Federal Collective Investment Schemes Act ("CISA") and are therefore neither governed by the CISA nor subject to supervision by the Swiss Financial Market Supervisory Authority (FINMA). Accordingly, Holders of the Product do not have the benefit of the specific investor protection provided under the CISA. Holders of the Product bear the issuer risk.**

Any Products which are intended to be publicly offered or admitted to trading on a trading venue in terms of Art. 26 of the Financial Markets Infrastructure Act ("FMIA") in Switzerland pursuant to Art. 35 para. 1 Financial Services Act ("FinSA) may only be offered, distributed or advertised in accordance with the FinSA. In particular, the Prospectus and the Final Terms must comply with the respective requirements of a FinSA prospectus according to Art. 35 para. 1 FinSA and Art. 43 Financial Services Ordinance ("FinSO") (as amended from time to time). The Products may be admitted to trading on any trading venue (exchange or multilateral trading facility) in Switzerland if and to the extent provided for in the Final Terms of the Products.

Any Products which may not intended to be publicly offered (such term including any invitation to acquire Products that contains sufficient information on the terms of the offer and the Products itself) or distributed (such term including any advertising type of activity whose object is the purchase of

Products by an investor) in Switzerland, may only be offered if (i) such offer is either strictly limited to investors that qualify as professional clients ("**Professional Clients**") according to Art. 4 para. 3 FinSA, or (ii) another exemption from the Swiss prospectus requirement pursuant to Art. 36 et seq. FinSA applies. Accordingly, such Products may only be offered or distributed, and the Offering Memorandum or any other marketing material relating to the Products may only be made available (i) to Professional Clients, or (ii) in accordance with other applicable exemptions (if any) in Switzerland.

A Key Information Document will be prepared in relation to the Products which are offered to private clients as defined under the FinSA and may be obtained, free of charge, upon request from Helvetische Bank AG, Seefeldstrasse 215, 8008 Zurich, Switzerland, via telephone (+41 44 204 56 78), fax (+41 44 204 56 99) or via e-mail ([products@helvetischebank.ch](mailto:products@helvetischebank.ch)). Within the transitory period of two years since the entering into force of the FinSA and FinsO pursuant to Art. 111 FinSO the Issuer reserves the right to prepare a simplified prospectus in accordance with Art. 5 para. 2 old CISA instead of a KID.

### **General**

With regard to each issue of Products, each Manager will be required to comply with such other additional restrictions as the Issuer shall agree and as shall be set out in the applicable Final Terms.

## TAXATION

Purchasers of Products may be required to pay stamp taxes and other charges in accordance with the laws and practices of the country of purchase in addition to the issue price of each Product.

**Potential purchasers who are in any doubt about the tax position of any aspect of transactions involving Products should consult their own tax advisers.**

Transactions involving Products may have tax consequences for potential purchasers which may depend, amongst other things, upon the status of the potential purchaser and laws relating to transfer and registration taxes.

Condition 11 should be considered carefully by all potential purchasers of any Products.

### Taxation in Switzerland

*The following summary does not purport to be a comprehensive description of all Swiss tax considerations that may be relevant to a decision to purchase, own or dispose of the Products and, in particular, does not consider specific facts or circumstances that may apply to a particular purchaser. It is for general information only and does not discuss all tax consequences of an investment in Products under the tax laws of Switzerland. This summary is based on the tax laws of Switzerland currently in force and as applied on the date of this Base Prospectus which are subject to changes (or changes in interpretation) which may have retroactive effect. Prospective purchasers are advised to consult their own tax advisers as to the tax consequences of the purchase, ownership and disposition of Products in the light of their particular circumstances.*

### Swiss Income Tax

#### *Swiss Resident Holders of Products*

Swiss residents receiving periodic interest payments during the investment or at redemption as one-time-interest generally must include these interest payments in their financial statements and/or in their income tax returns and owe individual income tax or corporate income tax on the relevant amounts.

Products which are not straight debt instruments but have components of debt instruments and derivatives intertwined generally qualify as combined instruments. The tax treatment of such Products depends on whether the Products are considered as transparent or not for Swiss income tax purposes.

If the Product is considered as not transparent for Swiss income tax purposes, any amount received by the Holder of the Product (upon sale, laps, exercise or redemption) in excess of the amount invested (at issue or upon purchase) is treated as taxable income in the hands of the Holder of the Product if the Product qualifies as a note with predominant one-time interest payment. If the Product does not qualify as a note with predominant one-time interest payment, the Holder of the Product is subject to tax on the periodic interest payments and (at redemption) on the difference between initial issuance price and the redemption price. For the purpose of determining whether the Product is a note with predominant one-time interest payment the difference between initial issuance price and the redemption price is treated as one-time interest.

If the Product is considered as transparent for Swiss income tax purposes, it will be split notionally in a debt instrument and a derivative instrument component. Gains or losses on the derivative instrument component are treated as capital gains or losses (see below). Interest payments received during the investment, at laps or exercise or at redemption as one-time interest related to the debt instrument component are treated as taxable income in the hands of the Holder of the Product. Such a treatment is also applicable for the purpose of determining whether the Product is a note with predominant one-time interest payment.

The Product is generally considered as transparent if the debt and the derivative components are traded separately or if the different elements of the Product (such as the guaranteed redemption amount, the issuance price of the debt component, the interest rates determining the issuance price of the debt component) are separately stated in the sales documentation as well as in the offering prospectus and if each one of such components is separately evaluated. Such evaluation has to be performed through calculations of financial mathematics determining the intrinsic value of the debt instrument and the derivative instrument components contained in the Product. In particular, the calculations have to determine the notional issuance price of the debt instrument, based on an interest rate taken into account by the Issuer which has to be at market value. The Swiss Federal Tax Administration has to approve such calculations. Such calculations have to be reviewed on a quarterly basis in order to take into account the evolution of the interest rates. If the tax authorities are not provided with sufficient information the Products can be treated as not transparent. Products with prevalent structures but for which the Issuer does not provide the information allowing to distinguish the different elements of a Product as described above are made transparent in retrospect by the tax authorities, banks or other channels of distribution if the following requirements are fulfilled: (a) the issuer of the product must have at least a single-A-rating; and (b) the product at hand has to be admitted to official quotation at the commercial exchange market or, at least, a market maker has to insure liquid trading of the product at hand. Liquid trading by a market maker is a condition that the key data of the product can be used as credible basis of calculation.

Products which are linked to Underlyings, such as bonds, shares, or baskets of such assets may also be treated, under certain circumstances, as direct investments in bonds, shares or in an investment fund. Products linked to a basket of investment funds may be treated as an investment in an investment fund.

Products in the form of reverse convertibles linked to shares, precious metals and commodities with no guaranteed payments and a duration of less than or equal to one year may be treated as straight derivatives.

#### *Non-Swiss Resident Holders of Products*

Non-Swiss resident Holders of Products are subject to the applicable tax laws and regulations of their home country. They may not be subject to Swiss income tax.

### **Capital Gains**

#### *Swiss Resident Private Holders of Products*

Swiss resident Holders of Products who do not qualify as so-called professional securities dealer for income tax purposes (*gewerbsmässiger Wertschriftenhändler*) and who hold the Products as part of their private (as opposed to business) assets are hereby defined as "Swiss Resident Private Holders of Products".

Swiss Resident Private Holders of Products realise a tax free capital gain upon the disposal of Products which do not qualify as notes with predominant one-time interest payment and realise taxable income if the Products qualify as notes with one-time predominant interest payment.

The tax treatment of capital gains on Products which qualify as combined instruments (see above) depends on whether the Product qualifies as tax transparent or not. Products which are not transparent for Swiss income tax purposes (see above) generally qualify as notes with predominant one-time interest payment and are treated as such. Products which qualify as tax transparent are notionally split into a debt instrument and a derivative instrument component. The debt instrument component follows the usual tax treatment either as note with predominant one-time interest payment or as note with no predominant one-time interest payment as applicable. Capital gains arising from the derivative instrument component of transparent Products are generally not subject to income tax in the hands of Swiss Resident Private Holders of Products.

With respect to capital gains arising from Products linked to Underlyings, such as investment funds, bonds, shares or baskets of any of them see above under "Swiss Income Tax – Swiss Resident Holders of Products".

#### *Swiss Resident Business Holders of Products*

Gains realised on the sale of Products, by Swiss resident individual Holders of Products holding the Products as part of their business assets as well as by Swiss resident legal entity Holders of Products, are part of their business profit subject to individual income tax or corporate income taxes, respectively. The same applies to Swiss Resident Private Holders of Products who qualify as so-called professional securities dealer (*gewerbsmässiger Wertschriftenhändler*).

#### *Non-Swiss Resident Holders of Products*

Under present Swiss tax law, a Holder of Products who is a non-resident of Switzerland and who, during the taxable year has not engaged in trade or business through a permanent establishment or a fixed place of business within Switzerland and who is not subject to taxation in Switzerland for any other reason, will not be subject to any Swiss federal, cantonal or municipal income tax on interest or gains realised on sale or redemption of the Products.

### **Swiss Stamp Duties**

The issuance of the Products is not subject to Swiss transfer stamp duty. The subsequent sale or transfer of the Products with a duration of more than one year, whether by Swiss resident or non-resident Holders, may be subject to Swiss transfer stamp duty at the current rate of up to 0.15 per cent., both calculated on the purchase price or the sales proceeds, respectively, if such sale or transfer occurs through or with a Swiss or Liechtenstein bank or another Swiss securities dealer as defined in the Swiss Stamp Tax Act and no exemption applies. The same applies in case of physical delivery of the Underlying(s) being a taxable security in the meaning of the Swiss Stamp Tax Act at redemption.

### **Swiss Withholding Tax**

All payments of interest (being periodic or one-time) in respect of the Products by a Swiss resident Issuer may be subject to the Swiss withholding tax (*Verrechnungssteuer*) currently at a rate of 35 per cent. The Issuer is obliged to deduct Swiss withholding tax from the interest payment and to pay the tax to the Swiss Federal Tax Administration.

A beneficiary of Products who is resident in Switzerland is eligible for a full refund or credit against income tax of the Swiss federal withholding tax, if he duly reports the underlying income in his financial statements or income tax return, as the case may be.

A non Swiss resident beneficiary of Products may be entitled to a total or partial refund of the Swiss federal withholding tax if such beneficiary is entitled to claim the benefits with regard to such an interest payment of a bilateral treaty for the avoidance of double taxation between Switzerland and his or her country of tax residency.

On 4 November 2015, the Swiss Federal Council announced that it had mandated the Swiss Federal Finance Department to appoint a group of experts to prepare a proposal for reform of the Swiss withholding tax system. The proposal presented by the group of experts as recommendations for a reform of the Swiss withholding tax in December 2018 provides, among other things, for a replacement of the current debtor-based regime applicable to interest payments with a paying agent-based regime for Swiss withholding tax. This paying agent-based regime is expected to be similar to the one contained in the draft legislation published by the Swiss Federal Council on 17 December 2014, which was subsequently withdrawn on 24 June 2015. However, on 23 October 2017, the Swiss Federal Economic Affairs and Taxation Committee of the Swiss National Council filed a parliamentary initiative reintroducing the request to replace the current debtor-based regime applicable to interest payments with a paying agent-based system that (i) subjects all interest



payments made to individuals resident in Switzerland to Swiss withholding tax and (ii) provides an exemption from Swiss withholding tax for interest payments to all other persons (including Swiss corporations). On 26 June 2019 and 27 September 2019, the Swiss Federal Council has adopted the key objectives of the reform and commissioned the Federal Department of Finance (EFD) to prepare a consultation draft by the 1<sup>st</sup> quarter 2020. On 3 April 2020, the Swiss Federal Council has published the consultation draft. If this legislation or similar legislation were enacted and an amount of, or in respect of, Swiss withholding tax were to be deducted or withheld from that payment, neither the Issuer nor the Paying Agent would be obliged to pay additional amounts with respect to any Product as a result of the deduction or imposition of such Swiss withholding tax.

### **International Automatic Exchange of Information in Tax Matters**

Switzerland has concluded a multilateral agreement with the European Union on the international automatic exchange of information (the "AEOI") in tax matters, which applies to all EU member states and some other jurisdictions. In addition, Switzerland has concluded the multilateral competent authority agreement on the automatic exchange of financial account information (the "MCAA"), and a number of bilateral AEOI agreements with other countries, most of them on the basis of the MCAA. Based on such agreements and the implementing laws of Switzerland, Switzerland collects and exchanges data in respect of financial assets, including, as the case may be, Products, held in, and income derived thereon and credited to, accounts or deposits with a paying agent in Switzerland for the benefit of individuals resident in an EU member state or in another treaty state. An up-to-date list of the AEOI agreements of Switzerland in effect or signed and becoming effective can be found on the website of the State Secretariat for International Financial Matters (SIF).

### **Swiss Facilitation of the Implementation of the U.S. Foreign Account Tax Compliance Act**

Switzerland has concluded an intergovernmental agreement with the U.S. to facilitate the implementation of FATCA (the "IGA"). Under the U.S.-Switzerland IGA, financial institutions acting out of Switzerland generally are directed to become participating foreign financial institutions ("FFIs"). The agreement ensures that the accounts held by U.S. persons with Swiss financial institutions are disclosed to the U.S. tax authorities either with the consent of the account holder or by means of group requests within the scope of administrative assistance. Information will not be transferred automatically in the absence of consent, and instead will be exchanged only within the scope of administrative assistance on the basis of the double taxation agreement between the U.S. and Switzerland ("DTA"). On 20 September 2019, Switzerland and the U.S. ratified the 2009 protocol (the "Protocol") amending the DTA. With the subsequent exchange of the ratification instruments, the amended DTA entered into force, and provide for a mechanism for the exchange of information upon request in tax matters between Switzerland and the United States, which is in line with international standards, and allows the United States to make group requests under FATCA concerning non-consenting U.S. accounts and non-consenting non-participating foreign financial institutions for periods from 30 June 2014. Furthermore, on 8 October 2014, the Swiss Federal Council approved a mandate for negotiations with the U.S. on changing the current direct-notification-based regime to a regime where the relevant information is sent to the Swiss Federal Tax Administration, which in turn provides the information to the U.S. tax authorities. It is not yet known when any new regime would come into force.

### **US Withholding Tax – Code Section 871(m)**

Special rules may apply to the extent that any portion of a payment is treated as a dividend or "dividend equivalent" for certain United States federal income tax purposes. The Issuer (or an applicable withholding agent) will withhold on such payments to the extent required by law. A dividend equivalent payment is treated as a dividend from sources within the United States and such payments generally would be subject to a 30 per cent. United States withholding tax (or less under an applicable treaty, if any) if paid to a United States Alien holder. Under U.S. Department of the Treasury (the "U.S. Treasury") regulations issued pursuant to Code Section 871(m), payments (including deemed payments) with respect to equity-linked instruments ("ELIs") that are "specified

ELIs" may be treated as dividend equivalents if such specified ELIs reference an interest in a U.S. "underlying security", which is generally any interest in an entity taxable as a corporation for U.S. federal income tax purposes if a payment with respect to such interest could give rise to a U.S. source dividend.

A specified ELI is an ELI that: (i) if it is classified as "simple", has a "delta" equal to 0.80 or greater with respect to a U.S. underlying security at the time it is issued, or (ii) if it is classified as "complex", meets a substantial equivalence test at the time it is issued. The regulations provide that the delta of an ELI is the ratio of the change in the fair market value of the ELI to the change in the fair market value of the property referenced by the ELI. The regulations are extremely complex, and significant aspects of the application of the regulations to the Instruments are uncertain. Specified ELIs generally do not include (1) ELIs issued prior to January 1, 2018 that are not delta-one instruments, or (2) ELIs that are treated as referencing a "qualified index". However, it is possible that Instruments could be treated as deemed reissued for U.S. federal income tax purposes upon the occurrence of certain events affecting the reference asset or the Instruments, and following such occurrence the Instruments could be treated as subject to withholding on dividend equivalent payments.

A qualified index is a passive index that (1) is based on a diverse basket of publicly traded securities, (2) is widely used by numerous market participants, and (3) meets certain specified requirements set forth in the applicable Treasury regulations. The qualified index determination is made on the first business day of the calendar year in which the ELI is issued. If, in connection with the purchase of an ELI that references an index, a taxpayer enters into one or more transactions that reduce exposure to components of the index, the ELI is not treated as referencing a qualified index.

If any payments are treated as dividend equivalents subject to withholding, the Issuer (or an applicable withholding agent) would be entitled to withhold taxes without being required to pay any additional amounts with respect to amounts so withheld.

The United States federal income and withholding tax consequences applicable to certain structured notes are uncertain. No statutory, judicial, or administrative authority directly addresses the characterization of such notes or notes similar to such notes for United States federal income, withholding, or other tax purposes. All Holders should consult their tax advisors regarding the United States federal income and withholding tax consequences to them of holding such notes.

## GENERAL INFORMATION

### (1) Authorisation

The establishment of the Programme and issues of Products thereunder have been duly authorised by the Issuer according to its Administrative Regulations.

### (2) Registration

The Issuer has obtained all necessary consents, approvals and clearances of the governmental authorities of Switzerland required and obtainable for the issue of the Products and for the performance of all its obligations thereunder.

### (3) Documents Available

From the date hereof and so long as Products are capable of being issued under the Programme, copies of the following documents will, when published, be available from the registered office of the Issuer:

- (i) the constitutional documents of the Issuer;
- (ii) the financial statements of the Issuer in respect of the two financial years preceding the date of this Base Prospectus and the most recently published audited annual financial statements, semi-annual financial statements, and interim earnings reports (if any) of the Issuer;
- (iii) this Base Prospectus and any future Base Prospectus, and supplements to the Base Prospectus, and any other documents incorporated herein or therein by reference;
- (iv) the (indicative or final) Final Terms (where applicable) which may be amended from time to time (save that specific Final Terms relating to any Product will only be available for inspection by a Holder of such Product and such Holder must produce evidence satisfactory to the Issuer as to the identity of such Holder); and
- (v) a KID (where applicable).

### (4) Clearing Systems

The Products have been accepted for clearance through the Clearance Institutions. The appropriate Valoren Number, ISIN and Common Code for each issue of Products will be specified in the applicable Final Terms. If any Products are to be cleared through an additional or alternative clearing system the appropriate information will be specified in the applicable Final Terms.

### (5) Auditor

The auditor of the Issuer is BDO AG, in Zurich, Switzerland. BDO has given and not withdrawn its agreement to the inclusion or incorporation by reference in this Base Prospectus of its report on the financial statements of the Issuer as of and for the years ended December 31, 2019 and December 31, 2018.

### (6) Interim Statements

The Issuer publishes semi-annual interim financial statements.

### (7) Material Adverse Change

Except as disclosed herein, there has been no significant change in the financial or trading position of the Issuer taken as a whole since the date of the most recently published audited annual financial statements of the Issuer and there has been no material adverse change in the financial position or prospects of the Issuer since that date.

**(8) Litigation**

Except as disclosed herein, the Issuer is not and has not been involved in any legal, arbitration or other proceedings (nor, so far as the Issuer is aware, are any legal, arbitration or other proceedings pending or threatened involving the Issuer) which may have or have had during the 12 months prior to the date of this Base Prospectus a material effect on the financial position of the Issuer and its subsidiaries taken as a whole.

**(9) Updating of this Base Prospectus**

The Issuer will, as long as any Product remains outstanding, in the event of any material adverse change in its financial condition which is not reflected in this Base Prospectus, prepare a supplement to this Base Prospectus or publish a new Base Prospectus for use in connection with any subsequent issue of Products. If the terms of the Programme are modified or amended in a manner which would make this Base Prospectus, as supplemented, inaccurate or misleading, a new or supplemental base prospectus will be prepared.

**(10) Responsibility for Documentation**

The Issuer accepts responsibility for all information contained in this Prospectus and has taken all reasonable care to ensure that the facts stated herein are true and accurate in all material respects and that there are no other material facts, the omission of which would make misleading any statement herein, whether of fact or opinion. The Issuer has taken all reasonable care to ensure that the facts stated herein are true and accurate in all material respects as of the date of this Base Prospectus and that as of such date there are no other material facts whose omission would render misleading any statement herein, whether of fact or opinion. Unless explicitly specified by the Issuer, or stated by applicable laws, the Issuer may not be held responsible for any loss or damage suffered by the purchaser of the Products in connection with an investment in the Products.

**Each investor contemplating purchasing Products should make its own independent investigation of the risks involved in an investment in the Products. Neither this document nor any other information supplied in connection with the Products constitutes any kind of investment advice.**

Zurich, \_\_\_\_\_

Helvetische Bank AG

\_\_\_\_\_

**ANNEX 1: ANNUAL REPORT 2019**

*(separate Document)*

**ANNEX 2: ANNUAL REPORT 2018**

*(separate Document)*

**ISSUER**  
**Helvetische Bank AG**  
Seefeldstrasse 215  
8008 Zurich  
Switzerland

**CALCULATION AGENT**  
**Helvetische Bank AG**  
Seefeldstrasse 215  
8008 Zurich  
Switzerland

**SWISS LEGAL ADVISER TO THE ISSUER**  
**Niederer Kraft Frey AG**  
Bahnhofstrasse 53  
8001 Zurich  
Switzerland